

Title	Dirhodium carboxylate catalysts from 2-fenchyloxy or 2-menthyloxy arylacetic acids: enantioselective C-H insertion, aromatic addition and oxonium ylide formation/rearrangement
Authors	Buckley, Aoife;Crowley, Daniel C.;Brouder, Thomas A.;Ford, Alan;Khandavilli, Udaya Bhaskara Rao;Lawrence, Simon E.;Maguire, Anita R.
Publication date	2021-10
Original Citation	Buckley, A. M., Crowley D. C., Brouder; T. A., Ford, A; Khandavilli, U. B. R., Lawrence, S. E. and Maguire, A. R. (2021) 'Dirhodium carboxylate catalysts from 2-fenchyloxy or 2-menthyloxy arylacetic acids: enantioselective C-H insertion, aromatic addition and oxonium ylide formation/rearrangement', ChemCatChem, 13 , pp. 4318-4324. doi:10.1002/cctc.202100924
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1002/cctc.202100924
Rights	© 2021, the Authors. ChemCatChem published by Wiley-VCHGmbH. This is an open access article under the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). - https://creativecommons.org/licenses/by/4.0/
Download date	2026-08-30 04:48:18
Item downloaded from	https://hdl.handle.net/10468/12603



UCC

University College Cork, Ireland
 Coláiste na hOllscoile Corcaigh

ChemCatChem

Supporting Information

Dirhodium Carboxylate Catalysts from 2-Fenchyloxy or 2-Menthyloxy Arylacetic Acids: Enantioselective C—H Insertion, Aromatic Addition and Oxonium Ylide Formation/Rearrangement

Aoife M. Buckley, Daniel C. Crowley, Thomas A. Brouder, Alan Ford, U. B. Rao Khandavilli, Simon E. Lawrence, and Anita R. Maguire*

Table of Contents

1. Experimental Procedures	3
2. Synthesis of Dirhodium Carboxylate Catalysts.....	5
2.1 Phenylacetic acid synthesis	5
2.2 <i>tert</i> -Butyl ester synthesis.....	6
2.3 α -Diazo ester synthesis.....	7
2.4 Fenchyloxy acetate synthesis	9
2.5 Menthylloxy acetate synthesis	11
2.6 Carboxylic acid synthesis.....	14
2.7 Dirhodium carboxylate synthesis	16
3. Synthesis of 2,3-dihydrobenzofurans	21
3.1 Ester Synthesis.....	21
3.2 α -Diazo ester synthesis.....	22
3.3 Rhodium Catalysed C–H Insertion Reactions - 2,3-Dihydrobenzofuran Synthesis.....	23
4. Synthesis of Thiopyran Dioxides	29
4.1 Preparation of α -Diazo- β -oxosulfone Compounds	29
4.2 Rhodium Catalysed C–H Insertion Reactions – Thiopyran Dioxide synthesis	32
4.2.1. <i>Cyclisation of α-diazo-β-oxosulfone 16</i>	34
4.2.2. <i>Cyclisation of α-diazo-β-oxosulfone 19</i>	36
4.2.3. <i>Cyclisation of α-diazo-β-oxosulfone 20</i>	38
4.2.4. <i>Cyclisation of α-diazo-β-oxosulfone 21</i>	40
4.2.5. <i>Cyclisation of α-diazo-β-oxosulfone 22</i>	42
4.2.6. <i>Cyclisation of α-diazo-β-oxosulfone 23</i>	43
4.2.7. <i>Cyclisation of α-diazo-β-oxosulfone 24</i>	45
5. Synthesis of α -diazoacetamides.....	47
6. Aromatic Addition	52
7. Synthesis of 2-allyl-2-methoxycarbonyl-2,3-dihydrobenzofuran-3-one.....	61
7.1 Synthesis of α -diazo- β -keto ester	61
7.2 Dihydrobenzofuranone synthesis.....	61
8. NMR Spectra.....	62
9. HPLC Chromatograms	174
10. Crystal Structures and Data	208
10. Author Contributions	218
11. References.....	218

1. Experimental Procedures

All solvents utilised in this work were distilled prior to use by the following methods: tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl; dichloromethane (DCM) was distilled from phosphorus pentoxide and, when used for rhodium catalysed C–H insertion reactions, the calcium hydride distilled DCM was deoxygenated using the freeze/thaw/pump method or was stored over 4 Å molecular sieves and deoxygenated by bubbling a stream of nitrogen through it; ethyl acetate was distilled from potassium carbonate; and hexane was distilled prior to use. All commercial reagents were used without further purification unless otherwise stated.

^1H (300 MHz) and ^{13}C (75.5 MHz) NMR spectra were recorded on a 300 MHz NMR spectrometer. ^1H (400 MHz) and ^{13}C (100.6 MHz) NMR spectra were recorded on a 400 MHz NMR spectrometer. ^1H (500 MHz) and ^{13}C (125.8 MHz) NMR spectra were recorded on a 500 MHz NMR spectrometer. ^1H (600 MHz) and ^{13}C (150.9 MHz) NMR spectra were recorded on a 600 MHz NMR spectrometer. All spectra were recorded at 300 K in deuterated chloroform (CDCl_3) unless otherwise stated, using tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ_{H} and δ_{C}) are reported in parts per million (ppm) relative to TMS, and coupling constants (J) are expressed in Hertz (Hz). Splitting patterns in ^1H NMR spectra are designated as s (singlet), br (broad), bs (broad singlet), d (doublet), t (triplet), q (quartet), qu (quintet), dd (doublet of doublets), dt (doublet of triplets), dq (doublet of quartets), ddd (doublet of doublet of doublets), dddd (doublet of doublet of doublet of doublets), dt (doublet of triplets), ddt (doublet of doublet of triplets), td (triplet of doublets), tt (triplet of triplets), qd (quartet of doublets), and m (multiplet). ^{13}C NMR spectra were calibrated using the solvent signal, *i.e.* CDCl_3 : δ_{C} 77.0 ppm. ^{19}F NMR spectra chemical shifts (δ_{F}) are reported relative to hexafluorobenzene (C_6F_6), which shows a single resonance at -163 ppm. For previously synthesised compounds, spectroscopic details were in agreement with reported values unless otherwise stated.

Infrared spectra were measured using a FTIR UATR2 spectrometer for characterisation of pure compounds. IR monitoring of reactions was conducted using a FTIR UATR2 spectrometer or by evaporation of a solution on sodium chloride plates and recording on a PerkinElmer Paragon 1000 FT-IR spectrometer.

All Celite® and activated charcoal filtrations were carried out in a sintered glass funnel using a tea spoon of both materials. Flash chromatography was carried out either manually or using automated chromatography. Automated chromatography was carried out using a Varian (971-FP) which is equipped with automated fraction collector and UV detector. In all cases, Kieselgel silica gel 60, 0.035–0.075 mm (Merck) was used. Thin layer chromatography (TLC) was carried out on pre-coated silica gel plates (Merck 60 PF254). Visualization was achieved by UV (254 nm) light absorption, and potassium permanganate staining.

The enantiopurity of chiral compounds was measured using chiral stationary phase high performance liquid chromatography (HPLC), carried out on a Lux® 3 μm Amylose-1 purchased from Phenomenex, or a Chiralcel® OJ–H, Chiralcel® purchased from Daicel Chemical Industries Limited. Details of the column conditions and mobile phase employed are included in **Table SI.6**. HPLC analysis was performed on a Waters Alliance 2695 separations

SUPPORTING INFORMATION


module with a Waters Alliance 2996 Photodiode Array detector. Optical rotations were measured on an Autopol V Plus Automatic Polarimeter at 589 nm in a 10 cm cell; concentrations (*c*) are expressed in g/100 mL. $[\alpha]_D^T$ is the specific rotation of a compound and is expressed in units of 10^{-1} deg cm² g⁻¹.

The Microanalysis Laboratory, National University of Ireland, Cork, performed elemental analysis using an Exeter Analytical CE440 elemental analyser. Low resolution mass spectra (LRMS) was recorded on a Waters Quattro Micro triple quadrupole instrument in electrospray ionization (ESI) mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. High resolution (precise) mass spectra (HRMS) was recorded on a Waters LCT Premier ToF LC-MS instrument in electrospray ionization (ESI) mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. High resolution (precise) mass spectra (HRMS) were recorded on an Agilent 6530B Accurate Mass Q-TOF LC/MS instrument in electrospray ionization (ESI) mode using 50% acetonitrile–water containing 0.1% formic acid as eluent. High resolution (precise) mass spectra (HRMS) was also recorded on a Waters Vion IMS instrument (SAA055K) with Waters Acquity I-class UPLC in electrospray ionization (ESI) mode using 50% acetonitrile–water containing 0.1% formic acid as eluent and Leucine Enkephalin as reference solution. Samples prepared for either LRMS or HRMS by employing acetonitrile as solvent.

Melting points were obtained using a unimelt Thomas–Hoover capillary melting point apparatus and are uncorrected.

Single crystal X-ray analysis was conducted on either a Bruker APEX II DUO diffractometer (for **7b-d**, **7f**, **7h**, **26a** and **47**) or a Bruker B8 Quest diffractometer (for **30a**) using either monochromatic Mo K α (λ = 0.7107 Å) or Cu K α (λ = 1.5418 Å) radiation. All calculation and refinement were made using APEX software.^[1] Analysis was undertaken with SHELX suite of programs and diagrams prepared with Mercury 3.0.18.^[2]


2. Synthesis of Dirhodium Carboxylate Catalysts



Scheme SI.1: An overview of the dirhodium carboxylate catalyst synthesis


2.1 Phenylacetic acid synthesis

2-Phenylacetic acid^[3] (S1)




A solution of methyl 2-phenylacetate (10.00 g, 64 mmol) in methanol (60 mL) was treated with a solution of sodium hydroxide (5.1 g, 127 mmol) in water (40 mL) and heated to 70 °C for 3 h. The resulting mixture was cooled, then concentrated under reduced pressure to remove the methanol. The residue was diluted with water (40 mL) and washed with diethyl ether (40 mL). The separated aqueous layer was acidified to pH 2 with 2M HCl and extracted with DCM (3 × 80 mL). The combined organic extracts were washed with brine (100 mL), dried over MgSO₄ and concentrated to give 2-phenylacetic acid **S1** (8.50 g, 94%) as a white solid which was used without further purification. Spectroscopic characteristics were consistent with previously reported data.^[3] **m.p.** 75–77 °C (Lit. 75–77 °C);^[3] **¹H NMR (300 MHz CDCl₃):** δ = 3.64 (2H, s), 7.25–7.37 (5H, m), 10.13 (1H, bs); **IR (neat):** 3200–2500 (COOH), 1690 (CO), 1407, 1228, 1186, 698.


SUPPORTING INFORMATION

2.2 *tert*-Butyl ester synthesis*tert*-Butyl 2-phenylacetate^[4] (**S2**)


A solution of oxalyl chloride (6.0 mL, 71 mmol) and 2-phenylacetic acid **S1** (8.43 g, 62 mmol) in DCM (50 mL) was treated with catalytic DMF (1 mL) and stirred for 2 h at room temperature. The reaction mixture was concentrated under reduced pressure, the residue was diluted with DCM (30 mL) and *tert*-butanol (*t*-BuOH) (30 mL) and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and following purification by column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, *tert*-butyl 2-phenylacetate **S2** (8.85g, 74%) was isolated as a clear oil. Spectroscopic characteristics were consistent with previously reported data.^[4] **¹H NMR (300 MHz, CDCl₃):** δ = 1.43 (9H, s), 3.52 (2H, s), 7.20–7.35 (5H, m); **IR (neat):** 2979, 1729 (CO), 1367, 1134, 695.

tert-Butyl 2-(naphthalen-2-yl)acetate^[5] (**S3**)

Oxalyl chloride (4.1 mL, 49 mmol), 2-naphthaleneacetic acid (8.00 g, 43 mmol), DCM (50 mL), DMF (1 mL) and *t*-BuOH/DCM (30mL/30mL) were used following the procedure described for **S2** to give, following column chromatography on silica gel employing hexane/ethyl acetate (93:7) as the eluent, *tert*-butyl 2-(naphthalen-2-yl)acetate **S3** (8.81, 85%) as a yellow solid. Spectroscopic characteristics were consistent with previously reported data.^[5] **m.p.** 44–45 °C (Lit., 45–46 °C);^[6] **¹H NMR (400 MHz, CDCl₃):** δ = 1.44 (9H, s), 3.68 (2H, s), 7.39–7.49 (3H, m), 7.71 (1H, s), 7.76–7.84 (3H, m); **IR (neat):** 2977, 1713 (CO), 1268, 1131, 800, 746.


tert-Butyl 2-(naphthalen-1-yl)acetate^[7] (**S4**)

Oxalyl chloride (5.2 mL, 62 mmol), 1-naphthaleneacetic acid (10.00 g, 54 mmol), DCM (75 mL), DMF (1 mL) and *t*-BuOH/DCM (35mL/35mL) were used following the procedure described for **S2** to give, following column chromatography on silica gel employing hexane/ethyl acetate (93:7) as the eluent, *tert*-butyl 1-naphthaleneacetate **S4** (10.02, 78%) as pale-yellow oil. Spectroscopic characteristics were consistent with previously reported data.^[7] **¹H NMR (400 MHz, CDCl₃):** δ = 1.41 (9H, s), 3.97 (2H, s), 7.35–7.44 (2H, m), 7.44–7.56 (2H, m), 7.76 (1H, d, *J* 7.7), 7.84 (1H, d, *J* 7.5), 7.99 (1H, d, *J* 8.3); **IR (neat):** 2977, 1726 (CO), 1367, 1134, 780.


tert-Butyl 2-(4-bromophenyl)acetate^[8] (**S5**)

Oxalyl chloride (5.4 mL, 64 mmol), 4-bromophenylacetic acid (12.0 g, 27 mmol), DCM (100 mL), DMF (2 mL) and *t*-BuOH/DCM (40mL/40mL) were used following the procedure described for **S2** to give, following column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, *tert*-butyl 2-(4-bromophenyl)acetate **S5** (12.57, 83%) as pale yellow oil. Spectroscopic characteristics were consistent with previously reported data.^[8] **¹H NMR (400 MHz, CDCl₃):** δ = 1.43 (9H, s), 3.47 (2H, s), 7.14 (2H, d, *J* 8.3), 7.44 (2H, d, *J* 8.4); **IR (neat):** 2978, 1730 (CO), 1488, 1139, 1012, 803.


SUPPORTING INFORMATION

***tert*-Butyl 2-(4-methoxyphenyl)acetate^[9] (S6)**

Oxalyl chloride (8.8 mL, 104 mmol), 4-methoxyphenylacetic acid (15 g, 90 mmol), DCM (125 mL), DMF (2 mL) and *t*-BuOH/DCM (50mL/50mL) were used following the procedure described for **S2** to give, following column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, *tert*-butyl 2-(4-methoxyphenyl)acetate **S6** (15.0 g, 75%) as pale yellow oil. Spectroscopic characteristics were consistent with previously reported data.^[9] **¹H NMR (300 MHz, CDCl₃):** δ = 1.43 (9H, s), 3.45 (2H, s), 3.78 (3H, s), 6.84 (2H, d, *J* 8.4), 7.18 (2H, d, *J* 8.6); **IR (neat):** 2978, 1726 (CO), 1512, 1277, 1135, 820.


2.3 α -Diazo ester synthesis***tert*-Butyl 2-diazo-2-phenylacetate^[10] (6a)**

1,8-Diazabicycloundec-7-ene (DBU) (19.9 mL, 113 mmol) was added dropwise over 5 minutes to a solution of 4-acetamidobenzenesulfonyl azide (*p*-ABSA) (13.01 g, 54 mmol) and *tert*-butyl 2-phenylacetate **S2** (8.68 g, 45 mmol) in DMSO (60 mL) at room temperature. After addition was complete, the solution was stirred at room temperature overnight. The reaction mixture was diluted with diethyl ether (60 mL) and water (60 mL) and the layers separated. The aqueous layer was extracted with diethyl ether (3 $\times$ 50 mL) and combined organic extracts were washed with water (50 mL), brine (50 mL), dried over MgSO₄ and concentrated under reduced pressure. The crude α -diazo ester was purified by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent, to give α -diazo ester **6a** (8.61 g, 88%) as a dark orange oil. Spectroscopic characteristics were consistent with previously reported data.^[10] **¹H NMR (300 MHz, CDCl₃):** δ = 1.55 (9H, s), 7.12–7.19 (1H, m), 7.32–7.41 (2H, m), 7.43–7.49 (2H, m); **IR (neat):** 2978, 2078 (CN₂), 1695 (CO), 1139, 754.


***tert*-Butyl 2-diazo-2-(naphthalen-2-yl)acetate^[11] (6b)**

p-ABSA (6.69g, 27 mmol), *tert*-butyl 2-naphthaleneacetate **S3** (4.5 g, 17 mmol), (DBU) (6.9 mL, 46 mmol) and DMSO (40 mL) were used following the procedure described for **6a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (97:3) as the eluent, α -diazo ester **6b** (4.37 g, 88%) as an orange solid. Spectroscopic characteristics were consistent with previously reported data.^[11] **m.p.** 84–85 °C; **¹H NMR (400 MHz, CDCl₃):** δ = 1.58 (9H, s), 7.38–7.55 (3H, m), 7.74–7.87 (3H, m), 8.02 (1H, s); **IR (neat):** 2977, 2080 (CN₂), 1689 (CO), 1144, 1125, 733.


SUPPORTING INFORMATION

***tert*-Butyl 2-diazo-2-(naphthalen-1-yl)acetate (6c)**

p-ABSA (6.20g, 26 mmol), *tert*-butyl 2-naphthaleneacetate **S4** (5.00 g, 21 mmol), DBU (7.7 mL, 52 mmol) and DMSO (50 mL) were used following the procedure described for **6a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (97:3) as the eluent, α -diazo ester **6c** (1.35 g, 64%) as an orange oil. **¹H NMR (400 MHz, CDCl₃):** δ = 1.53 (9H, s), 7.46–7.65 (4H, m), 7.81–7.90 (3H, m); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 28.4, 82.0, 122.6, 124.5, 125.6, 126.1, 126.7, 128.8, 129.37, 129.41, 131.5, 134.1, 165.6; **IR (neat):** 2977, 2078 (CN₂), 1694 (CO), 1148, 1100, 771; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ for C₁₆H₁₇N₂O₂, 269.1286, found 269.1290.

***tert*-Butyl 2-(4-bromophenyl)-2-diazoacetate^[11] (6d)**


p-ABSA (13.17 g, 55 mmol), *tert*-butyl 2-(4-bromophenyl)acetate **S5** (12.39 g, 46 mmol), DBU (16.9 mL, 114 mmol) and DMSO (100 mL) were used following the procedure described for **6a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (97:3) as the eluent, α -diazo ester **6d** (12.46 g, 92%) as an orange solid. Spectroscopic characteristics were consistent with previously reported data.^[11] **m.p.** 71–73 °C; **¹H NMR (400 MHz, CDCl₃):** δ = 1.54 (9H, s), 7.35 (2H, d, *J* 8.7), 7.47 (2H, d, *J* 8.7); **IR (neat):** 2976, 2082 (CN₂), 1689 (CO), 1489, 1147, 1001, 809.

***tert*-Butyl 2-(4-methoxyphenyl)-2-diazoacetate^[12] (6e)**

p-ABSA (19.45 g, 81 mmol), *tert*-butyl 2-(4-methoxyphenyl)acetate **S6** (15.00 g, 68 mmol), DBU (25.2 mL, 169 mmol) and DMSO (120 mL) were used following the procedure described for **6a**. Upon work up, ~1/3 of the original ester starting material was still present in the reaction product. The reaction product was re-dissolved in 120 mL DMSO with a further 0.66 equiv. of *p*-ABSA and 1 equiv. DBU and stirred at room temperature for a further 24h. Upon work-up, ~10% starting material remained and an additional 0.1 equiv ABSA and 0.15 DBU were added and the reaction mixture stirred for 24h at room temperature. Column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, gave α -diazo ester **6e** (9.57 g, 57%) as an orange oil. **¹H NMR (400 MHz, CDCl₃):** δ = 1.54 (9H, s), 3.80 (3H, s), 6.93 (2H, d, *J* 8.9), 7.37 (2H, d, *J* 8.9); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 28.4, 55.4, 81.9, 114.5, 117.6, 125.9, 157.8, 165.1; **IR (neat):** 2934, 2073 (CN₂), 1693 (CO), 1511, 1243, 1139, 1000, 825; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ for C₁₃H₁₇N₂O₃, 249.1239, found 249.1235.

SUPPORTING INFORMATION


2.4 Fenchyloxy acetate synthesis

tert-Butyl (2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-phenylacetate (7a)

Rhodium(II) acetate (7.4 mg, 0.017 mmol) was added in one portion to a stirring solution of (1R)-endo-(+)-fenchyl alcohol (2.58 g, 17 mmol) and α -diazo ester **6a** (4.00 g, 18 mmol) in DCM (70 mL). After the evolution of gas subsided, the solution was stirred for 2 h at room temperature and the reaction mixture was concentrated under reduced pressure to give compound **7a** as an 83:17 [(2S)/(2R)] mixture of diastereomers. Purification of the crude

product by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent allowed partial fractionation of diastereomers but not complete separation (combined yield, 3.37 g, 70%). Sequential recrystallisations from acetonitrile gave (2S)-**7a** (0.56 g, 12%), a white crystalline solid, as a single isomer. The other isomer was not isolated in pure form. (2S)-**7a**, less polar isomer; **m.p.** 57–59 °C; **Spec. Rot.:** $[\alpha]_D^{20} +54.9$ (*c* 1.0, CHCl₃); **¹H NMR (300 MHz, CDCl₃):** δ = 0.89–1.10 (11H, m, contains 2H, m and 3 $\times$ 3H, s at 1.00, 1.04, 1.06), 1.29–1.49 (11H, m, contains 9H, s at 1.39 and 2H, m), 1.61–1.66 (1H, m), 1.67–1.79, (1H, m), 1.80–1.93 (1H, m), 2.99 (1H, d, *J* 1.7), 4.76 (1H, s), 7.27–7.37 (3H, m), 7.41–7.49 (2H, m); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 20.2, 20.9, 26.0, 26.2, 28.0, 31.2, 39.9, 41.4, 48.6, 49.4, 81.3, 81.8, 91.2, 127.2, 128.0, 128.1, 137.9, 170.7; **IR (neat):** 2937, 1742 (CO), 1106, 700; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₂H₃₃O₃, 345.2430, found 345.2436; **Elemental Analysis:** calcd (%) for C₂₂H₃₂O₃: C, 76.70; H, 9.36. Found: C, 76.76; H, 9.23.

A characteristic signal of the (2R)-**S7** isomer is the 1H d of C(2'')H observed at 3.09 ppm, *J* 1.7, in the ¹H NMR spectrum of the crude product. The ratio of diastereomers was calculated based on this signal which occurs at 2.99 ppm for the (2S)-**7a** isomer and 3.09 ppm for the (2R)-**S7** isomer.

tert-Butyl (2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-(naphthalen-2'-yl)acetate (7b)


Rhodium(II) acetate (5.8 mg, 0.013 mmol), (1R)-endo-(+)-fenchyl alcohol (2.04 g, 13 mmol), α -diazo ester **6b** (3.90 g, 15 mmol) and DCM (70 mL) were used following the procedure described for **7a** to give compound **7b** as an 83:17 [(2S)/(2R)] mixture of diastereomers. Purification of the crude product by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent allowed partial fractionation of diastereomers but not complete separation (combined yield, 4.27 g, 82%).

Sequential recrystallisations from acetonitrile gave (2S)-**7b** (1.62 g, 31%), a white crystalline solid, as a single isomer. The other isomer was not isolated in pure form. (2S)-**7b**, less polar isomer; **m.p.** 113–114 °C; **Spec. Rot.:** $[\alpha]_D^{20} +80.2$ (*c* 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.92–1.15 (11H, m, contains 2H, m and 3 $\times$ 3H, s at 1.00, 1.07, 1.10), 1.33–1.45 (11H, m, contains 9H, s at 1.38 and 2H, m), 1.61–1.68 (1H, m), 1.70–1.80 (1H, m), 1.85–1.95 (1H, m), 3.04 (1H, d, *J* 1.7), 4.90 (1H, s), 7.42–7.51 (2H, m), 7.56–7.65 (1H, m), 7.78–7.87 (3H, m), 7.89 (1H, s); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 20.2, 20.9, 26.0, 26.2, 28.0, 31.3, 39.8, 41.4, 48.7, 49.3, 81.4, 81.8, 91.1, 125.1, 126.0, 126.7, 127.7, 127.9, 128.1, 133.1, 133.3, 135.3, 170.6; **IR (neat):** 2928, 1714 (CO), 1290, 1128, 477; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₆H₃₅O₃, 395.2567, found 395.2586; **Elemental Analysis:** calcd (%) for C₂₆H₃₄O₃: C, 79.15; H, 8.69. Found: C, 79.03; H, 8.57.

SUPPORTING INFORMATION

A characteristic signal of the (2*R*)-**S8** isomer is the ¹H d of C(2'')*H* observed at 3.14 ppm, *J* 1.7, in the ¹H NMR spectrum of the crude product. The ratio of diastereomers was calculated based on this signal which occurs at 3.04 ppm for the (2*S*)-**7b** isomer and 3.14 ppm for the (2*R*)-**S8** isomer.


tert-Butyl (2*S*)-2-(1''*R*,2''*R*,4''*S*)-fenchyloxy-2-(naphthalen-1'-yl)acetate (7c)



Rhodium(II) acetate (4.9 mg, 0.010 mmol), (1*R*)-*endo*-(+)-fenchyl alcohol (1.57 g, 10 mmol), α -diazo ester **6c** (3.00 g, 11 mmol) and DCM (50 mL) were used following the procedure described for **7a** to give the compound **7c** as a 47:53 [(2*S*)/(2*R*)] mixture of diastereomers. Purification of the crude product by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent allowed partial fractionation of diastereomers but not complete separation (combined yield, 2.84 g, 72%). Sequential recrystallisations from acetonitrile gave (2*S*)-**7c** (1.13 g, 29%), a white crystalline solid, as a single isomer. The other isomer was not isolated in pure form. (2*S*)-**7c**, less polar isomer; **m.p.** 69–71 °C; **Spec. Rot.:** $[\alpha]_D^{20} = -2.0$ (*c* 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.80–0.96 (4H, m, contains 1H, m and 3H, s at 0.84), 1.00 (1H, d, *J* 10.1), 1.09, 1.14 (2 $\times$ 3H, s), 1.26–1.43 (11H, m, contains 9H, s at 1.30 and 2H, m), 1.63 (1H, apparent d, *J* 3.0), 1.69–1.79 (1H, m), 1.81–1.92 (1H, m), 3.07 (1H, d, *J* 1.4), 5.34 (1H, s), 7.42–7.55 (3H, m), 7.67 (1H, d, *J* 7.0), 7.78–7.88 (2H, m), 8.30 (1H, d, *J* 8.2) **¹³C NMR (100.6 MHz, CDCl₃):** δ = 20.1, 21.1, 26.0, 26.2, 27.9, 31.4, 39.9, 41.4, 48.7, 49.3, 80.2, 81.5, 91.6, 124.8, 125.2, 125.5, 125.9, 126.8, 128.5, 128.7, 131.1, 133.8, 134.0, 170.6 ; **IR (neat):** 2952, 1743 (CO), 1368, 1151, 789; **Elemental Analysis:** calcd (%) for C₂₆H₃₄O₃: C, 79.15; H, 8.69. Found: C, 79.34; H, 8.63.

A characteristic signal of the (2*R*)-**S9** isomer is the ¹H d of C(2'')*H* observed at 3.26 ppm, *J* 1.4, in the ¹H NMR spectrum of the crude product. The ratio of diastereomers was calculated based on this signal which occurs at 3.07 ppm for the (2*S*)-**7c** isomer and 3.26 ppm for the (2*R*)-**S9** isomer.

tert-Butyl (2*S*)-2-(4'-bromophenyl)-2-(1''*R*,2''*R*,4''*S*)-fenchyloxyacetate (7d)




Rhodium(II) acetate (8.5 mg, 0.019 mmol), (1*R*)-*endo*-(+)-fenchyl alcohol (2.95 g, 19 mmol), α -diazo ester **6d** (6.00 g, 21 mmol) and DCM (70 mL) were used following the procedure described for **7a** to give compound **7d** as a 79:21 [(2*S*)/(2*R*)] mixture of diastereomers. Purification of the crude product by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent allowed partial fractionation of diastereomers but not complete separation (combined yield, 6.35 g, 79%). Sequential recrystallisations from acetonitrile gave (2*S*)-**7d** (3.26 g, 37%), a white crystalline solid, as a single isomer. The other isomer was not isolated in pure form. (2*S*)-**7d**, less polar isomer; **m.p.** 100–102 °C; **Spec. Rot.:** $[\alpha]_D^{20} = +48.3$ (*c* 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.90–1.10 (11H, m, contains 2H, m and 3 $\times$ 3H, 2 $\times$ s, one at 1.00 and two at 1.04), 1.33–1.46 (11H, m, contains 9H, s at 1.38 and 2H, m), 1.60–1.66 (1H, m), 1.67–1.76 (1H, m), 1.77–1.87 (1H, m), 2.97 (1H, bs, *J* 1.5), 4.71 (1H, s), 7.33 (2H, d, *J* 8.4), 7.46 (2H, d, *J* 8.4); **¹³C NMR (100.6 MHz,**

SUPPORTING INFORMATION

CDCl₃: δ = 20.3, 20.8, 26.0, 26.2, 27.9, 31.2, 39.8, 41.4, 48.6, 49.3, 81.2, 81.6, 91.5, 122.1, 128.9, 131.3, 136.9, 170.2; **IR (neat)**: 2943, 1744 (CO), 1116, 1097, 785; **Elemental Analysis**: calcd (%) for C₂₂H₃₁O₃Br: C, 62.41; H, 7.38. Found: 62.49; H, 7.35.

A characteristic signal of the (2*R*)-**S10** isomer is the 1H bs of C(2'')H observed at 3.07 ppm in the ¹H NMR spectrum of the crude product. The ratio of diastereoisomers was calculated based on the signal which occurs at 2.97 ppm for the (2*S*)-**7d** isomer and 3.07 ppm for the (2*R*)-**S10** isomer.

tert-Butyl (2*S*)-2-(1''*R*,2''*R*,4''*S*)-fenchyloxy-2-(4'-methoxyphenyl)acetate (7e**)**




Rhodium(II) acetate (7.6 mg, 0.017 mmol), (1*R*)-*endo*-(+)-fenchyl alcohol (2.66 g, 17 mmol), α -diazo ester **6e** (4.50 g, 18 mmol) and DCM (50 mL) were used following the procedure described for **7a** to give compound **7e** as a 83:17 [(2*S*)/(2*R*)] mixture of diastereomers. Purification of the crude product by column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent allowed partial fractionation of diastereomers but not complete separation (combined yield, 5.06 g, 80%). Sequential recrystallisations from acetonitrile gave (2*S*)-**7e** (2.32 g, 36%), a white crystalline solid, as a single isomer. The other isomer was not isolated in pure form. (2*S*)-**7e**, less polar isomer; **m.p.** 66–68 °C; **Spec. Rot.:** $[\alpha]_D^{20}$ = +60.4 (c 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃)**: δ = 0.87–1.07 (11H, m, contains 2H, m and 3 $\times$ 3H, s at 0.99, 1.03 and 1.04), 1.31–1.46 (11H, m, contains 9H, s at 1.39 and 2H, m), 1.59–1.64 (1H, m), 1.66–1.77 (1H, m), 1.79–1.91 (1H, m), 2.96 (1H, d, *J* 1.4), 3.80 (3H, s), 4.70 (1H, s), 7.86 (2H, d, *J* 8.7), 7.36 (2H, d, *J* 8.7); **¹³C NMR (100.6 MHz, CDCl₃)**: δ = 20.2, 20.8, 26.0, 26.2, 28.0, 31.2, 39.8, 41.4, 48.6, 49.3, 55.2, 81.1, 81.2, 90.8, 113.5, 128.6, 130.0, 159.4, 170.9; **IR (neat)**: 2946, 1714 (CO), 1239, 1095, 847; **Elemental Analysis**: calcd (%) for C₂₃H₃₄O₄: C, 73.76; H, 9.15. Found: C, 73.84; H, 9.00.

A characteristic signal of the (2*R*)-**S11** isomer is the 1H d of C(2'')H observed at 3.05 ppm, *J* 1.4, in the ¹H NMR spectrum of the crude product. The ratio of diastereomers was calculated based on this signal which occurs at 2.96 ppm for the (2*S*)-**7e** isomer and 3.05 ppm for the (2*R*)-**S11** isomer.

2.5 Menthylxy acetate synthesis


tert-Butyl (2*S*)-2-(1''*R*,2''*S*,5''*R*)-menthyloxy-2-phenylacetate (7f**)**




Rhodium(II) acetate (10.6 mg, 0.026 mmol), (–)-menthol (3.76 g, 24 mmol) and α -diazo ester **6a** (5.75 g, 26 mmol) and DCM (80 mL) were used following the procedure for **7a** to give compound **7f** as a 77:23 [(2*S*)/(2*R*)] mixture of diastereomers. Purification of the mixture by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent allowed partial separation of isomers but not complete separation (combined yield, 6.93 g, 83%). Sequential recrystallisations from acetonitrile gave (2*S*)-**7f** (3.35 g, 40%), a white crystalline solid, as a single isomer. (2*S*)-**7f**, less polar isomer; **m.p.** 75–77 °C; **Spec. Rot.:** $[\alpha]_D^{20}$ = –61.6 (c 1.0, CHCl₃); **¹H NMR (300 MHz, CDCl₃)**: δ = 0.79–1.08 (12H, m, which contains, 3H, m, 3H,

SUPPORTING INFORMATION

d, J 6.9 at 0.85, 3H, d, J 6.8 at 0.89 and 3H, d, J 7.1 at 0.94), 1.23–1.46 (11H, m, contains 2H, m, and 9H, s at 1.39), 1.58–1.71 (2H, m), 2.01–2.13 (1H, m), 2.44–2.61 (1H, m), 3.31 (1H, td, J 10.5, 4.2), 4.94 (1H, s), 7.23–7.37 (3H, m), 7.42–7.50 (2H, m); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 16.4, 21.2, 22.3, 23.2, 25.2, 27.9, 31.5, 34.5, 40.4, 48.4, 78.5, 78.6, 81.4, 126.9, 128.0, 128.3, 138.3, 170.8; IR (neat): 2958, 1734 (CO), 1146, 1097, 701; Elemental Analysis: calcd (%) for $\text{C}_{22}\text{H}_{34}\text{O}_3$: C, 76.26; H, 9.89. Found: 76.45; H, 9.80.

tert-Butyl (2R)-2-(1''R,2''S,5''R)-menthyloxy-2-phenylacetate (S12)


(2R)-**S12**, more polar isomer (0.65 g, 8%), m.p. 80–81 °C; Spec. Rot.: $[\alpha]_D^{20} = -137.3$ (c 1.0, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ = 0.49 (3H, d, J 6.9), 0.78–0.96 (8H, m, contains 2H, m and 3H, d, J 7.0 at 0.85 and 3H, d, J 7.0 at 0.92), 1.02 (1H, q, J 11.1), 1.23–1.45 (11H, m), 1.55–1.70 (2H, m), 2.07–2.17 (1H, m), 2.22–2.35 (1H, m), 3.09 (1H, td, J 10.5, 4.1), 4.83 (1H, s), 7.28–7.37 (3H, m), 7.39–7.47 (2H, m); ^{13}C NMR (100.6 MHz, CDCl_3): δ = 15.6, 21.1, 22.4, 22.9, 25.1, 27.9, 31.6, 34.4, 40.5, 48.1, 78.2, 79.2, 81.3, 127.4, 128.1, 128.3, 137.7, 171.0; IR (neat): 2959, 2930, 1735 (CO), 1151, 1049, 697; Elemental Analysis: calcd (%) for $\text{C}_{22}\text{H}_{34}\text{O}_3$: C, 76.26; H, 9.89. Found C, 75.95; H, 9.75.

tert-Butyl (2S)-(1''R,2''S,5''R)-menthyloxy-2-(naphthalen-2-yl)acetate^[13] (7g)

Rhodium(II) acetate (10.5 mg, 0.024 mmol), (–)-menthol (3.71 g, 24 mmol) and α -diazo ester **6b** (7.00 g, 26 mmol) and DCM (60 mL) were used following the procedure for **7a** to give compound **7g** as a 76:24 [(2S)/(2R)] mixture of diastereomers. Purification of the mixture by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent allowed partial separation of isomers (combined yield, 7.16 g, 75%). Sequential recrystallisations from acetonitrile gave (2S)-**7g** (2.35, 29%), a white crystalline solid, as a single isomer. (2S)-**7g**, less polar isomer; m.p.

77–79 °C; Spec. Rot.: $[\alpha]_D^{20} = -33.1$ (c 1.0, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ = 0.78–1.08 (12H, m, contains, 3H, m, 2 $\times$ overlapping 3H, d, J ~7.0, at 0.87 and 0.88 and 3H, d, J 7.1 at 0.96), 1.26–1.46 (11H, m, contains 2H, m and 9H, s at 1.36), 1.60–1.72 (2H, m), 2.08 (1H, bd, J 11.6), 2.51–2.65 (1H, m), 3.36 (1H, td, J 10.5, 4.1), 5.10 (1H, s), 7.42–7.51 (2H, m), 7.60 (1H, dd, J 8.5, 1.4), 7.77–7.89 (3H, m), 7.92 (1H, s); ^{13}C NMR (100.6 MHz, CDCl_3): δ = 16.4, 21.3, 22.4, 23.2, 25.3, 28.0, 31.6, 34.5, 40.5, 48.4, 78.9, 79.0, 81.6, 124.8, 125.99, 126.06, 126.1, 127.7, 128.0, 128.2, 133.21, 133.23, 135.8, 170.8; IR (neat): 2953, 1737 (CO), 1147, 1095, 760; Elemental Analysis: calcd (%) for $\text{C}_{26}\text{H}_{36}\text{O}_3$: C, 78.75; H, 9.15. Found: 78.75; H, 9.08.


SUPPORTING INFORMATION

***tert*-Butyl (2*R*)-(1''*R*,2''*S*,5''*R*)-menthyloxy-2-(naphthalen-2-yl)acetate^[13] (**S13**)**

(2*R*)-**S13**, more polar, minor isomer, white solid (0.52, 5%), **m.p.** 92–93 °C; **Spec.**

Rot.: $[\alpha]_D^{20} = -156.1$ (c 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.46 (3H, d, *J* 6.9), 0.75–0.99 [8H, m, contains, 2H, m, 3H, d, *J* 7.1 at 0.86 and 3H, d, *J* 6.5 at 0.93], 1.05 (1H, q, *J* 11.1), 1.21–1.49 (11H, m, contains 2H, m and 9H, s at 1.37), 1.54–1.67 (2H, m), 2.18 (1H, bd, *J* 11.7), 2.29–2.43 (1H, m), 3.13 (1H, td, *J* 10.5,

4.1), 5.02 (1H, s), 7.43–7.53 (2H, m), 7.57 (1H, dd, *J* 8.5, 1.4), 7.78–7.93 (3H, m), 7.89 (1H, s); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 15.7, 21.1, 22.4, 22.9, 25.1, 27.9, 31.6, 34.4, 40.4, 48.1, 78.0, 79.2, 81.5, 125.1, 126.07, 126.10, 126.8, 127.8, 128.13, 128.15, 133.1, 133.3, 135.1, 170.9; **IR (neat):** 2920, 1732 (CO), 1148, 1084, 817; **Elemental Analysis:** calcd (%) for C₂₆H₃₆O₃: C, 78.75; H, 9.15. Found: 78.64; H, 9.06.

***tert*-Butyl (2*S*)-2-(4'-bromophenyl)-2-(1''*R*,2''*S*,5''*R*)-menthyloxyacetate (**7h**)**

Rhodium(II) acetate (8.8 mg, 0.020 mmol), (–)-menthol (3.19 g, 20 mmol) and α -diazo ester **6d** (6.10 g, 21 mmol) and DCM (60 mL) were used following the procedure for **7a** to give compound **7h** as a 87:13 [(2*S*)/(2*R*)] mixture of diastereomers. Purification of the mixture by column chromatography on silica gel employing hexane/ethyl acetate (98:2) as the eluent allowed partial separation of isomers (combined yield, 6.89 g, 81%). Sequential recrystallisations from acetonitrile


gave (2*S*)-**7h** (3.93 g, 44%), a white crystalline solid, as a single isomer. The other isomer was not isolated in pure form. (2*S*)-**7h**, less polar isomer; **m.p.** 100–102 °C; **Spec. Rot.:** $[\alpha]_D^{20} = -45.7$ (c 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.76–1.07 (12H, m, contains, 3H, m, 3H, d, *J* 6.9 at 0.84, 3H, d, *J* 6.5 at 0.89 and 3H, d, *J* 7.1 at 0.94), 1.26–1.44 (11H, m, contains 2H, m and 9H, s at 1.39), 1.60–1.71 (2H, m), 2.03 (1H, bd, *J* 12.0), 2.42–2.57 (1H, m), 3.30 (1H, td, *J* 10.5, 4.1), 4.89 (1H, s), 7.31–7.37 (2H, m), 7.42–7.49 (2H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 16.3, 21.2, 22.3, 23.1, 25.3, 27.9, 31.5, 34.4, 40.3, 48.4, 78.0, 78.8, 81.7, 122.1, 128.6, 131.4, 137.4, 170.3; **IR (neat):** 2929, 1737 (CO), 1144, 1096, 780; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₂H₃₄O₃⁷⁹Br, 425.169, found 425.1684; **Elemental Analysis:** calcd (%) for C₂₂H₃₃O₃Br: C, 62.12; H, 7.82. Found: C, 62.19; H, 7.75.

A characteristic signal of the (2*R*)-**S14** isomer is the 1H triplet of doublets of C(1'')H, *J* 10.5, 4.1, observed at 3.08 ppm in the ¹H NMR spectrum of the crude product. The ratio of diastereomers was calculated based on this signal which occurs at 3.30 ppm for the (2*S*)-**7h** isomer and 3.08 ppm for the (2*R*)-**S14** isomer.

SUPPORTING INFORMATION

2.6 Carboxylic acid synthesis


(2S)-2-(1''R,2''R,4''S)-Fenchyloxy-2-phenylacetic acid (8a)



Trifluoroacetic acid (TFA) (1.5 mL) was added to a stirring solution of (2S)-**7a** (0.50 g, 1.7 mmol) in DCM (5mL). The solution was stirred for 2 h at room temperature and was then concentrated under reduced pressure to give the crude product. Following purification by column chromatography on silica gel employing hexane/ethyl acetate (99:1) as eluent, the pure acid **8a** (0.44 g, 90%) was isolated as a white solid. **m.p.** 113–115 °C; **Spec. Rot.:**

$[\alpha]_D^{20} = +137.5$ (c 0.75, CHCl_3); **^1H NMR (400 MHz, CDCl_3):** δ = 0.91 (3H, s), 0.98–1.11 (8H, m, contains 2H, m and 2 × overlapping 3H, s at 1.04), 1.34–1.51 (2H, m), 1.64–1.68 (1H, m), 1.69–1.80 (2H, m), 3.08 (1H, finely split s, J 1.3), 4.88 (1H, s), 7.32–7.44 (5H, m), ~9.30 (1H, bs); **^{13}C NMR (100.6 MHz, CDCl_3):** δ = 19.8, 20.9, 26.05, 26.07, 31.4, 39.6, 41.3, 48.7, 49.1, 80.5, 91.0, 127.7, 128.6, 129.0, 135.8, 172.9; **IR (neat):** 3400–2500 (COOH), 2951, 1721 (CO), 1455, 1114, 1099, 697; **Elemental Analysis:** calcd (%) for $\text{C}_{18}\text{H}_{24}\text{O}_3$: C, 74.97; H, 8.39. Found: 74.97; H, 8.38.


(2S)-2-(1''R,2''R,4''S)-Fenchyloxy-2-(naphthalen-2'-yl)acetic acid (8b)



TFA (1 mL), (2S)-**7b** (0.15 g, 0.38 mmol) in DCM (5mL) were used following the procedure for **8a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, the acid **8b** (95 mg, 74%) as a clear, viscous oil. **Spec. Rot.:** $[\alpha]_D^{20} = +130.9$ (c 1.2, CHCl_3); **^1H NMR (400 MHz, CDCl_3):** δ = 0.81–1.13

(11H, m, contains 2H, m, 3 × 3H, s at 0.92, 1.05 and 1.08), 1.31–1.48 (2H, m), 1.61–1.68 (1H, m), 1.69–1.88 (2H, m), 3.10 (1H, bs), 5.04 (1H, s), 7.42–7.58 (3H, m), 7.77–7.90 (4H, m), ~9.21 (1H, bs); **^{13}C NMR (100.6 MHz, CDCl_3):** δ = 19.9, 20.9, 26.09, 26.11, 31.5, 39.7, 41.3, 48.7, 49.1, 80.7, 91.0, 124.7, 126.4, 126.6, 127.6, 127.8, 128.1, 128.6, 133.0, 133.4, 133.6, 174.3; **IR (neat):** 3300–2400 (COOH), 2950, 1717 (CO), 1112, 1101, 774, 732; **HRMS (ESI-TOF):** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{27}\text{O}_3$, 339.1960, found 339.1960.


(2S)-2-(1''R,2''R,4''S)-Fenchyloxy-2-(naphthalen-1'-yl)acetic acid (8c)



TFA (1 mL), (2S)-**7c** (0.15 g, 0.38 mmol) and DCM (2.5mL) were used following the procedure for **8a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, the acid **8c** (0.12 g, 93%) as a clear, viscous oil. **Spec. Rot.:** $[\alpha]_D^{20} = 170.2$ (c 1.5, CHCl_3); **^1H NMR (400 MHz, CDCl_3):** δ = 0.71 (3H, s),

0.77–1.17 (8H, m, contains 2H, m and 2 × 3H, s at 1.06, 1.12), 1.19–1.47 (2H, m), 1.61–1.67 (1H, m), 1.68–1.83 (2H, m), 3.10 (1H, finely split s, J 1.2), 5.44 (1H, s), 7.41–7.53 (3H, m), 7.59 (1H, d, J 6.7), 7.81–7.88 (2H, m), 8.15 (1H, d, J 7.9), ~9.88 (1H, bs); **^{13}C NMR (100.6 MHz, CDCl_3):** δ = 19.7, 21.1, 26.0, 26.1, 31.5, 39.8, 41.3, 48.7, 49.1, 79.3, 91.6, 124.2, 125.0, 126.0, 126.6, 127.7, 128.8, 129.7, 131.1, 132.0, 134.0, 174.4; **IR (neat):** 3500–2600 (COOH), 2950, 1717 (CO), 1111, 1101, 774; **Elemental Analysis:** calcd (%) for $\text{C}_{22}\text{H}_{26}\text{O}_3$: C, 78.07; H, 7.56. Found: 77.93; H, 7.56.


SUPPORTING INFORMATION

(2S)- 2-(4'-Bromophenyl)-2-(1''R,2''R,4''S)-fenchyloxyacetic acid (8d)

TFA (2 mL), (2S)-**7d** (0.25 g, 0.59 mmol) and DCM (5 mL) were used following the procedure for **8a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, the acid **8d** (0.16 g, 74%) as a white solid.

m.p. 65–68 °C; **Spec. Rot.:** $[\alpha]_D^{25} = +98.1$ (c 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.95 (3H, s), 0.98–1.09 (8H, m, contains 2H, m and 2 × overlapping 3H, s at 1.02), 1.35–


1.48 (2H, m), 1.62–1.68 (1H, m), 1.68–1.82 (2H, m), 3.02 (1H, finely split s, *J* 1.1), 4.84 (1H, s), 7.31 (2H, d, *J* 8.4), 7.49 (2H, d, *J* 8.4), ~9.20 (1H); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 20.0, 20.9, 26.0, 26.1, 31.3, 39.7, 41.3, 48.6, 49.2, 80.0, 91.5, 123.1, 129.2, 131.8, 135.2, 174.8; **IR (neat):** 3300–2400 (COOH), 2950, 1722 (CO), 1094, 816; **Elemental Analysis:** calcd (%) for C₁₈H₂₃O₃Br: C, 58.86; H, 6.31. Found: 58.92; H, 6.27.

(2S)-2-(1''R,2''R,4''S)-Fenchyloxy-2-(4'-methoxy)phenylacetic acid (8e)

A solution of (2S)-**7e** (0.60 g, 1.6 mmol) in methanol (15 mL) was treated with sodium hydroxide (0.64 g, 16 mmol) and heated under reflux for 4 h. The resulting mixture was cooled, then concentrated under reduced pressure to remove the methanol. The residue was dissolved in DCM (30 mL) and washed with 2M HCl (30 mL). The combined organic extracts were washed with brine (50 mL), dried over MgSO₄ and

concentrated to give compound **8e** (0.47 g, 92%), a white solid, as a 95:5 [(2S):(2R)] mixture of diastereomers which was used without further purification. **m.p.** 90–93 °C; **Spec. Rot.:** $[\alpha]_D^{25} = +133.6$ (c 1.0, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.91 (3H, s), 0.99–1.12 (8H, m, contains 2H, m and 2 × 3H, s, at 1.028, 1.033), 1.33–1.50 (2H, m), 1.62–1.68 (1H, m), 1.68–1.80 (2H, m), 3.06 (1H, finely split s, *J* 1.2), 3.81 (3H, s), 4.82 (1H, s), 6.89 (2H, d, *J* 8.6), 7.32 (2H, d, *J* 8.6), COOH not observed; **¹³C NMR (100.6 MHz, CDCl₃):** δ = 19.8, 20.9, 26.05, 26.08, 31.4, 39.5, 41.3, 48.7, 49.0, 55.3, 80.0, 90.5, 114.0, 127.9, 129.1, 160.1, 173.5; **IR (neat):** 3500–2300 (COOH), 2951, 1721 (CO), 1512, 1033, 829; **Elemental Analysis:** calcd (%) for C₁₉H₂₆O₄: C, 71.67; H, 8.23. Found C, 71.40; H, 8.09.

A characteristic signal of the (2R)-**S15** isomer is the 1H, finely split singlet of C(2)H, *J* 1.2 observed at 3.12 ppm in the ¹H NMR spectrum of the crude product. The ratio of diastereomers was calculated based on this signal which occurs at 3.06 ppm for the (2S)-**8e** isomer and 3.12 ppm for the (2R)-**S15** isomer.


(2S)-2-(1''R,2''S,5''R)-Menthhyloxy-2-phenylacetic acid (8f)

TFA (5 mL), (2S)-**7f** (2.00 g, 5.8 mmol) and DCM (5mL) were used following the procedure for **8a** to give compound **8f** (1.61 g, quantitative) as a white solid which was used without further purification. **m.p.** 96–98 °C; **Spec. Rot.:** $[\alpha]_D^{20} = -14.05$ (c 1.0, CHCl₃); **¹H NMR (300 MHz, CDCl₃):** δ = 0.73–1.06 (12H, m, contains, 3H, m, 3H, d, *J* 6.6 at 0.81, 3H, d, *J* 7.0 at 0.85 and 3H, d, *J* 7.0 at 0.94), 1.18–1.45 (2H, m), 1.58–1.73 (2H, m), 1.90 (1H, bd, *J* 12.1), 2.28–2.47 (1H, m), 3.36 (1H, td, *J* 10.5, 4.2), 5.04 (1H, s), 7.29–


7.41 (3H, m), 7.42–7.50 (2H, m), 9.01 (1H, bs); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 16.0, 21.2, 22.2, 23.0, 25.5, 31.5,

SUPPORTING INFORMATION


34.3, 40.7, 48.6, 78.3, 79.5, 127.1, 128.6, 128.7, 137.0, 175.6; **IR (neat)**: 3400–3000 (COOH), 2932, 1721 (CO), 1694, 1105, 1095, 696; **Elemental Analysis**: calcd (%) for $C_{18}H_{26}O_3$: C, 74.45; H, 9.02, found: C, 74.55; H, 8.99.

(2S)-2-(1''R,2''S,5''R)-Menthyloxy-2-(naphthalen-2'-yl)acetic acid (8g)

TFA (5 mL), (2S)-**7g** (0.90 g, 2.5 mmol) and DCM (5mL) were used following the procedure for **8a** to give compound **8g** (0.71 g, quantitative) as an off white foamy solid which was used without further purification. **m.p.** 112–115 °C; **Spec. Rot.**: $[\alpha]_D^{20} = 19.25$ (c 1.0, $CHCl_3$); **1H NMR (400 MHz, $CDCl_3$)**: δ = 0.73–1.05 (12H, m, contains, 3H, m, 3H, d, *J* 6.5 at 0.81, 3H, d, *J* 6.9 at 0.85, and 3H, d, *J* 7.0 at 0.96), 1.18–1.34 (1H, m), 1.34–1.48 (1H, m), 1.57–1.71 (2H, m), 1.91 (1H, bd, *J* 11.9), 2.34–2.48 (1H, m), 3.40 (1H, td, *J* 10.5, 4.1), 5.19 (1H, s), 7.44–7.52 (2H, m), 7.57 (1H, dd, *J* 8.5, 1.4), 7.77–7.87 (3H, m), 7.91 (1H, s), 8.57 (1H, bs); **^{13}C NMR (100.6 MHz, $CDCl_3$)**: δ = 16.0, 21.3, 22.2, 22.9, 25.5, 31.5, 34.3, 40.9, 48.6, 78.7, 79.8, 124.5, 126.3, 126.4, 126.6, 127.7, 128.2, 128.5, 133.1, 133.5, 134.4, 175.3; **IR (neat)**: 3500–2200 (COOH), 2955, 1707 (CO), 1113, 1085, 747; **Elemental Analysis**: calcd (%) for $C_{22}H_{28}O_3$: C, 77.61; H, 8.29. Found: C, 77.62; H, 8.19.

(2S)- 2-(4'-Bromophenyl)-2-(1''R,2''S,5''R)-menthyloxyacetic acid (8h)


TFA (2.5 mL), (2S)-**7h** (0.60 g, 1.4 mmol) and DCM (5mL) were used following the procedure for **8a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, the acid **8h** (0.36 g, 70%) as a colourless oily solid. **Spec. Rot.**: $[\alpha]_D^{20} = -9.1$ (c 1.7, $CHCl_3$); **1H NMR (400 MHz, $CDCl_3$)**: δ = 0.71–1.04 (12H, m, contains, 3H, m, 3H, d, *J* 6.8 at 0.79, 3H, d, *J* 6.6 at 0.86 and 3H, d, *J* 7.0 at 0.93), 1.22–1.40 (2H, m), 1.58–1.71 (2H, m), 1.93 (1H, bd, *J* 11.6), 2.31–2.47 (1H, m), 3.34 (1H, td, *J* 10.5, 4.1), 5.01 (1H, s), 7.34 (2H, d, *J* 8.4), 7.47 (2H, d, *J* 8.3), 11.10 (1H, bs); **^{13}C NMR (100.6 MHz, $CDCl_3$)**: δ = 16.0, 21.2, 22.3, 23.0, 25.3, 31.5, 34.3, 40.5, 48.5, 77.4, 79.4, 122.8, 128.8, 131.7, 136.2, 176.5; **IR (neat)**: 3500–2200 (COOH), 2921, 1718 (CO), 1487, 1011, 813; **Elemental Analysis**: calcd (%) for $C_{18}H_{25}O_3Br$: 58.54; H, 6.82. Found: 58.21; H, 6.97.

2.7 Dirhodium carboxylate synthesis**Sodium rhodium carbonate $[Na_4Rh_2(CO_3)_4 \cdot 2.5H_2O]^{[14]}$ (S16)**

Rhodium acetate dimer (1.50 g, 3.4 mmol) in aqueous sodium carbonate (2M, 25 mL) was heated under reflux for 1 h. The resulting mixture was cooled to room temperature, filtered and washed with water (20 mL), methanol (20 mL) and diethyl ether (20 mL) to give the sodium salt of rhodium carbonate **S16** (1.92 g, 97%) as a blue purple solid.


***Note:** Four ligands surround the dirhodium unit throughout with just one shown for clarity.

SUPPORTING INFORMATION

Dirhodium tetrakis [(2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-phenylacetate] (2S-FPA) (**9a**)

Sodium rhodium carbonate [$\text{Na}_4\text{Rh}_2(\text{CO}_3)_4 \cdot 2.5\text{H}_2\text{O}$] **S16** (98 mg, 0.17 mmol) and (2S)-**8a** (0.39 g, 1.3 mmol) were added to water (20 mL) and refluxed overnight. The solution was cooled, extracted with DCM (3 $\times$ 30 mL) and the combined organic extracts were washed with saturated sodium bicarbonate solution (2 $\times$ 30 mL), brine (30 mL), dried over MgSO_4 and concentrated. Following purification by column chromatography on silica gel employing hexane/ethyl acetate (92:8) as the eluent, the rhodium complex **9a** (70 mg, 31%) was isolated as a green oil. **^1H NMR (400 MHz, CDCl_3):** δ = 0.79–0.99 (11H, m, contains, 2H, m, 3H, s at 0.81, 3H, s at 0.85 and 3H, s at 0.94), 1.22–1.38 (2H, m), 1.55–1.61 (1H, m), 1.63–1.79 (2H, m), 2.49 (1H, bs), 4.44 (1H, s), 7.11–7.26 (5H, m); **^{13}C NMR (100.6 MHz, CDCl_3):** δ = 20.1, 20.9, 26.1, 26.2, 30.9, 39.8, 41.1, 48.5, 49.4, 82.0, 91.5, 126.8, 127.6, 128.0, 138.3, 191.7; **IR (neat):** 2947, 2869, 1689 (weak), 1602 (strong), 1400, 1129, 733.

Ethyl acetate (1.4 mol/ Rh dimer) and water (0.8 mol/Rh dimer) were observed in the NMR spectra of compound **9a** as axial ligands; ethyl acetate: δ_{H} 1.29 (t), 2.04 (s), 4.22 (q); δ_{C} 14.2, 20.9, 60.9, 173.0; H_2O : δ_{H} 2.25.

Dirhodium tetrakis [(2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-(naphthalen-2'-yl)acetate] (2S-F-2'-NA) (**9b**)


Sodium rhodium carbonate **S16** (0.24 g, 0.41 mmol), **8b** (1.10 g, 3.3 mmol) and water (50 mL) were used following the procedure for **9a** to give, following purification by column chromatography on silica gel employing hexane/ethyl acetate (92:8) as the eluent, the rhodium complex **9b** (0.50 g, 79%) as a green foamy solid. **Spec. Rot.:** $[\alpha]_{\text{D}}^{20} = +59.8$ (c 0.2, CHCl_3); **^1H NMR (400 MHz, CDCl_3):** δ = 0.64 (3H, s), 0.73–0.97 (8H, m, contains 2H, m and 2 $\times$ 3H, s at 0.89, 0.91), 1.06–1.13 (1H, m), 1.24–1.36 (1H, m), 1.52–1.57 (1H, m), 1.62–1.73 (2H, m), 2.45 (1H, bs), 4.47 (1H, s), 7.16 (1H, dd, J 8.6, 1.2), 7.39–7.52 (3H, m), 7.57 (1H, d, J 8.6), 7.69–7.77 (2H, m); **^{13}C NMR (100.6 MHz, CDCl_3):** δ = 19.9, 20.9, 26.1, 31.0, 39.8, 41.0, 48.5, 49.2, 82.1, 91.6, 124.4, 125.89, 125.94, 126.1, 127.6, 127.7, 128.2, 132.9, 135.5, 191.7; **IR (neat):** 2927, 1685 (weak), 1605 (strong), 1402, 1014, 756; **HRMS (ESI-TOF):** m/z $[\text{M} + \text{CH}_3\text{CN} + \text{H}_2\text{O} + \text{H}]^+$ calcd for $\text{C}_{90}\text{H}_{106}\text{NO}_{13}\text{Rh}_2$, 1614.5769, found 1614.4830.

Ethyl acetate (0.8 mol/ Rh dimer) and water (2 mol/Rh dimer) were observed in the NMR spectra of compound **9b** as axial ligands; ethyl acetate: δ_{H} 1.27 (t), 2.04 (s), 4.17 (q); δ_{C} 14.2, 21.0, 60.7; H_2O : δ_{H} 1.85.

SUPPORTING INFORMATION

Dirhodium tetrakis [(2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-(naphthalen-1'-yl)acetate]

(2S-F-1'-NA) (9c)




Sodium rhodium carbonate **S16** (37 mg, 0.06 mmol), **8c** (0.17 g, 0.51 mmol) in water (10 mL) were used following the procedure for **9a** to give, after purification by column chromatography on silica gel employing hexane/ethyl acetate (92:8) as the eluent, the rhodium complex **9c** (70 mg, 31%) as a green oil. **Spec. Rot.:** $[\alpha]_D^{20} = +92.6$ (c 0.29, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.67–0.93 (7H, m, contains, 1H, m, 3H, s at 0.73 and 3H, s at 0.86), 0.94–0.99 (1H, m), 1.07 (3H, s), 1.21–1.41 (2H, m), 1.50–1.70 (3H, m), 2.71 (1H, bs), 4.74 (1H, s), 7.15 (1H, d, *J* 6.9), 7.33 (2H, t, *J* 7.6), 7.42 (1H, t, *J* 7.6), 7.65 (1H, d, *J* 8.5), 7.75 (1H, d, *J* 8.1), 7.81 (1H, d, *J* 8.0); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 20.0, 21.0, 26.0, 26.1, 31.2, 40.0, 41.2, 48.6, 49.3, 79.2, 93.0, 124.7, 125.1, 125.3, 125.8, 125.9, 128.28, 128.31, 131.0, 133.6, 134.9, 191.1; **IR (neat):** 2947, 2869, 1684 (weak), 1605 (strong), 1388, 1118, 773; **HRMS (ESI-TOF):** *m/z* [M+CH₃CN+H₂O]⁺ calcd for C₉₀H₁₀₅NO₁₃Rh₂, 1613.5691, found 1613.5752.

Ethyl acetate (1.4 mol/ Rh dimer) and water (0.9 mol/Rh dimer) were observed in the NMR spectra of compound **9c** as axial ligands; ethyl acetate: δ_H 1.24 (t), 1.88 (s), 4.13 (q); δ_C 14.2, 20.8, 60.7, 172.4; H₂O: δ_H 1.85.

Dirhodium tetrakis [(2S)-2-(4'-bromophenyl)-2-(1''R,2''R,4''S)-fenchyloxyacetate]

(2S-FBrPA) (9d)




Sodium rhodium carbonate **S16** (0.26 g, 0.45 mmol), **8d** (1.33 g, 3.6 mmol) in water (50 mL) were used following the procedure for **9a** to give, after purification by column chromatography on silica gel employing hexane/ethyl acetate (92:8) as the eluent, the rhodium complex **9d** (0.47 g, 62%) as a green solid. **Spec. Rot.:** $[\alpha]_D^{20} = +17.6$ (c 0.21, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.80–1.03 (11H, m, contains 2H, m, 3 × 3H, s, one at 0.84 and two at 0.91), 1.22–1.41 (2H, m), 1.56–1.77 (3H, m), 2.46 (1H, d, *J* 1.4), 4.40 (1H, s), 7.06 (2H, d, *J* 8.4), 7.36 (2H, d, *J* 8.5); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 20.1, 20.9, 26.0, 26.1, 31.0, 39.8, 41.0, 48.4, 49.3, 81.2, 92.0, 121.8, 128.4, 131.2, 137.0, 191.3; **IR (neat):** 2948, 2858, 1685 (weak), 1604 (strong), 1386, 1129, 1010, 770.

Ethyl acetate (0.4 mol/ Rh dimer) and water (1.8 mol/Rh dimer) were observed in the NMR spectra of compound **9d** as axial ligands; ethyl acetate: δ_H 1.30 (t), 2.06 (s), 4.23 (q); δ_C 14.2, 21.0, 60.9; H₂O: δ_H 2.16.

SUPPORTING INFORMATION

Dirhodium tetrakis [(2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-(4'-methoxyphenyl)acetate]


(2S-FMeOPA) (9e)



Sodium rhodium carbonate **S16** (84 mg, 0.14 mmol), **8e** (0.37 g, 1.15 mmol) in water (20 mL) were used following the procedure for **9a** to give, after purification by column chromatography on silica gel employing hexane/ethyl acetate (90:10) as the eluent, the rhodium complex **9e** (85 mg, 40%) as a green oil. **Spec. Rot.:** $[\alpha]_D^{20} = +45.4$ (c 0.23, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.78–1.00 (11H, m, contains 2H, m, 3 × 3H, s at 0.83, 0.91 and 0.93), 1.24–1.37 (2H, m), 1.53–1.61 (1H, m), 1.62–1.78 (2H, m), 2.48 (1H, bs), 3.75 (3H, s), 4.43 (1H, s), 6.76 (2H, d, J 8.6), 7.12 (2H, d, J 8.7); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 20.0, 20.9, 26.1, 26.2, 30.9, 39.8, 41.1, 48.5, 49.3, 55.1, 81.4, 91.3, 113.3, 128.0, 130.5, 158.9, 191.7; **IR (neat):** 2949, 2869, 1691 (weak), 1604 (strong), 1511, 1247, 1100; **HRMS (ESI-TOF):** m/z [M+CH₃CN+H₂O+H]⁺ calcd for C₇₈H₁₀₆NO₁₇Rh₂, 1534.5565, found 1534.4889.

Ethyl acetate (1.4 mol/ Rh dimer) and water (0.9 mol/Rh dimer) were observed in the NMR spectra of compound **9e** as axial ligands; ethyl acetate: δ_H 1.30 (t), 2.07 (s), 4.24 (q); δ_C 14.2, 21.0, 61.0, 173.1; H₂O: δ_H 2.59.


Dirhodium tetrakis [(2S)-2-(1''R,2''S,5''R)-menthyloxy-2-phenylacetate] (2S-MPA) (9f)



Sodium rhodium carbonate **S16** (0.12 g, 0.2 mmol), **8f** (0.47 g, 1.6 mmol) in water (25 mL) were used following the procedure for **9a** to give, after purification by column chromatography on silica gel employing hexane/ethyl acetate (90:10) as the eluent, the rhodium complex **9f** (0.11 g, 40%) as a foamy green solid. **Spec. Rot.:** $[\alpha]_D^{20} = -41.8$ (c 0.2, CHCl₃); **¹H NMR (300 MHz, CDCl₃):** δ = 0.65 (1H, q, J 11.1), 0.73–0.99 (11H, m, contains, 2H, m, 3H, d, J 6.9 at 0.77, 3H, d, J 6.5 at 0.82 and 3H, d, J 7.0 at 0.91), 1.10–1.24 (2H, m), 1.53–1.66 (2H, m), 1.72–1.83 (1H, m), 2.35–2.49 (1H, m), 2.89 (1H, td, J 10.3, 3.9), 4.53 (1H, s), 7.07–7.14 (2H, m), 7.17–7.24 (3H, m); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 16.5, 21.3, 22.3, 23.1, 24.9, 31.3, 34.5, 40.3, 48.6, 78.2, 78.6, 126.9, 127.6, 128.1, 139.1, 191.6; **IR (neat):** 2922, 1602, 1398, 1099, 754; **HRMS (ESI-TOF):** m/z [M+CH₃CN+H₂O+H]⁺ calcd for C₇₄H₁₀₆NO₁₃Rh₂, 1422.5769, found 1422.6068.


Ethyl acetate (0.8 mol/ Rh dimer) and water (1.2 mol/Rh dimer) were observed in the NMR spectra of compound **9f** as axial ligands; ethyl acetate: δ_H 1.28 (t), 2.02 (s), 4.19 (q); δ_C 14.2, 21.0, 60.8, 172.5; H₂O: δ_H 2.81.

SUPPORTING INFORMATION

Dirhodium tetrakis [(2S)-2-(1''R,2''S,5''R)-menthyloxy-2-(naphthalen-2'-yl)acetate]**(2S-M-2'-NA) (9g)**

Sodium rhodium carbonate **S16** (0.11 g, 0.18 mmol), **8g** (0.50 g, 1.4 mmol) in water (20 mL) were used following the procedure for **9a** to give, after purification by column chromatography on silica gel employing hexane/ethyl acetate (92:8) as the eluent, the rhodium complex **9g** (55 mg, 29%) as a green oil. **Spec. Rot.:** $[\alpha]_D^{20} = -9.5$ (c 0.2, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.56 (1H, q, *J* 11.2), 0.65–0.99 (11H, m, contains, 2H, m, 3H, d, *J* 6.4 at 0.72, 3H, d, *J* 6.8 at 0.75, and 3H, d, *J* 7.0 at 0.91), 1.11–1.34 (2H, m), 1.45–1.67 (3H, m), 2.37–2.50 (1H, m), 2.79 (1H, td, *J* 10.3, 3.9), 4.52 (1H, s), 7.09 (1H, dd, *J* 8.5, 1.2), 7.39–7.48 (3H, m), 7.52 (1H, d, *J* 8.5), 7.72 (2H, d, *J* 7.8); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 16.5, 21.3, 22.3, 23.1, 24.9, 31.2, 34.4, 40.4, 48.5, 78.8, 79.3, 124.6, 125.8, 125.88, 125.89, 127.59, 127.64, 128.2, 132.9, 133.0, 136.5, 191.6; **IR (neat):** 2923, 1688 (weak), 1608 (strong), 1401, 1106, 758; **HRMS (ESI-TOF):** *m/z* [M+CH₃CN+H₂O+H]⁺ calcd for C₉₀H₁₁₄NO₁₃Rh₂, 1622.6395, found 1622.6412.

Ethyl acetate (0.7 mol/ Rh dimer) and *water* (1.2 mol/Rh dimer) were observed in the NMR spectra of compound **9g** as axial ligands; *ethyl acetate*: δ_H 1.28 (t), 2.02 (s), 4.19 (q); δ_C 14.2, 21.0, 60.6; *H₂O*: δ_H 2.25.

Dirhodium tetrakis [(2S)-2-(4'-bromophenyl)-2-(1''R,2''S,5''R)-menthyloxyacetate]**(2S-MBrPA) (9h)**


Sodium rhodium carbonate **S16** (58 mg, 0.10 mmol), **8h** (0.29 g, 0.79mmol) in water (15 mL) were used following the procedure for **9a** to give, after purification by column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, the rhodium complex **9h** (73 mg, 50%) as a green solid. **Spec. Rot.:** $[\alpha]_D^{20} = -23.0$ (c 0.12, CHCl₃); **¹H NMR (400 MHz, CDCl₃):** δ = 0.71–1.04 (12H, m, contains, 3H, m, 3H, d, *J* 6.8 at 0.74, 3H, d, *J* 6.4 at 0.83 and 3H, d, *J* 7.0 at 0.93), 1.10–1.35 (2H, m), 1.55–1.66 (2H, m), 1.68–1.97 (1H, m), 2.31–2.44 (1H, m), 2.86 (1H, td, *J* 10.3, 3.8), 4.45 (1H, s), 6.99 (2H, d, *J* 8.3), 7.35 (2H, d, *J* 8.4); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 16.5, 21.2, 22.3, 23.1, 25.0, 31.4, 34.4, 40.4, 48.5, 77.8, 79.4, 121.7, 128.5, 131.2, 138.0, 191.3; **IR (neat):** 2952, 2921, 1604, 1388, 1011, 772; **HRMS (ESI-TOF):** *m/z* [M+CH₃CN+H₂O]⁺ calcd for C₇₄H₁₀₁⁸¹Br₄NO₁₃Rh₂, 1737.2070, found 1737.2301

Ethyl acetate (0.2 mol/ Rh dimer) and *water* (0.8 mol/Rh dimer) were observed in the NMR spectra of compound **9h** as axial ligands; *ethyl acetate*: δ_H 1.30 (t), 2.04 (s), 4.21 (q); δ_C 14.2, 20.9, 60.9, 173.0; *H₂O*: δ_H 2.49.


SUPPORTING INFORMATION

3. Synthesis of 2,3-dihydrobenzofurans

3.1 Ester Synthesis


Methyl 2-(2-(benzyloxy)phenyl)acetate^[15] (**S17**)

Concentrated sulfuric acid (1 mL) was added to a stirring solution of 2-(2-(benzyloxy)phenyl)acetic acid (4.70 g, 19.39 mmol) in methanol (50 mL) and the reaction mixture was heated under reflux for 3 h. The reaction mixture was cooled to room temperature followed by addition of anhydrous sodium bicarbonate (1.5 g). The mixture was filtered and concentrated under reduced pressure to afford methyl 2-(2-(benzyloxy)phenyl)acetate **S17** (4.65 g, quantitative) as a pale yellow oil which was used without further purification. Spectroscopic characteristics were consistent with previously reported data.^[15] ¹H NMR (300 MHz, CDCl₃): δ = 3.63 (3H, s), 3.69 (2H, s), 5.08 (2H, s), 6.87–6.98 (2H, m), 7.18–7.45 (7H, m); IR (neat): 2950, 1736 (CO), 1244, 1156, 1015, 750, 696.


Benzyl 2-(2-(benzyloxy)phenyl)acetate^[16] (**S18**)

Anhydrous potassium carbonate (10.60 g, 77 mmol) was added in one portion to a stirring solution of 2-(2-hydroxyphenyl)acetic acid (5.0 g, 33.0 mmol) in *N,N*-dimethylformamide (75 mL) at room temperature. Neat benzyl bromide (7.8 mL, 66 mmol) was added dropwise to the reaction mixture followed by stirring at room temperature for 24 h. The reaction mixture was diluted with ether (100 mL) and water (50 mL), followed by gradual addition of aqueous hydrochloric acid (2.0 M, 100 mL). The layers were separated and the aqueous layer was extracted using ether (3 × 100 mL). The combined organic extracts were washed with aqueous hydrochloric acid (2.0 M, 2 × 75 mL), water (75 mL) and brine (75 mL), dried using magnesium sulfate and concentrated under reduced pressure to give the crude dibenzylated ester as a pale pink solid. The crude product was recrystallized from hot acetonitrile to give the purified dibenzylated ester **S18** (8.02 g, 73%) as a white solid. Spectroscopic characteristics were consistent with previously reported data.^[16] m.p. 72–75 °C (Lit. 74.4–74.6 °C);^[16] ¹H NMR (400 MHz, CDCl₃): δ = 3.73 (2H, s), 5.04 (2H, s), 5.08 (2H, s), 6.88–6.97 (2H, m), 7.18–7.42 (12H, m); IR (neat): 1735 (CO), 1173, 1013, 728.


SUPPORTING INFORMATION

3.2 α -Diazo ester synthesisMethyl 2-(2-(benzyloxy)phenyl)-2-diazoacetate^[17] (**10**)

p-ABSA (7.26g, 30 mmol), methyl 2-(2-(benzyloxy)phenyl)acetate **S17** (2.56 g, 10 mmol), DBU (6.25 mL, 42 mmol) and DMSO (30 mL) were used following the procedure described for **6a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (90:10) as the eluent, to give α -diazo ester **10** (2.71 g, 80%) as a yellow oil. Spectroscopic characteristics were consistent with previously reported data.^[17] **¹H NMR (400 MHz, CDCl₃):** δ = 3.82 (3H, s), 5.10 (2H, s), 6.97 (1H, d, *J* 8.2), 7.03 (1H, t, *J* 7.6), 7.18–7.27 (1H, m), 7.29–7.44 (5H, m), 7.57 (1H, dd, *J* 7.8, 1.4); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 52.0, 59.8, 70.7, 112.2, 114.0, 121.5, 127.5, 128.1, 128.6, 130.4, 136.3, 154.7, 166.7; **IR (neat):** 2951, 2093 (CN₂), 1694 (CO), 1247, 745, 696.

Benzyl 2-(2-(benzyloxy)phenyl)-2-diazoacetate (**12**)


p-ABSA (2.17 g, 9 mmol), benzyl 2-(2-(benzyloxy)phenyl)acetate **S18** (1.38 g, 4.2 mmol), DBU (2.0 mL, 14 mmol) and DMSO (20 mL) were used following the procedure described for **6a** to give, following column chromatography on silica gel employing hexane/ethyl acetate (90:10) as the eluent, α -diazo ester **12** (1.25 g, 83%) as a yellow oil; **¹H NMR (400 MHz, CDCl₃):** δ = 5.10 (2H, s), 5.28 (2H, s), 6.97 (1H, d, *J* 8.3), 7.03 (1H, td, *J* 7.6, 1.0), 7.20–7.24 (1H, m), 7.29–7.44 (10H, m), 7.59 (1H, dd, *J* 7.7, 1.4); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 59.9, 66.4, 70.7, 112.2, 114.0, 121.5, 127.6, 128.10, 128.15, 128.18, 128.56, 128.58, 128.61, 130.4, 136.1, 136.3, 154.7, 166.1; **IR (neat):** 2093 (CN₂), 1693 (CO), 1242, 1147, 1009, 741, 694; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₂H₁₉N₂O₃ 359.1396, found 359.1391.

Isopropyl 2-(2-(benzyloxy)phenyl)-2-diazoacetate (**13**)

Elemental sodium (0.14 g, 6 mmol) was added to IPA (20 mL) at 0 °C. The mixture was removed from the ice bath and stirred at room temperature for 30 minutes. Benzyl 2-(2-(benzyloxy)phenyl)-2-diazoacetate **12** (0.1 g, 2.8 mmol) was dissolved in IPA (20 mL) and added to the stirring sodium isopropoxide solution. The resulting solution was stirred at room temperature for 48 h then it was evaporated onto silica gel and following column chromatography on silica gel employing hexane/ethyl acetate (95:5) as the eluent, α -diazo ester **13** (0.49 g, 57%) was isolated as a yellow oil; **¹H NMR (400 MHz, CDCl₃):** δ = 1.29, (6H, d, *J* 6.2), 5.10 (2H, s), 5.16 (1H, septet, *J* 6.3), 6.96 (1H, d, *J* 8.2), 7.03 (1H, t, *J* 7.0, with further unresolved splitting), 7.18–7.25 (1H, m), 7.30–7.47 (5H, m), 7.59 (1H, dd, *J* 7.8, 1.4); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 22.1, 68.5, 70.7, 112.2, 114.3, 121.4, 127, 128, 128.3, 128.6, 130.3, 136.4, 154.6, 165.9; **IR (neat):** 2093 (CN₂), 1692 (CO), 1244, 1003, 746, 696; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₈H₁₉N₂O₃ 311.1396, found 311.1390.

SUPPORTING INFORMATION

3.3 Rhodium Catalysed C–H Insertion Reactions - 2,3-Dihydrobenzofuran Synthesis

Table SI.1: Investigation of reaction conditions on the cyclisation of **10**^a

Entry	Solvent	Atmospheric Conditions	Temperature (°C)	11a:11b:S19 ^b
1	toluene	under N ₂	rt	53:32:15 ^c
2	DCM	under N ₂	rt	1.3:0.7:98 ^d
3	toluene	under N ₂	−60→rt ^e	0.8:0.8:98.4
4	toluene	open to air	rt	0.7:0.8:98.5
5	toluene	Schlenk	rt	46:28:26
6	toluene	degassed solvent, Schlenk	rt	60:35:5

^aThe general procedure for the $\text{Rh}_2(\text{OAc})_4$ catalysed C–H insertion involved the dropwise addition of a solution of aryl diazoacetate (in 8 mL solvent) to a stirring suspension of rhodium acetate (in 3 mL solvent). Reactions were monitored by IR spectroscopy and were generally complete within 30 min. ^bThe ratio of **11a:11b:S19** was determined by the relative integration of signals at δ_{H} 6.12 (1H, d), 5.99 (1H, d) and 7.91 (1H, dd) ppm, respectively, in the ¹H NMR spectra of the crude reaction mixtures. ^cExperiment was repeated and the ratio of **11a:11b:S19** was 58:35:7. ^dExperiment was repeated and the ratio of **180a:180b:S19** was 2:1.5:96.5. ^eThe reaction mixture was found to still contain aryldiazoacetate (by IR spectroscopy of a sample withdrawn) after 1.5 h stirring between −50 °C and −60 °C so was allowed to warm up to room temperature over 30 min.


Procedure A:**General procedure for rhodium catalysed C–H insertion reactions to afford 2,3-dihydrobenzofurans**

A solution of α -diazoacetate (0.10 g, 1 equiv.) in HPLC grade toluene or freshly distilled DCM (8 mL, further degassed using freeze, pump, thaw technique) was added dropwise via syringe pump over ~30 min to a stirring solution of rhodium(II) catalyst (1 mol%) in HPLC grade toluene or freshly distilled DCM (3 mL). The reaction was carried out at 0–3 °C or −45 °C using Schlenk techniques. The mixture was stirred at this temperature for 30 minutes after addition was complete. The mixture was then concentrated under reduced pressure to provide the crude product(s), a ¹H NMR spectrum obtained and following column chromatography on silica gel (25 g) employing hexane/ethyl acetate (99:1) as the eluent, both isomers of the dihydrobenzofuran were isolated. The less polar trans isomers were isolated as colourless oils while the more polar cis isomers were found to be white solids.


SUPPORTING INFORMATION

3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran^[17] (11)


The title compound was prepared according to **Procedure A** from methyl 2-(2-(benzyloxy)phenyl)-2-diazoacetate **10** (100 mg, 0.35 mmol) and Rh₂(2S-M-2'-NA)₄ **9g** (6 mg, 1 mol%) in toluene (11 mL) at -45 °C.

(2R,3R)-trans-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran^[17] (11a)

Spectroscopic characteristics were consistent with previously reported data.^[17] **11a**, Colourless oil (45.2 mg, 50%); **Spec. Rot.:** $[\alpha]_D^{20} = -67.6$ (c 1.39, CHCl₃) [lit. $[\alpha]_D^{21} = -58.2$ (c 1.12, CHCl₃) for 80% ee of (2R,3R)-**11a**]; **HPLC:** 86% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 3.82 (3H, s), 4.29 (1H, d, *J* 7.4), 6.12 (1H, d, *J* 7.4), 6.86–6.98 (2H, m), 7.20–7.29 (1H, m), 7.29–7.46 (6H, m); **IR (neat):** 2922, 1736 (CO), 1478, 1234, 748. The preferred absolute configuration of **11a** was determined to be (2R,3R) by comparison of the recorded optical rotation values and HPLC data with literature reports.


(2S,3R)-cis-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran^[17] (11b)

Spectroscopic characteristics were consistent with previously reported data.^[17] **11b**, white solid (3.5 mg, 4%); **m.p.** 90–92 °C [lit. 90–91 °C]^[17]; **Spec. Rot.:** $[\alpha]_D^{20} = -16.3$ (c 0.01, CHCl₃) [lit. $[\alpha]_D^{21} = +57.9$ (c 1.00, CHCl₃) for 70% ee of (2R,3S)-**11b**]^[17]; **HPLC:** 18% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 3.21 (3H, s), 4.62 (1H, d, *J* 9.8), 5.99 (1H, d, *J* 9.8), 6.91–7.00 (2H, m), 7.20–7.45 (7H, m); **IR (neat):** 2980, 1727 (CO), 1480, 1104, 748. The preferred absolute configuration of **11b** was determined to be (2S,3R) by specific rotation and HPLC analysis following conversion to (2S,3S)-**11a** (*vide infra*).

Isomerization Reaction: Preparation of (2S,3S)-11a from (2S,3R)-11b


To a solution of **11b** (8.9 mg, 0.035 mmol, 33% ee) in THF (0.8 mL) at -45 °C was added a solution of NaOMe in MeOH (0.1 M, 0.08 mL, 0.008 mmol, 0.44 eq). After 0.5 h of stirring at -45 °C, the reaction was quenched with saturated ammonium chloride solution (3 mL) and the whole mixture was extracted with EtOAc (3 x 6 mL). The combined organic extracts were washed with water (2 x 5 mL) and brine (2 x 5 mL), and dried over anhydrous MgSO₄. Filtration and evaporation furnished the crude product (8.8 mg as colorless oil), $[\alpha]_D^{20} = +13.90$ (c 0.41, CHCl₃). The enantiomeric excess of **11a** was determined to be 33% by chiral HPLC analysis (*vide supra*).

SUPPORTING INFORMATION


Methyl 2-(2-(benzyloxy)phenyl)-2-oxoacetate^[18] (S19)

Spectroscopic characteristics were consistent with previously reported data.^[18] White solid; **m.p.** 84–86 °C [Lit. 84–85 °C];^[18] **¹H NMR (400 MHz, CDCl₃)**: δ = 3.34 (3H, s), 5.08 (2H, s), 7.03–7.13 (2H, m), 7.32–7.47 (5H, m), 7.54–7.62 (1H, m), 7.91 (1H, dd, *J* 7.7, 1.4); **¹³C NMR (100.6 MHz, CDCl₃)**: δ = 51.9, 71.3, 112.8, 121.5, 122.8, 128.5, 128.6, 128.7, 131.0, 135.2, 136.3, 159.5, 165.5, 186.5; **IR (neat)**: 1739 (CO), 1665, 1596 (CO), 1274, 1009, 751, 698; **HRMS (ESI-TOF)**: *m/z* [M+H]⁺ calcd for C₁₆H₁₅O₄, 271.0970, found 287.0973.


Table SI.2: Investigation of reaction conditions in the enantioselective cyclisation of **12**^a

								
Entry	Catalyst	Temp (°C)	14a:14b:S20:S21 ^b	Yield ^c		Enantiopurity ^{d,e}		
				14a (%)	14b (%)	14a (% ee)	14b (% ee)	
1 ^f	Rh ₂ (S-PTTL) ₄ 3	−45	1.2:1.5:97.3:0	–	–	–	–	
2 ^f	Rh ₂ (S-PTTL) ₄ 3	−20	0.7:1.3:5:93	–	–	–	–	
3 ^f	Rh ₂ (S-PTTL) ₄ 3	−5	0.7:4.5:5.7:89.1	–	–	–	–	
4	Rh ₂ (S-PTTL) ₄ 3	0–3	1:61.5:9:28.5 ^g	–	69	–	98 ^h	
5	Rh ₂ (S-PTTL) ₄ 3	0–3	1.5:51.5:11:36 ⁱ	–	55	–	98 ^h	
6	Rh ₂ (2S-MPA) ₄ 9f	−45	3.9:2.1:12.3:81.7 ^j	3	1	– ^k	– ^k	
7	Rh ₂ (2S-MPA) ₄ 9f	0–3	48.5:28:7.5:16 ^j	18	– ^k	78	– ^k	
8 ^f	Rh ₂ (2S-M-2'-NA) ₄ 9g	−45	9:7.8:19.2:64 ^j	– ^k	– ^k	– ^k	– ^k	
9	Rh ₂ (2S-M-2'-NA) ₄ 9g	−45	54.5:19.5:9:17 ^m	26	8	75 ⁿ	60 ^o	
10	Rh ₂ (2S-F-1'-NA) ₄ 9c	0–3	9:74:4:13 ^j	3	42	91 ⁿ	62 ^o	
11	Rh ₂ (2S-FBrPA) ₄ 9d	0–3	56:28.8:5:10.2 ^g	27	10	78 ⁿ	70 ^o	

^aReactions conducted using the general **Procedure A** for rhodium-catalysed C–H insertion reactions. ^bThe ratio of **14a:14b:S20:S21** was determined by the relative integration of signals at 6.13 (1H, d), 5.98 (1H, d), 7.93 (1H, dd) and 5.41 (1H, d), respectively, in the ¹H NMR spectra of the crude reaction mixtures. ^cIsolated yield following column chromatography. ^dEnantiopurity determined by chiral stationary phase HPLC (see **Table SI.6** for further details). ^eStereochemical assignments made by analogy to **11a** and **11b**. ^fCrude reaction mixture not purified. ^gCrude reaction mixture contains ~10% unknown side-product. ^hStereochemistry assigned as 2*R*,3*S* by analogy to **11b**. ⁱCrude reaction mixture contained ~5% unknown side-product. ^jCrude reaction mixture contained ~40% unknown side-product. ^kA sample of sufficient purity to allow accurate determination of enantiopurity was not isolated. ^lCrude reaction mixture contained ~20% unknown side-product. ^mCrude reaction mixture contained ~50% unknown side-product. ⁿStereochemistry assigned as 2*R*,3*R* by analogy to **11a**. ^oStereochemistry assigned as 2*S*,3*R* by analogy to **11b**.


Figure SI.1: Ratio of known products in Rh(II) catalysed reaction of **12**.**3-Benzyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14)**

The title compound was prepared according to **Procedure A** from benzyl 2-(2-benzyloxyphenyl)-2-diazoacetate **12** (100 mg, 0.28 mmol) and Rh₂(2S-MPA)₄ **9f** (4 mg, 1 mol%) in toluene (11 mL).


(2R,3R)-trans-3-Benzyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14a)

Colourless oil (50 mg, 54%); **Spec. Rot.**: $[\alpha]_D^{20} = -76.2$ (c 2.11, CHCl₃); **HPLC**: 79% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃)**: δ = 4.32 (1H, d, *J* 7.5), 5.20–5.29 (2H, fine AB q, *J* 12.5), 6.13 (1H, d, *J* 7.5), 6.86–6.95 (2H, m), 7.20–7.28 (1H, m), 7.28–7.43 (11H, m, ArH); **¹³C NMR (100.6 MHz, CDCl₃)**: δ = 55.9, 67.5, 85.5, 110.0, 121.0, 123.7, 125.3, 125.8, 128.3, 128.4, 128.5, 128.7, 128.8, 129.7, 135.4, 140.6, 159.4, 170.7; **IR (neat)**: 3034, 1733 (CO), 1478, 1232, 748, 696; **HRMS (ESI-TOF)**: *m/z* [M+H]⁺ calcd for C₂₂H₁₉O₃, 331.1334, found 331.1345.


SUPPORTING INFORMATION

(2S,3R)-cis-3-Benzoyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14b)

White solid (15 mg, 16%); **m.p.** 89–90 °C; **Spec. Rot.:** $[\alpha]_D^{20} = -10.4$ (c 0.47, CHCl₃); **HPLC:** 22% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 4.50 (1H, d, *J* 12.2), 4.64 (1H, d, *J* 9.8), 4.71 (1H, d, *J* 12.3), 5.98 (1H, d, *J* 9.8), 6.90–7.03 (4H, m), 7.19–7.40 (10H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 53.8, 66.7, 85.7, 110.0, 121.3, 124.8, 125.9, 126.4, 128.17, 128.25, 128.28, 128.4, 128.5, 129.7, 135.2, 137.0, 160.4, 169.8; **IR (neat):** 3033, 1733 (CO), 1478, 1150, 748, 696; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₂H₁₉O₃, 331.1334, found 331.1345.

Methyl 2-(2-(benzyloxy)phenyl)-2-oxoacetate (S20)


¹H NMR (400 MHz, CDCl₃): δ = 4.78 (2H, s), 4.99 (2H, s), 6.99–7.04 (1H, m), 7.05–7.12 (1H, m), 7.16–7.43 (10H, m), 7.52–7.60 (1H, m), 7.93 (1H, dd, *J* 7.8, 1.5).

Benzyl 2-(2-(benzyloxy)phenyl)-2-hydroxyacetate (S21)

¹H NMR (400 MHz, CDCl₃): δ = 3.60 (1H, d, *J* 6.0, appears reduced in a D₂O shake), 4.94–5.07 (2H, ABq, *J* 11.9), 5.08–5.18 (2H, ABq, *J* 12.4), 5.41 (1H, d, 4.3), 6.89–7.01 (2H, m), 7.11–7.19 (2H, m), 7.22–7.39 (10H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 67.2, 70.2, 70.3, 112.3, 121.1, 127.2, 127.9, 128.0, 128.2, 128.5, 128.6, 129.5, 129.9, 135.4, 136.5, 156.2, 173.5; **IR (neat):** 3100–3600, 1733 (CO), 1492, 1453, 1242, 1246, 752, 696.


3-Isopropoxyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (15)

The title compound was prepared according to **Procedure A** from isopropyl 2-(2-benzyloxyphenyl)-2-diazoacetate **13** (100 mg, 0.32 mmol) and Rh₂(2S-MPA)₄ **9f** (4 mg, 1 mol%) in toluene (11 mL).

(2R,3R)-trans-3-Isopropoxyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (15a)

Colourless oil (31.8 mg, 35%); **Spec. Rot.:** $[\alpha]_D^{20} = -53.6$ (c 1.20, CHCl₃); **HPLC:** 78% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.30 (3H, d, *J* 6.2), 1.31 (3H, d, *J* 6.2), 4.23 (1H, d, *J* 7.7), 5.13 (1H, septet, *J* 6.3), 6.11 (1H, d, *J* 7.7), 6.86–6.97 (2H, m), 7.18–7.28 (1H, m), 7.28–7.45 (6H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 21.86, 21.89, 55.9, 69.3, 85.5, 109.9, 120.9, 124.2, 125.0, 125.8, 128.3, 128.8, 129.6, 140.8, 159.3, 170.3; **IR (neat):** 2981, 1729 (CO), 1478, 1234, 749, 698; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₈H₁₉O₃, 283.1334, found 283.1310.


SUPPORTING INFORMATION

(2S,3R)-cis-3-Isopropoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (15b)


White solid (15.4 g, 17%); **m.p.** 56–58 °C; **Spec. Rot.:** $[\alpha]_D^{20} = -12.6$ (c 0.12, CHCl₃); **HPLC:** 27% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 0.67 (3H, d, *J* 6.2), 0.92 (3H, d, *J* 6.3), 4.52–4.63 (2H, m, contains 1H, septet), 5.97 (1H, d, *J* 9.9), 6.91–6.99 (2H, m), 7.21–7.42 (7H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 20.9, 21.4, 53.7, 68.5, 85.6, 109.9, 121.2, 125.1, 125.9, 126.6, 128.2, 128.3, 129.4, 137.3, 160.3, 169.4; **IR (neat):** 2984, 1727 (CO), 1480, 1101, 757, 695; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₈H₁₉O₃, 283.1334, found 283.1310.

SUPPORTING INFORMATION

4. Synthesis of Thiopyran Dioxides


4.1 Preparation of α -Diazo- β -oxosulfone CompoundsMethyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate^[19] (**16**)

Potassium carbonate (3.07 g, 22.2 mmol) was added to a stirring solution of methyl 2-((4'-phenylbutyl)sulfonyl)acetate^[19a] (5.0 g, 18.5 mmol) in acetonitrile (100 mL) at room temperature. The reaction mixture was stirred for 10 min before being cooled to 0 °C while a solution of 4-acetamidobenzenesulfonyl azide (*p*-ABSA) (5.78 g, 24.0 mmol) in acetonitrile (50 mL) was added. The reaction mixture was stirred at 0 °C for 30 min, returned to room temperature and stirred overnight before the addition of a non-polar co-solvent, hexane (60 mL) and diethyl ether (30 mL), to precipitate sulfonamide salts. The reaction mixture was stirred for a further 15 minutes, concentrated under reduced pressure and dichloromethane was added in order to decant from the bulk sulfonamide salts. Purification by column chromatography on silica gel, using ethyl acetate/hexane (20:80 to 40:60) as eluent, gave pure methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate **16** as a yellow oil (5.08 g, 93%). Spectroscopic characteristics were consistent with previously reported data.^[19] ¹H NMR (300 MHz, CDCl₃): δ = 1.69–1.94 (4H, m), 2.65 (2H, t, *J* 7.2), 3.34–3.43 (2H, m), 3.85 (3H, s), 7.11–7.23 (3H, m), 7.23–7.33 (2H, m); ¹³C NMR (75.5 MHz, CDCl₃): δ = 22.1, 29.6, 35.1, 53.0, 56.4, 72.8, 126.0, 128.2, 128.4, 141.0, 160.4; IR (neat): 2125 (CN₂), 1713 (CO), 1332, 1293, 1145, 1083 (SO₂); HRMS (ESI-TOF): *m/z* [M+H]⁺ calcd for C₁₃H₁₇N₂O₄S, 297.0904, found 297.0907.


Methyl 2-diazo-2-((4'-(*p*-tolyl)butyl)sulfonyl)acetate^[19] (**19**)

The title compound was prepared using the procedure described for methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate **16**, using potassium carbonate (1.75 g, 12.7 mmol), methyl 2-((4'-(*p*-tolyl)butyl)sulfonyl)acetate^[19a] (3.0 g, 10.6 mmol) in acetonitrile (100 mL) and *p*-ABSA (3.30 g, 13.7 mmol) in acetonitrile (30 mL). The mixture was stirred at 0 °C for 30 min, returned to room temperature and stirred overnight. Purification by column chromatography on silica gel, using ethyl acetate/hexane (20:80) as eluent, gave the pure product methyl 2-diazo-2-((4'-(*p*-tolyl)butyl)sulfonyl)acetate **19** as a yellow oil (2.68 g, 82%) which solidified upon storage in the freezer. Spectroscopic characteristics were consistent with previously reported data.^[19] *m.p.* 35–37 °C; ¹H NMR (300 MHz, CDCl₃): δ = 1.66–1.91 (4H, m), 2.30 (3H, s), 2.60 (2H, t, *J* 7.3), 3.32–3.42 (2H, m), 3.84 (3H, s), 7.03 (2H, apparent d, *J* 8.0), 7.08 (2H, apparent d, *J* 8.0); ¹³C NMR (75.5 MHz, CDCl₃): δ = 20.8, 22.0, 29.6, 34.5, 52.8, 56.3, 72.7, 128.0, 129.0, 135.3, 137.8, 160.3; IR (neat): 2125 (CN₂), 1713 (CO), 1333, 1293, 1145, 1082 (SO₂).


SUPPORTING INFORMATION

Methyl 2-diazo-2-((4'-(4"-methoxyphenyl)butyl)sulfonyl)acetate^[19] (20)

The title compound was prepared using the procedure described for methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate **16**, using potassium carbonate (1.66 g, 12.0 mmol), methyl 2-((4'-(4"-methoxyphenyl)butyl)sulfonyl)acetate^[19a] (3.0 g, 10.0 mmol) in acetonitrile (100 mL) and *p*-ABSA (3.12 g, 13.0 mmol) in acetonitrile (30 mL). The mixture was stirred at 0 °C for 30 min, returned to room temperature and stirred overnight. Purification by column chromatography on silica gel, using ethyl acetate/hexane (20:80) as eluent, gave the pure product methyl 2-diazo-2-((4'-(4"-methoxyphenyl)butyl)sulfonyl)acetate **20** as a yellow solid (2.74 g, 84%). Spectroscopic characteristics were consistent with previously reported data.^[19] **m.p.** 50–51 °C (lit. 49–51 °C);^[19b] ¹H NMR (300 MHz, CDCl₃): δ= 1.65–1.93 (4H, m), 2.59 (2H, t, *J* 7.3), 3.30–3.43 (2H, m), 3.78 (3H, s), 3.85 (3H, s), 6.82 (2H, apparent d, *J* 8.6), 7.07 (2H, apparent d, *J* 8.6); ¹³C NMR (75.5 MHz, CDCl₃): δ= 22.0, 29.8, 34.2, 53.0, 55.2, 56.4, 72.8, 113.8, 129.1, 133.0, 157.9, 160.4; IR (neat): 2117 (CN₂), 1724 (CO), 1331, 1299, 1147 (SO₂).


Methyl 2-diazo-2-((4'-(4"-fluorophenyl)butyl)sulfonyl)acetate^[19a] (21)

The title compound was prepared using the procedure described for methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate **16**, using potassium carbonate (1.81 g, 13.1 mmol), methyl 2-((4'-(4"-fluorophenyl)butyl)sulfonyl)acetate^[19a] (3.15 g, 10.9 mmol) in acetonitrile (100 mL) and *p*-ABSA (3.41 g, 14.2 mmol) in acetonitrile (30 mL). The mixture was stirred at 0 °C for 30 min, returned to room temperature and stirred overnight. Purification by column chromatography on silica gel, using ethyl acetate/hexane (20:80) as eluent, gave the pure product methyl 2-diazo-2-((4'-(4"-fluorophenyl)butyl)sulfonyl)acetate **21** as a yellow oil (3.03 g, 88%). Spectroscopic characteristics were consistent with previously reported data.^[19a] ¹H NMR (300 MHz, CDCl₃): δ= 1.64–1.94 (4H, m), 2.63 (2H, t, *J* 7.3), 3.35–3.44 (2H, m), 3.86 (3H, s), 6.91–7.02 (2H, m), 7.06–7.16 (2H, m); ¹³C NMR (75.5 MHz, CDCl₃): δ= 22.0, 29.7, 34.3, 53.0, 56.3, 72.8, 115.1 (d, ²*J*_{CF} 21.2), 129.6 (d, ³*J*_{CF} 7.9), 136.6 (d, ⁴*J*_{CF} 3.3), 160.4, 161.3 (d, ¹*J*_{CF} 244.1); IR (neat): 2126 (CN₂), 1713 (CO), 1333, 1294, 1216, 1145, 1083 (SO₂).


2-Diazo-1-phenyl-2-((4'-phenylbutyl)sulfonyl)ethan-1-one^[19] (22)

The title compound was prepared using the procedure described for methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate **16**, using potassium carbonate (1.57 g, 11.38 mmol), 1-phenyl-2-((4'-phenylbutyl)sulfonyl)ethan-1-one^[19a] (3.0 g, 9.48 mmol) in acetonitrile (100 mL) and *p*-ABSA (2.96 g, 12.33 mmol) in acetonitrile (30 mL). The mixture was stirred at 0 °C for 30 min, returned to room temperature and stirred overnight. Purification by column chromatography on silica gel, using ethyl acetate/hexane (10:90–30:70) as eluent, gave the pure product 2-diazo-1-phenyl-2-((4'-phenylbutyl)sulfonyl)ethan-1-one **22** as a yellow solid (2.79 g, 86%). Spectroscopic characteristics were consistent with previously reported data.^[19] **m.p.** 93–95 °C (lit. 97–99 °C);^[19b] ¹H NMR (300 MHz, CDCl₃): δ= 1.73–1.95 (4H, m), 2.66 (2H, t, *J* 7.2), 3.50–3.60 (2H, m), 7.10–7.21 (3H, m), 7.22–7.31 (2H, m), 7.45–7.54 (2H, m), 7.56–7.67 (3H, m); ¹³C NMR (75.5 MHz, CDCl₃): δ= 22.1, 29.6, 35.1, 56.5, 80.1, 126.0, 127.3, 128.3, 128.4, 129.0, 133.3, 135.6, 141.0, 183.3; IR (neat): 2112 (CN₂), 1647 (CO), 1327, 1282, 1224, 1137 (SO₂).

SUPPORTING INFORMATION

Benzyl 2-diazo-2-(dodecylsulfonyl)acetate^[19] (23)


The title compound was prepared using the procedure described for methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate **16**, using potassium carbonate (2.17 g, 15.7 mmol), benzyl 2-(dodecylsulfonyl)acetate^[19a] (5.0 g, 13.1 mmol) in acetonitrile (100 mL) and *p*-ABSA (4.08 g, 17.0 mmol) in acetonitrile (50 mL). The mixture was stirred at 0 °C for 30 min, returned to room temperature and stirred overnight. Purification by column chromatography on silica gel, using ethyl acetate/hexane (20:80) as eluent, gave the pure product benzyl 2-diazo-2-(dodecylsulfonyl)acetate **23** as a yellow solid (4.19 g, 78%). Spectroscopic characteristics were consistent with previously reported data.^[19b] **m.p.** 50–51 °C (lit. 48–50 °C);^[19] **¹H NMR (300 MHz, CDCl₃):** δ= 0.83–0.94 (3H, apparent t), 1.19–1.45 (18H, m), 1.72–1.86 (2H, m), 3.30–3.39 (2H, m), 5.29 (2H, s), 7.37 (5H, s); **¹³C NMR (75.5 MHz, CDCl₃):** δ= 14.1, 22.6, 27.9, 28.9, 29.2, 29.3, 29.4, 29.52, 29.53, 31.8, 56.7, 67.8, 73.0, 128.4, 128.7, 128.8, 134.6, 160.0; **IR (neat):** 2124 (CN₂), 1720 (CO), 1330, 1288, 1217, 1142 (SO₂).

Methyl 2-((2'-cyclohexylethyl)sulfonyl)-2-diazoacetate^[20] (24)

The title compound was prepared using the procedure described for methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate **16**, using potassium carbonate (1.85 g, 13.4 mmol), methyl 2-((2-cyclohexylethyl)sulfonyl) acetate^[20] (3.03 g, 12.2 mmol) in acetonitrile (30 mL) and *p*-ABSA (2.93 g, 12.2 mmol) in acetonitrile (30 mL). The mixture was stirred at 0 °C for 30 min, returned to room temperature and stirred overnight. Purification by column chromatography on silica gel, using ethyl acetate/hexane (20:80) as eluent, gave pure methyl 2-((2'-cyclohexylethyl)sulfonyl)-2-diazoacetate **24** as a yellow oil (2.65 g, 79%). Spectroscopic characteristics were consistent with previously reported data.^[20] **¹H NMR (300 MHz, CDCl₃):** δ= 0.84–1.05 (2H, m), 1.06–1.46 (4H, m), 1.58–1.81 (7H, m), 3.34–3.46 (2H, symmetrical m), 3.88 (3H, s); **¹³C NMR (75.5 MHz, CDCl₃):** δ= 25.9, 26.1, 29.5, 32.7, 36.4, 52.9, 54.6, 72.8, 160.4; **IR (neat):** 2124 (CN₂), 1713 (CO), 1331, 1294, 1144 (SO₂).

SUPPORTING INFORMATION

4.2 Rhodium Catalysed C–H Insertion Reactions – Thiopyran Dioxide synthesis


Table SI.3: Chiral rhodium(II) catalysis of α -diazo- β -oxosulfones **16**, **19–23**

Entry ^a	Diazo	R	R ¹	d.r. ^b A:B	A % Yield ^c (% ee) ^d	B % Yield ^c (% ee) ^d	C & D % Yield ^{c,e,f}	E % Yield
					17a	17b	18a&b	S22
1	16	Ph	OMe	90:10	41 (92) ^h	5 (4) ⁱ	21	0
2^g	16	Ph	OMe	92:8	64 (92) ^h	4 (6) ⁱ	23	1
					25a	25b	S23a&b	S24
3	19	<i>p</i> -MeC ₆ H ₄	OMe	93:7	50 (89) ^h	4 (11) ^j	11	7
					26a	26b	S25a&b	S26
4	20	<i>p</i> -OMeC ₆ H ₄	OMe	– ^k	42 (51) ^h	11 (9) ⁱ	13	8
					27a	27b	S27a&b	S28
5	21	<i>p</i> -FC ₆ H ₄	OMe	89:11	53 (90) ^h	7 (6) ⁱ	12	1
					28a	28b	S29a&b	–
6ⁱ	22	Ph	Ph	– ^k	1 (69) ^m	2 ⁿ (–)	25 ⁿ	–
					29a	29b	S30a&b	–
7	23	C ₈ H ₁₇	OBn	– ^k	31 (56) ^h	0	0	–

^aThe relative ratio of C–H insertion products could not be determined due to overlapping signals in the ¹H NMR spectra of the crude product mixtures. The spectra for the samples were recorded in both CDCl₃ and in C₆D₆ in an attempt to resolve signals.

^bThe diastereomeric ratio was determined by integration of the methyl signals in the ¹H NMR spectra of the crude product mixtures in C₆D₆. ^cIsolated yield after column chromatography. ^dThe enantiomeric excess was measured by chiral-phase HPLC analysis (for full details see **Table SI.6**). ^eThe *trans*-sulfolane (**C**) and *cis*-sulfolane (**D**) were not isolated as pure compounds due to epimerisation of the *cis*-sulfolane (**D**) to the *trans*-sulfolane (**C**) during column chromatography on silica gel. The isolated yields of *trans*-sulfolane (**C**) are for samples which contain traces of the *cis*-sulfolane (**C**) (See Experimental for details). ^fClear baseline resolution of chiral HPLC peaks was difficult to achieve for the mixed sulfolane samples and therefore enantiomeric excess was unable to be determined for the *trans*-sulfolane (**C**) and *cis*-sulfolane (**D**). ^gReaction was conducted on a 1 gram scale (3.5 mmol). ^hThe major enantiomer has a 2*R*,3*S* configuration. ⁱThe major enantiomer has a 2*S*,3*S* configuration. ^jThe major enantiomer has a 2*R*,3*R* configuration. ^kDiastereomeric ratio was not determined due to overlapping signals in the ¹H NMR spectra of the crude product mixtures. ^mReaction conducted under reflux. ⁿAbsolute configuration undetermined. ^oSample was not isolated pure. Conatined unknown side-products. ^p**29b** and **S30a&b** were isolated in 42% yield as a combined mixture.


SUPPORTING INFORMATION

Table SI.4: Chiral rhodium(II) catalysis of α -diazo- β -oxosulfones **24**

Entry	Rhodium catalyst	Solvent	Temp (°C)	Time (h)	d.r. ^a 30a:30b	30a % Yield ^b (% ee) ^c	30b % Yield ^b (% ee) ^c
No Molecular Sieves used							
1	Rh ₂ (S-DOSP) ₄	CH ₂ Cl ₂	rt	0.5	96:4	64 (22) ^d	-
2^e	Rh ₂ (5R-MEPY) ₄	CH ₂ Cl ₂	reflux	24	-	0	0
3	Rh ₂ (S-PTTL) ₄	CH ₂ Cl ₂	rt	0.5	98:2	80 (36) ^d	-
4	Rh ₂ (S-PTPA) ₄	CH ₂ Cl ₂	rt	0.5	94:6	65 (25) ^d	-
5	Rh ₂ (S-TCPTTL) ₄	CH ₂ Cl ₂	rt	0.5	97:3	81 (10) ^d	-
6	Rh ₂ (2S-F-2'-NA) ₄	CH ₂ Cl ₂	rt	2	94:6	67 (60) ^d	-
7	Rh ₂ (S-PTTL) ₄	toluene	rt	0.5	97:3	63 (43) ^d	-
8	Rh ₂ (S-PTTL) ₄	toluene	-20	2	97:3	62 (47) ^d	-
9	Rh ₂ (2S-F-2'-NA) ₄	toluene	-20	2	91:9	52 (62) ^d	-
10	Rh ₂ (2S-F-2'-NA) ₄	toluene	-70	2	91:9	56 (60) ^d	-
4Å Molecular Sieves used							
11	Rh ₂ (2S-FBrPA) ₄	CH ₂ Cl ₂	-20	18	88:12	82 (53) ^d	12 (27) ^f
12	Rh ₂ (2S-MBrPA) ₄	CH ₂ Cl ₂	-20	18	92:8	88 (28) ^d	6 (13) ^f
13	Rh ₂ (2S-F-2'-NA) ₄	CH ₂ Cl ₂	-20	18	95:5	85 (84) ^d	-
14^g	Rh ₂ (2S-F-2'-NA) ₄	CH ₂ Cl ₂	-20	18	96:4	91 (84) ^d	2 (~0)


^aDiastereomeric ratio was calculated from ¹H NMR spectra of the crude product mixture. ^bIsolated yield after column chromatography. ^cThe enantiomeric excess was measured by chiral-phase HPLC analysis (for full details see **Table SI.6**). ^dSecond peak in the HPLC trace. ^eOnly starting material (**24**) was evident in the ¹H NMR spectrum of the crude product mixture. ^fThe major enantiomer has a (1S,4aS,8aR) configuration. ^gReaction conducted on a 2 mmol scale compared to 0.35–0.85 mmol for **entry 1–13**.

SUPPORTING INFORMATION


4.2.1. Cyclisation of α -diazo- β -oxosulfone **16**Methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (**17a**)

An oven dried 60 mL Schlenk tube (27 × 150 mm) containing 4 Å molecular sieves (~ 600–800 mg) and a magnetic stir bar was flame dried and cooled under nitrogen. $\text{Rh}_2(2\text{S-F-2'-NA})_4$ **9b** (53.1 mg, 34.2 μmol) was charged as a solid to the Schlenk tube. Methyl 2-diazo-2-(4'-phenylbutylsulfonyl)acetate **16** (1.01 g, 3.42 mmol) was charged into a dry 25 mL roundbottom flask. The Schlenk tube and roundbottom flask were both placed under vacuum and back filled with nitrogen 3 times. The $\text{Rh}_2(2\text{S-F-2'-NA})_4$ **9b** was dissolved in deoxygenated dichloromethane (DCM, 5 ml), and the methyl 2-diazo-2-(4'-phenylbutylsulfonyl)acetate **16** was dissolved in deoxygenated DCM (20 ml). The Schlenk tube containing the rhodium solution was placed into an ethanol cooling bath set at $-20\text{ }^\circ\text{C}$ while stirring. Once the ethanol bath had stabilised at $-20\text{ }^\circ\text{C}$, the diazo **16** solution was added dropwise over 240 minutes via syringe to the Schlenk tube using a syringe pump. The reaction solution was stirred overnight at $-20\text{ }^\circ\text{C}$ before warming to room temperature. The reaction solution was filtered through a short pad of Celite® and activated charcoal, and concentrated under reduced pressure to give the crude product, which was then analysed by ^1H NMR spectroscopy in CDCl_3 and in C_6D_6 . The ^1H NMR in CDCl_3 showed that compound **17a** was the major product, d at δ_{H} 4.16 (J 12.2), with minor compounds: **17b**, s at δ_{H} 3.53, **18a**, s at δ_{H} 3.74, **18b**, s at δ_{H} 3.83 and **S22**, d at δ_{H} 6.55 (J 15.8). The ^1H NMR analysed in C_6D_6 allowed the determination of the thiopyran diastereomeric ratio (92:8 dr, **17a**:**17b**, s at δ_{H} 3.06: s at δ_{H} 2.98) compared to overlapping peaks in the CDCl_3 ^1H NMR spectra. The crude product mixture, which was loaded using Celite®, was purified using column chromatography on silica gel, employing ethyl acetate/hexane (10:90 to 50:50) as eluent, and gave methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **17a** (589 mg, 64%), methyl (2*S*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **17b** (41 mg, 4%), methyl (2*R**,3*R**)-3-benzyltetrahydrothiophene-2-carboxylate 1,1-dioxide **18a** (208 mg, 23%, of which contains ~15% **18b**, s at 3.83) and methyl 2-((4'-phenylbut-3'-en-1'-yl)sulfonyl)acetate **S22** (8 mg, 1%). **18a** or **18b** were not isolated as single pure compounds, but as a mixture. An enriched **18b** sample was obtained by taking the first few test tubes of the second least polar component, and an enriched **18a** sample was obtained by taking the last few test tubes of the third least polar component. **17a**, most polar component, white solid; m.p. 152–154 $^\circ\text{C}$; Spec. Rot.: $[\alpha]_{\text{D}}^{20} -34.9$ (c 1.0, CH_2Cl_2); HPLC: 92% ee (determined by chiral phase HPLC, see Table SI.6 for HPLC conditions); ^1H NMR (300 MHz, CDCl_3): δ = 1.64–1.81 (1H, m), 2.03–2.14 (1H, m), 2.14–2.40 (2H, m), 3.02–3.15 (1H, m), 3.26 (1H, dt, J 14.2, 3.6, 3.6), 3.58 (3H, s), 3.64 (1H, td, J 12.4, 12.4, 3.3), 4.16 (1H, d, J 12.2), 7.15–7.36 (5H, m); ^1H NMR (300 MHz, C_6D_6): δ = 0.78–0.97 (1H, m), 1.04–1.16 (1H, m), 1.25–1.40 (1H, m), 1.64–1.82 (1H, m), 2.23 (1H, td, J 13.8, 13.8, 3.6), 2.43–2.53 (1H, m), 3.06 (3H, s), 3.57 (1H, td, J 12.4, 12.4, 3.4), 3.91 (1H, d, J 12.2), 6.87–7.12 (5H, m); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 23.2, 32.7, 45.5, 52.3, 53.1, 71.4, 127.2, 127.7, 129.0, 140.1, 163.1; IR (neat): 1732 (CO), 1320, 1293, 1142, 1124 (SO_2); HRMS (ESI-TOF): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{17}\text{O}_4\text{S}$, 269.0842, found 269.0845; Elemental Analysis: calcd (%) for $\text{C}_{13}\text{H}_{16}\text{O}_4\text{S}$: C, 58.19; H, 6.01, found: C, 58.41; H, 6.12.


SUPPORTING INFORMATION

Methyl (2S,3S)-3-phenyltetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide^[19] 17b


Methyl (2S,3S)-3-phenyltetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide **17b** (41 mg, 4%) was isolated as a white solid (least polar component). Spectroscopic characteristics were consistent with previously reported data.^[19] **m.p.** 112–115 °C (lit 116–118 °C);^[19b] **¹H NMR (300 MHz, CDCl₃):** δ= 1.86 (1H, dq, *J* 14.0, 3.3, 3.3, 3.3), 2.11–2.36 (2H, m), 2.61 (1H, dq, *J* 13.3, 13.3, 13.3, 4.0), 3.04 (1H, dq, *J* 14.1, 3.3, 3.3, 3.3), 3.53 (3H, s), 3.61–3.75 (2H, m), 3.99 (1H, dd, *J* 4.5, 2.9), 7.15–7.21 (2H, m), 7.23–7.37 (3H, m); **¹H NMR (300 MHz, C₆D₆):** δ= 1.22 (1H, dq, *J* 13.8, 3.4, 3.4, 3.4), 1.30–1.43 (1H, m), 1.62–1.81 (1H, m), 2.23–2.47 (2H, m), 2.98 (3H, s), 3.30–3.46 (2H, m), 3.99 (1H, dd, *J* 4.5, 2.9), 6.76–6.85 (2H, m), 6.92–7.05 (3H, m); **¹³C NMR (75.5 MHz, CDCl₃):** δ= 23.0, 23.7, 44.6, 47.9, 52.7, 70.5, 127.0, 127.9, 129.0, 139.6, 166.6; **IR (neat):** 1725 (CO), 1310, 1294, 1169, 1112 (SO₂); **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₃H₁₇O₄S, 269.0842, found 269.0839.

Methyl (2R*,3R*)-3-benzyltetrahydrothiophene-2-carboxylate 1,1-dioxide (18a)

Methyl (2R*,3R*)-3-benzyltetrahydrothiophene-2-carboxylate 1,1-dioxide **18a** (208 mg, 23%, of which contains ~15% **18b**, s at 3.83) was isolated as a colourless oil (an enriched **18a** sample was obtained by taking the last few test tubes of the third least polar component); **¹H NMR (300 MHz, CDCl₃):** δ= 1.78–1.96 (1H, m), 2.21–2.34 (1H, m), 2.73 (1H, dd, *J* 13.5, 8.0), 2.91 (1H, dd, *J* 13.5, 6.4), 2.97–3.13 (2H, m), 3.27 (1H, qd, *J* 13.0, 7.2, 2.1), 3.66 (1H, d, *J* 9.8), 3.74 (3H, s), 7.09–7.19 (2H, m), 7.20–7.35 (3H, m); **¹H NMR (300 MHz, C₆D₆):** δ= 0.96–1.14 (1H, m), 1.21–1.40 (1H, m), 2.00 (1H, dd, *J* 13.5, 8.0), 2.18–2.31 (1H, m), 2.37–2.47 (2H, m), 2.64–2.80 (1H, m), 3.29 (3H, s), 3.46 (1H, d, *J* 9.9 Hz), 6.79–6.86 (2H, m), 6.97–7.10 (3H, m); **¹³C NMR (75.5 MHz, CDCl₃):** δ= 26.2, 39.9, 41.6, 52.7, 53.3, 70.3, 127.0, 128.7, 129.1, 137.1, 165.5; **IR (neat):** 1739 (CO), 1315, 1268, 1168, 1119 (SO₂); **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₃H₁₇O₄S, 269.0842, found 269.0841.


Methyl (2S*,3R*)-3-benzyltetrahydrothiophene-2-carboxylate 1,1-dioxide (18b)

Methyl (2S*,3R*)-3-benzyltetrahydrothiophene-2-carboxylate 1,1-dioxide **18b** was isolated as a mixture with **18a** (an enriched **18b** sample was obtained by taking the first few test tubes of the second least polar component); characteristic peaks of **18b**: **¹H NMR (300 MHz, CDCl₃):** δ= 3.38–3.51 (1H, m), 3.80 (1H, d, *J* 6.3), 3.83 (3H, s).


Methyl 2-((4'-phenylbut-3'-en-1'-yl)sulfonyl)acetate (S22)

Methyl 2-((4'-phenylbut-3'-en-1'-yl)sulfonyl)acetate **S22** (8 mg, 1%) was isolated as a mixture with **18a**; colourless oil; **¹H NMR (600 MHz, CDCl₃):** δ= 2.77–2.85 (2H, m), 3.40–3.46 (2H, m), 3.83 (3H, s), 4.00 (2H, s), 6.19 (1H, dt, *J* 15.8, 7.0, 7.0), 6.55 (1H, d, *J* 15.8), 7.22–7.39 (5H, m); **¹H NMR (300 MHz, C₆D₆):** δ= 2.37–2.48 (2H, m), 2.89–2.98 (2H, m), 3.15 (3H, s), 3.36 (2H, s), 5.75 (1H, dt, *J* 15.8, 7.0), 6.14 (1H, d, *J* 15.8), 6.74–7.16 (5H, m); **¹³C NMR (150.9 MHz, CDCl₃):** δ= 25.7, 53.0, 53.4, 57.7, 124.8, 126.2, 127.8, 128.7, 133.2, 136.5, 163.6; **IR (neat):** 1744 (CO), 1317, 1300, 1263, 1143, 1111 (SO₂); **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₃H₁₇O₄S, 269.0842, found 269.0838.

SUPPORTING INFORMATION

4.2.2. Cyclisation of α -diazo- β -oxosulfone 19Methyl (2*R*,3*S*)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (25a)


The title compound was prepared following the procedure described for methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **17a** using methyl 2-diazo-2-(4'-(4"-methylphenyl)butylsulfonyl)acetate **19** (113 mg, 0.36 mmol), Rh₂(2*S*-F-2'-NA)₄ **9b** (5.7 mg, 3.64 μ mol) in deoxygenated DCM (15 mL). The diazo **19** solution was added dropwise over 120 minutes via syringe to the Schlenk tube using a syringe pump. The reaction solution was stirred overnight at -20 °C before warming to room temperature. The reaction solution was filtered through a short pad of Celite® and activated charcoal, and concentrated under reduced pressure to give the crude product, which was then analysed by ¹H NMR spectroscopy in CDCl₃ and in C₆D₆. The ¹H NMR in CDCl₃ showed that compound **25a** was the major product, d at δ_{H} 4.16 (*J* 12.2), with minor compounds: **25b**, s at δ_{H} 3.56, **S23a**, s at δ_{H} 3.76, **S23b**, s at δ_{H} 3.83 and **S24**, d at δ_{H} 6.51 (*J* 15.8). The ¹H NMR analysed in C₆D₆ allowed the determination of the thiopyran diastereomeric ratio (93:7 dr, **25a**:**25b**, s at δ_{H} 3.10: s at δ_{H} 3.02) compared to overlapping peaks in the CDCl₃ ¹H NMR spectra. The crude product mixture, which was loaded using Celite®, was purified using column chromatography on silica gel, employing ethyl acetate/hexane (10:90 to 30:70) as eluent, and gave methyl (2*R*,3*S*)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **25a** (51 mg, 50%), methyl (2*R*,3*R*)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **25b** (4 mg, 4%), methyl (2*R**,3*R**)-3-(4'-methylbenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S23a** (11 mg, 11%, of which contains <10% **S23b**, s at 3.83), and methyl 2-((4"-methyphenyl)but-3'-en-1'-yl)sulfonyl)acetate **S24** (7 mg, 7%). **S23a** or **S23b** were not isolated as single pure compounds, but as a mixture. An enriched **S23b** sample was obtained by taking the first few test tubes of the second least polar component, and an enriched **S23a** sample was obtained by taking the last few test tubes of the third least polar component. **25a**, most polar component, white solid; m.p. 150–151 °C; Spec. Rot.: [α]_D²⁰ -41.1 (*c* 1.0, CH₂Cl₂); HPLC: 89% ee (determined by chiral phase HPLC, see Table SI.6 for HPLC conditions); ¹H NMR (300 MHz, CDCl₃): δ = 1.62–1.80 (1H, m), 1.98–2.11 (1H, m), 2.12–2.38 (5H, m containing s at 2.31), 3.02–3.16 (1H, m), 3.24 (1H, dt, *J* 14.2), 3.53–3.66 (4H, m containing s at 3.58), 4.16 (1H, d, *J* 12.2), 7.04–7.15 (4H); ¹H NMR (300 MHz, C₆D₆): δ = 0.94–1.11 (1H, m), 1.15–1.26 (1H, m), 1.36–1.46 (1H, m), 1.73–1.91 (1H, m), 2.04 (3H, s), 2.43 (1H, td, *J* 13.7, 3.6), 2.55–2.65 (1H, m), 3.10 (3H, s), 3.61 (1H, td, *J* 12.3, 3.3), 4.05 (1H, d, *J* 12.2), 6.91 (4H, s); ¹³C NMR (75.5 MHz, CDCl₃): δ = 21.0, 23.2, 32.7, 45.0, 52.2, 53.0, 71.4, 127.0, 129.5, 137.1, 137.3, 163.1; IR (neat): 1730 (CO), 1310, 1137, 1124 (SO₂); HRMS (ESI-TOF): *m/z* [M+H]⁺ calcd for C₁₄H₁₉O₄S, 283.0999, found 283.0996; Elemental Analysis: calcd (%) for C₁₄H₁₈O₄S: C, 59.55; H, 6.43, found: C, 59.55; H, 6.36;

Methyl (2*R*,3*R*)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide^[19] (25b)


Methyl (2*R*,3*R*)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **25b** (4 mg, 4%) was isolated as a white solid (least polar component). Spectroscopic characteristics were consistent with previously reported data.^[19] ¹H NMR (300 MHz, CDCl₃): δ = 1.83 (1H, dq, *J* 14.0, 3.4), 2.10–2.36 (5H, m containing s at 2.32), 2.58 (1H, qd, *J* 13.4, 4.1), 3.03 (1H, dq, *J* 14.0, 3.3), 3.53–3.74 (5H, m containing s 3.56), 3.97 (1H, dd, *J* 4.5, 3.0), 7.06 (2H, d, *J* 8.2), 7.13 (2H, d, *J* 8.2); ¹H NMR (300 MHz, C₆D₆): δ = 1.21–1.32 (1H, m), 1.33–1.45 (1H, m), 1.65–1.84 (1H, m), 2.01

SUPPORTING INFORMATION


(3H, s), 2.27–2.49 (2H, m), 3.02 (3H, s), 3.32–3.49 (2H, m), 4.02 (1H, dd, J 4.5, 2.9), 6.77 (2H d, J 8.2), 6.85 (2H, d, J 8.2); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 21.0, 23.1, 23.8, 44.3, 47.9, 52.7, 70.6, 126.9, 129.6, 136.6, 137.6, 166.7; IR (neat): 1736, 1310, 1173, 1120; HRMS (ESI-TOF): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_{18}\text{O}_4\text{SNa}$, 305.0818, found 305.0816.

Methyl (2*R**,3*R**)-3-(4'-methylbenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (S23a)

Methyl (2*R**,3*R**)-3-(4'-methylbenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S23a** (11 mg, 11%, containing <10% **S23b**, s at 3.83) as a white solid (an enriched **S23a** sample was obtained by taking the last few test tubes of the third least polar component); ^1H NMR (300 MHz, CDCl_3): δ = 1.76–1.95 (1H, m), 2.20–2.37 (4H, m containing s 2.32), 2.68 (1H, dd, J 13.5, 8.0), 2.88 (1H, dd, J 13.5, 6.3), 2.94–3.12 (2H, m), 3.26 (1H, qd, J 12.9, 7.2, 2.2), 3.65 (1H, d, J 9.8), 3.76 (3H, s, OCH_3), 7.03 (2H, d, J 8.1), 7.11 (2H, d, J 8.1); ^1H NMR (300 MHz, C_6D_6): δ = 0.99–1.17 (1H, m), 1.26–1.42 (1H, m), 1.97–2.15 (4H, m containing s at 2.09), 2.20–2.33 (1H, m), 2.38–2.48 (2H, m), 2.66–2.83 (1H, m), 3.30 (3H, s), 3.48 (1H, d, J 9.8), 6.77 (2H, d, J 8.0), 6.91 (2H, d, J 8.0); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 21.0, 26.1, 39.4, 41.6, 52.7, 53.3, 70.3, 129.0, 129.4, 134.0, 136.6, 165.5; IR (neat): 1742, 1311, 1273, 1171, 1126, 1120; HRMS (ESI-TOF): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{19}\text{O}_4\text{S}$, 283.0999, found 283.1000.


Methyl (2*R**,3*S**)-3-(4'-methylbenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (S23b)

Methyl (2*R**,3*S**)-3-(4'-methylbenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S23b** was isolated as a mixture with **S23a** (an enriched **S23b** sample was obtained by taking the first few test tubes of the second least polar component); characteristic peaks of **S23b**: ^1H NMR (300 MHz, CDCl_3): δ = 3.38–3.50 (1H, m), 3.79 (1H, d, J 6.2), 3.83 (3H, s).


Methyl 2-((4'-(*p*-tolyl)but-3'-en-1'-yl)sulfonyl)acetate (S24)

Methyl 2-((4'-(*p*-tolyl)but-3'-en-1'-yl)sulfonyl)acetate **S24** (7 mg, 7%) was isolated as a white solid; m.p. 91–93 °C; ^1H NMR (300 MHz, CDCl_3): δ = 2.33 (3H, s), 2.72–2.84 (2H, m), 3.37–3.46 (2H, m), 3.82 (3H, s), 3.99 (2H, s), 6.12 (1H, dt, J 15.8, 7.0), 6.51 (1H, d, J 15.8), 7.12 (2H, d, J 8.1), 7.24 (2H, d, J 8.1); ^1H NMR (300 MHz, C_6D_6): δ = 2.10 (3H, s), 2.40–2.53 (2H, m), 2.93–3.03 (2H, m), 3.18 (3H, s), 3.44 (2H, s), 5.76 (1H, dt, J 15.8, 7.0), 6.19 (1H, d, J 15.8), 6.96 (2H, d, J 8.0), 7.12 (2H, d, J 8.0); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 21.2, 25.7, 53.1, 53.4, 57.7, 123.7, 126.1, 129.3, 133.0, 133.8, 137.6, 163.6; IR (neat): 1753, 1745, 1300, 1260, 1144, 1110; HRMS (ESI-TOF): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{19}\text{O}_4\text{S}$, 283.0999, found 283.0997; Elemental Analysis: calcd (%) for $\text{C}_{14}\text{H}_{18}\text{O}_4\text{S}$: C, 59.55; H, 6.43, found: C, 59.30; H, 6.38.

SUPPORTING INFORMATION

4.2.3. Cyclisation of α -diazo- β -oxosulfone **20**Methyl (2*R*,3*S*)-3-(4'-methoxyphenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide^[19b] (**26a**)


The title compound was prepared following the procedure described for methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **17a** using methyl 2-diazo-2-(4'-(4''-methoxyphenyl)butylsulfonyl)acetate **20** (147.5 mg, 0.45 mmol), Rh₂(2*S*-F-2'-NA)₄ **9b** (7.0 mg, 4.52 μ mol) in deoxygenated DCM (15 mL). The diazo **20** solution was added dropwise over 120 minutes via syringe to the Schlenk tube using a syringe pump. The reaction solution was stirred overnight at -20°C before warming to room temperature. The reaction solution was filtered through a short pad of Celite® and activated charcoal, and concentrated under reduced pressure to give the crude product, which was then analysed by ¹H NMR spectroscopy in CDCl₃ and in C₆D₆. The ¹H NMR in CDCl₃ showed that compound **26a** was the major product, d at δ_{H} 4.09 (*J* 12.1), with minor compounds: **26b**, s at δ_{H} 3.56, **S25b**, s at δ_{H} 3.83, and **S26**, s at δ_{H} 3.80, also evident. No evidence of **S25a**. Both the CDCl₃ and C₆D₆ ¹H NMR spectra contained overlapping peaks making it difficult to determine accurately the thiopyran diastereomeric ratio. The crude product mixture, which was loaded using Celite®, was purified using column chromatography on silica gel, employing ethyl acetate/hexane (20:80 to 40:60) as eluent, and gave methyl (2*R*,3*S*)-3-(4'-methoxyphenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **26a** (56 mg, 42%), methyl (2*S*,3*S*)-3-(4'-methoxyphenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **26b** (15 mg, 11%), methyl (2*R**,3*R**)-3-(4'-methoxybenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S25a** (14 mg, 13%, of which contains ~20% **S25b**, s at 3.83), and methyl 2-(4'-(4''-methoxyphenyl)but-3'-en-1'-yl)sulfonyl)acetate **S26** (11 mg, 8%). **S25a** or **S25b** were not isolated as single pure compounds, but as a mixture. An enriched **S25b** sample was obtained by taking the first few test tubes of the second least polar component, and an enriched **S25a** sample was obtained by taking the last few test tubes of the third least polar component. **26a**, most polar component, white solid; m.p. 175–177 $^\circ\text{C}$; **Spec. Rot.**: $[\alpha]_{\text{D}}^{20} -19.4$ (*c* 1.0, CH₂Cl₂); **HPLC**: 51% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (300 MHz, CDCl₃)**: δ = 1.60–1.79 (1H, m), 2.00–2.11 (1H, m), 2.12–2.38 (2H, m), 2.99–3.13 (1H, m), 3.24 (1H, dt, *J* 14.3, 3.6), 3.52–3.65 (4H, m containing s at 3.59), 3.78 (3H, s), 4.09 (1H, d, *J* 12.1), 6.80–6.88 (2H, m), 7.08–7.15 (2H, m); **¹³C NMR (75.5 MHz, CDCl₃)**: δ = 23.2, 32.7, 44.7, 52.2, 53.1, 55.2, 71.7, 114.3, 128.2, 132.1, 159.0, 163.1; **IR (neat)**: 1726, 1325, 1257, 1140; **HRMS (ESI-TOF)**: *m/z* [M+H]⁺ calcd for C₁₄H₁₉O₅S, 299.0948, found 299.0946. **Elemental Analysis**: calcd (%) for C₁₄H₁₈O₅S: C, 56.36; H, 6.08. Found: C, 56.11; H, 5.96.

Methyl (2*S*,3*S*)-3-(4'-methoxyphenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide^[19] (**26b**)


Methyl (2*S*,3*S*)-3-(4'-methoxyphenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **26b** (14.8 mg, 11%) was isolated as a white solid (least polar component). Spectroscopic characteristics were consistent with previously reported data.^[19] m.p. 110–113 $^\circ\text{C}$ (lit. 90–92 $^\circ\text{C}$ of a 91% ee **26b** sample);^[19b] **¹H NMR (300 MHz, CDCl₃)**: δ = 1.82 (1H, dq, *J* 14.0, 3.4), 2.09–2.34 (2H, m), 2.57 (1H, qd, *J* 13.3, 4.0), 3.03 (1H, dq, *J* 14.0, 3.3), 3.52–3.73 (5H, m containing s at 3.56), 3.79 (3H, s), 3.96 (1H, dd, *J* 4.5, 2.9), 6.81–6.90 (2H, m), 7.06–7.14 (2H, m); **¹³C NMR (75.5 MHz, CDCl₃)**: δ = 23.0, 23.9, 43.8, 47.8, 52.7, 55.2, 70.6, 114.2, 128.0, 131.6,

SUPPORTING INFORMATION


159.0, 166.6; **IR (neat)**: 1723, 1324, 1249, 1172, 1117; **HRMS (ESI-TOF)**: m/z $[M+H]^+$ calcd for $C_{14}H_{19}O_5S$, 299.0948, found 299.0952.

Methyl (2*R,3*R**)-3-(4'-methoxybenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (S25a)**


Methyl (2*R**,3*R**)-3-(4'-methoxybenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S25a** (14 mg, 13%, of which contains ~20% **S25b**, s at 3.83) as a white solid (an enriched **S25a** sample was obtained by taking the last few test tubes of the third least polar component); **m.p.** 127–129 °C; **¹H NMR (300 MHz, CDCl₃)**: δ = 1.77–1.94 (1H, m), 2.20–2.33 (1H, m), 2.68 (1H, dd, J 13.6, 7.9), 2.85 (1H, dd, J 13.6, 6.4), 2.93–3.13 (2H, m), 3.26 (1H, qd, J 13.0, 7.2, 2.2), 3.65 (1H, d, J 9.8), 3.76 (3H, s), 3.79 (3H, s), 6.81–6.87 (2H, m), 7.02–7.12 (2H, m); **¹³C NMR (75.5 MHz, CDCl₃)**: δ = 26.1, 39.0, 41.8, 52.7, 53.3, 55.3, 70.2, 114.1, 129.1, 130.1, 158.6, 165.5; **IR (neat)**: 1742, 1311, 1300, 1245, 1171, 1121; **HRMS (ESI-TOF)**: m/z $[M+H]^+$ calcd for $C_{14}H_{19}O_5S$, 299.0948, found 299.0944.

Methyl (2*R,3*S**)-3-(4'-methoxybenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (S25b)**



Methyl (2*R**,3*S**)-3-(4'-methoxybenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S25b** was isolated as a mixture with **S25a** (an enriched **S25b** sample was obtained by taking the first few test tubes of the second least polar component); characteristic peaks of **S25b**: **¹H NMR (300 MHz, CDCl₃)**: δ = 3.38–3.50 (1H, m), 3.83 (3H, s).

Methyl 2-((4'-(4''-methoxyphenyl)but-3'-en-1'-yl)sulfonyl)acetate (S26)


Methyl 2-((4'-(4''-methoxyphenyl)but-3'-en-1'-yl)sulfonyl)acetate **S26** (11 mg, 8%) was isolated as a colourless oil; **¹H NMR (300 MHz, CDCl₃)**: δ = 2.72–2.83 (2H, m), 3.36–3.46 (2H, m), 3.80 (3H, s), 3.82 (3H, s), 3.99 (2H, s), 6.03 (1H, dt, J 15.8, 7.0), 6.48 (1H, d, J 15.8), 6.81–6.88 (2H, m),

7.24–7.32 (2H, m); **¹³C NMR (75.5 MHz, CDCl₃)**: δ = 25.7, 53.1, 53.3, 55.3, 57.7, 114.1, 122.5, 127.4, 129.4, 132.5, 159.3, 163.6; **IR (neat)**: 1728, 1306, 1243, 1101; **HRMS (ESI-TOF)**: m/z $[M+H]^+$ calcd for $C_{14}H_{19}O_5S$, 299.0948, found 299.0945.


SUPPORTING INFORMATION

4.2.4. Cyclisation of α -diazo- β -oxosulfone 21Methyl (2*R*,3*S*)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (27a)

The title compound was prepared following the procedure described for methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **17a** using methyl 2-diazo-2-(4'-(4''-fluorophenyl)butylsulfonyl)acetate **21** (127.5 mg, 0.41 mmol), Rh₂(2*S*-F-2'-NA)₄ **9b** (6.3 mg, 4.06 μ mol) in deoxygenated DCM (15 mL). The diazo **21** solution was added dropwise over 120 minutes via syringe to the Schlenk tube using a syringe pump. The reaction solution was stirred overnight at -20 °C before warming to room temperature. The

reaction solution was filtered through a short pad of Celite® and activated charcoal, and concentrated under reduced pressure to give the crude product, which was then analysed by ¹H NMR spectroscopy in CDCl₃ and in C₆D₆. The ¹H NMR in CDCl₃ showed that compound **27a** was the major product, d at δ_{H} 4.15 (*J* 12.2), with minor compounds: **27b**, s at δ_{H} 3.56, **S27a**, s at δ_{H} 3.76, **S27b**, s at δ_{H} 3.83, and **S28**, dt at δ_{H} 6.10 (*J* 15.8, 7.0) also evident. The ¹H NMR analysed in C₆D₆ allowed the determination of the thiopyran diastereomeric ratio (89:11 dr, **27a**:**27b**) compared to overlapping peaks in the CDCl₃ ¹H NMR spectra. The crude product mixture, which was loaded using Celite®, was purified using column chromatography on silica gel, employing ethyl acetate/hexane (15:85 to 50:50) as eluent, and gave methyl (2*R*,3*S*)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **27a** (61 mg, 53%), methyl (2*S*,3*S*)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **27b** (8 mg, 7%), methyl (2*R**,3*R**)-3-(4'-fluorobenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S27a** (14 mg, 12%, of which contains <10% **S27b**, s at 3.83), and methyl 2-(4'-(4''-fluorophenyl)but-3'-en-1'-yl)sulfonyl)acetate **S28** (1 mg, 1%). **S27a** or **S27b** were not isolated as single pure compounds, but as a mixture. An enriched **S27b** sample was obtained by taking the first few test tubes of the second least polar component, and an enriched **S27a** sample was obtained by taking the last few test tubes of the third least polar component. **27a**, most polar component, white solid; **m.p.** 154–155 °C; **Spec. Rot.:** [α]_D²⁰ -31.1 (*c* 1.0, CH₂Cl₂); **HPLC:** 90% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (300 MHz, CDCl₃):** δ = 1.62–1.80 (1H, m), 2.00–2.11 (1H, m), 2.14–2.39 (2H, m), 3.04–3.18 (1H, m), 3.26 (1H, dt, *J* 14.2, 3.7), 3.56–3.70 (4H, m containing s at 3.59), 4.15 (1H, d, *J* 12.2), 6.95–7.06 (2H, m), 7.14–7.23 (2H, m); **¹H NMR (300 MHz, C₆D₆):** δ = 0.73–0.90 (1H, m), 1.07–1.30 (2H, m), 1.64–1.82 (1H, m), 2.31 (1H, td, *J* 13.8, 3.6), 2.47–2.58 (1H, m), 3.07 (3H, s), 3.48 (1H, td, *J* 12.4, 3.4), 3.83 (1H, d, *J* 12.1), 6.71 (4H, d, *J* 7.0); **¹⁹F NMR (282.4 MHz, CDCl₃):** δ = -114.3 (1F, s); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 23.1, 32.6, 44.7, 52.1, 53.1, 71.4, 115.8 (d, ²*J*_{CF} 21.5), 128.8 (d, ³*J*_{CF} 8.2), 135.9 (d, ⁴*J*_{CF} 3.3), 162.0 (d, ¹*J*_{CF} 247.0), 163.0; **IR (neat):** 1727, 1312, 1291, 1122; **HRMS (ESI-TOF):** *m/z* [M+Na]⁺ calcd for C₁₃H₁₅FO₄SNa, 309.0567, found 309.0564; **Elemental Analysis:** calcd (%) for C₁₃H₁₅FO₄S: C, 54.53; H, 5.28, found: C, 54.60; H, 5.34.

SUPPORTING INFORMATION

Methyl (2*S*,3*S*)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide^[19a] (27b**)**

Methyl (2*S*,3*S*)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **27b** (8 mg, 7%) was isolated as a white solid (least polar fraction). Spectroscopic characteristics were consistent with previously reported data.^[19a] **m.p.** 155–157 °C (lit 155–156 °C);^[19a]


HPLC: 6% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H**

NMR (300 MHz, CDCl₃): δ = 1.84 (1H, dq, *J* 13.9, 3.4), 2.10–2.36 (2H, m), 2.58 (1H, qd, *J*

13.3, 4.1), 3.05 (1H, dq, *J* 14.0, 3.3), 3.56 (3H, s, OCH₃), 3.60–3.73 (2H, m), 3.96 (1H, dd, *J* 4.5, 2.9), 6.97–7.07 (2H, m), 7.12–7.21 (2H, m); **¹H NMR (300 MHz, C₆D₆):** δ = 1.11 (1H, dq, *J* 13.9, 3.4), 1.28–1.41 (1H, m), 1.59–1.78 (1H, m), 2.18 (1H, qd, *J* 13.5, 3.6), 2.40 (1H, dq, *J* 14.0, 3.3), 2.97 (3H, s), 3.21–3.39 (2H, m), 3.87 (1H, dd, *J* 4.5,

2.9), 6.51–6.69 (4H, m); **¹⁹F NMR (282.4 MHz, CDCl₃):** δ = –114.1 (1F, s); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 23.0, 23.9, 43.8, 47.8, 52.8, 70.5, 115.9 (d, ²*J*_{CF} 21.4), 128.6 (d, ³*J*_{CF} 8.0), 135.4 (d, ⁴*J*_{CF} 3.3), 162.2 (d, ¹*J*_{CF} 247.2), 166.5;

IR (neat): 1735, 1309, 1220, 1173, 1118; **HRMS (ESI-TOF):** *m/z* [M+Na]⁺ calcd for C₁₃H₁₅FO₄SNa, 309.0567, found 309.0562.


Methyl (2*R,3*R**)-3-(4'-fluorobenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (**S27a**)**

Methyl (2*R**,3*R**)-3-(4'-fluorobenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S27a** (14 mg, 12%, of which contains <10% **S27b**, s at 3.83) was isolated as an opaque oil (an

enriched **S27a** sample was obtained by taking the last few test tubes of the third least polar component); **¹H NMR (300 MHz, CDCl₃):** δ = 1.76–1.95 (1H, m), 2.20–2.33 (1H, m), 2.71 (1H, dd, *J* 13.6, 8.0), 2.89 (1H, dd, *J* 13.6, 6.5), 2.95–3.13 (2H, m), 3.28 (1H, qd, *J* 13.0, 7.1,

2.1), 3.65 (1H, d, *J* 9.8), 3.76 (3H, s), 6.95–7.05 (2H, m), 7.08–7.17 (2H, m); **¹H NMR (300 MHz, C₆D₆):** δ = 0.89–1.08 (1H, m), 1.14–1.27 (1H, m), 1.87 (1H, dd, *J* 13.4, 8.5), 2.19–2.33 (2H, m), 2.42 (1H, qd, *J* 12.9, 7.2, 2.3), 2.53–2.69 (1H, m), 3.29 (3H, s), 3.39 (1H, d, *J* 9.9),


6.51–6.60 (2H, m), 6.66–6.77 (2H, m); **¹⁹F NMR (282.4 MHz, CDCl₃):** δ = –115.6 (1F, s); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 26.2, 39.2, 41.6, 52.6, 53.4, 70.2, 115.6 (d, ²*J*_{CF} 21.3), 130.5 (d, ³*J*_{CF} 8.0), 132.9 (d, ⁴*J*_{CF} 3.3), 161.9 (d, ¹*J*_{CF} 245.4), 165.4; **IR (neat):** 1741, 1317, 1266, 1219, 1158, 1120; **HRMS (ESI-TOF):** *m/z* [M+Na]⁺ calcd for C₁₃H₁₅FO₄SNa, 309.0567, found 309.0564.

Methyl (2*R,3*S**)-3-(4'-fluorobenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (**S27b**)**

Methyl (2*R**,3*S**)-3-(4'-fluorobenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide **S27b** was isolated as a mixture with **S27a** (an enriched **S27b** sample was obtained by taking the


first few test tubes of the second least polar component); characteristic peaks of **S27b**: **¹H NMR (300 MHz, CDCl₃):** 3.39–3.50 (1H, m), 3.83 (3H, s, CH₃).

SUPPORTING INFORMATION

Methyl 2-((4'-(4''-fluorophenyl)but-3'-en-1'-yl)sulfonyl)acetate (**S28**)

Methyl 2-((4'-(4''-fluorophenyl)but-3'-en-1'-yl)sulfonyl)acetate **S28**; colourless oil, second most polar fraction; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ = 2.74–2.85 (2H, m), 3.38–3.47 (2H, m), 3.83 (3H, s), 3.99 (2H, s), 6.10 (1H, dt, J 15.8, 7.0), 6.50 (1H, d, J 15.8), 6.95–7.05 (2H, m), 7.24–7.36


(2H, m); $^1\text{H NMR}$ (300 MHz, C_6D_6): δ = 2.35–2.46 (2H, m), 2.89–2.98 (2H, m), 3.15 (3H, s), 3.35 (2H, s), 5.57 (1H, dt, J 15.8, 7.0), 5.99 (1H, d, J 15.7), 6.69–6.80 (2H, m), 6.83–6.93 (2H, m); $^{19}\text{F NMR}$ (282.4 MHz, CDCl_3): δ = –114.2 (1F, s); $^{13}\text{C NMR}$ (75.5 MHz, CDCl_3): δ = 25.6, 53.0, 53.4, 57.7, 115.6 (d, $^2J_{\text{CF}}$ 21.7), 124.6 (d, $^6J_{\text{CF}}$ 2.3), 127.8 (d, $^3J_{\text{CF}}$ 8.0), 132.0, 132.7 (d, $^4J_{\text{CF}}$ 3.3), 162.4 (d, $^1J_{\text{CF}}$ 246.7), 163.6; **IR** (neat): 1744, 1313, 1259, 1227, 1110; **HRMS** (ESI-TOF): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{13}\text{H}_{15}\text{FO}_4\text{SNa}$, 309.0567, found 309.0567.

4.2.5. Cyclisation of α -diazo- β -oxosulfone **22**((2*R**,3*S**)-1,1-Dioxido-3-phenyltetrahydro-2*H*-thiopyran-2-yl)(phenyl)methanone (**28a**)


An oven dried 60 mL Schlenk tube (27 × 150 mm) containing 4Å molecular sieves (~600–800 mg) and a magnetic stir bar was flame dried and cooled under nitrogen. $\text{Rh}_2(2\text{S-F-2'-NA})_4$ **9b** (10.8 mg, 6.92 μmol) was charged as a solid to the Schlenk tube. 2-Diazo-1-phenyl-2-((4'-phenylbutyl)sulfonyl)ethan-1-one **22** (237 mg, 0.69 mmol) was charged into a dry 25 mL roundbottom flask. The Schlenk tube and roundbottom flask were both placed under vacuum

and back filled with nitrogen 3 times. The $\text{Rh}_2(2\text{S-F-2'-NA})_4$ **9b** was dissolved in deoxygenated DCM (5 ml), and the 2-diazo-1-phenyl-2-((4'-phenylbutyl)sulfonyl)ethan-1-one **22** was dissolved in deoxygenated DCM (10 ml). The Schlenk tube containing the rhodium solution was placed into an oil bath set at 55 °C. Once the rhodium solution began to reflux, the diazo solution **22** was added dropwise over 120 minutes via syringe to the Schlenk tube using a syringe pump. The reaction solution was stirred overnight while heating under reflux before cooling to room temperature. The reaction solution was filtered through a short pad of Celite® and activated charcoal, and concentrated under reduced pressure to give the crude product, which was then analysed by $^1\text{H NMR}$ spectroscopy in CDCl_3 . The $^1\text{H NMR}$ in CDCl_3 showed that compound **S29** was the major product, d at δ_{H} 4.62 (J 9.7) and d at δ_{H} 4.77 (J 6.6), with minor compound **28a**, d at δ_{H} 5.26. The crude product mixture, which was loaded using Celite®, was purified using column chromatography on silica gel, employing ethyl acetate/hexane (10:90 to 40:60) as eluent, and gave ((2*R**,3*S**)-1,1-dioxido-3-phenyltetrahydro-2*H*-thiopyran-2-yl)(phenyl)methanone **28a** (3 mg, 1%), ((2*R**,3*R**)-1,1-dioxido-3-phenyltetrahydro-2*H*-thiopyran-2-yl)(phenyl)methanone **28b** (4 mg, 2%), ((2*R**,3*R**)-3-benzyl-1,1-dioxidotetrahydrothiophen-2-yl)(phenyl) methanone **S29a** (52 mg, 25% of which contains ~5% **S29b**, d at 4.77). **28a**, most polar fraction, white solid; **m.p.** 244–245 °C; **HPLC**: 69% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **Spec. Rot.**: $[\alpha]_{\text{D}}^{20} +25.50$ (c 0.5, CH_2Cl_2); $^1\text{H NMR}$ (600 MHz, CDCl_3): δ = 1.77–1.89 (1H, m), 2.09–2.19 (1H, m), 2.20–2.29 (1H, m), 2.31–2.43 (1H, m), 3.21 (1H, td, J 14.0, 3.8), 3.32 (1H, dt, J 14.2, 3.5), 3.95 (1H, td, J 12.4, 3.3), 5.26 (1H, d, J 11.7), 7.09–7.22 (5H, m), 7.36–7.42 (2H, m), 7.49–7.55 (1H, m), 7.82–7.87 (2H, m); $^{13}\text{C NMR}$ (150.9 MHz, CDCl_3): δ = 23.3, 33.0, 45.5, 53.0, 70.9, 127.3, 127.4, 128.6, 128.86, 128.88, 133.8, 137.7, 140.5, 189.1; **IR** (neat): 1671, 1322, 1291, 1139; **HRMS** (ESI-TOF): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{19}\text{O}_3\text{S}$, 315.1049, found 315.1052.

SUPPORTING INFORMATION

((2*R,3*R**)-1,1-Dioxido-3-phenyltetrahydro-2*H*-thiopyran-2-yl)(phenyl)methanone^[19] (**28b**)**


((2*R**,3*R**)-1,1-dioxido-3-phenyltetrahydro-2*H*-thiopyran-2-yl)(phenyl)methanone **28b** (4 mg, 2%) was isolated as an impure colourless oil (least polar fraction). Spectroscopic characteristics were consistent with previously reported data.^[19] **¹H NMR (400 MHz, CDCl₃):** δ = 1.88 (1H, dq, *J* 14.0, 3.3), 2.20–2.42 (2H, m), 2.72 (1H, dq, *J* 13.5, 4.0), 3.09 (1H, dq, *J* 13.9, 3.2), 3.79–3.90 (2H, m), 5.07 (1H, dd, *J* 4.5, 2.8), 7.06–7.18 (5H, m), 7.20–7.30 (2H, m), 7.36–7.46 (3H, m); **IR (neat):** 1668, 1324, 1297, 1245, 1125; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₈H₁₉O₃S, 315.1049, found 315.1053.

((2*R,3*R**)-3-Benzyl-1,1-dioxidotetrahydrothiophen-2-yl)(phenyl)methanone (**S29a**)**

((2*R**,3*R**)-3-Benzyl-1,1-dioxidotetrahydrothiophen-2-yl)(phenyl)methanone **S29a** (52 mg, 25% of which contains ~5% **S29b**, d at 4.77) was isolated as a white solid; **m.p.** 111–113 °C; **¹H NMR (400 MHz, CDCl₃):** δ = 1.91–2.06 (1H, m), 2.27–2.39 (1H, m), 2.72 (1H, dd, *J* 13.4, 8.2), 2.88 (1H, dd, *J* 13.4, 6.1), 3.07–3.19 (1H, m), 3.28–3.48 (2H, m), 4.61 (1H, d, *J* 9.7), 7.08–7.29 (5H, m), 7.45–7.55 (2H, m), 7.58–7.66 (1H, m), 7.92–8.01 (2H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 26.2, 40.0, 41.5, 53.5, 71.0, 127.0, 128.7, 128.9, 129.0, 129.1, 134.3, 136.5, 137.4,

189.8; **IR (neat):** 1688, 1303, 1267, 1121; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₈H₁₉O₃S, 315.1049, found 315.1049.

Only trace amount of the *cis*-sulfolane **S29b** was evident from a d at δ_H 4.77 (*J* 6.6)


4.2.6. Cyclisation of α -diazo- β -oxosulfone **23****Benzyl (2*R*,3*R*)-3-octyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide^[19] (**29a**)**

The title compound was prepared following the procedure described for methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **17a** using benzyl 2-diazo-2-(dodecylsulfonyl)acetate **23** (161 mg, 0.39 mmol), Rh₂(2*S*-F-2'-NA)₄ **9b** (6.1 mg, 3.94 μ mol) in deoxygenated DCM (15 mL). The diazo **23** solution was added dropwise over 120 minutes via syringe to the Schlenk tube using a syringe pump. The reaction solution was stirred


overnight at –20 °C before warming to room temperature. The reaction solution was filtered through a short pad of Celite® and activated charcoal, and concentrated under reduced pressure to give the crude product, which was then analysed by ¹H NMR spectroscopy in CDCl₃ and in C₆D₆. The ¹H NMR in CDCl₃ showed that compound **29a**, d at δ_H 3.70 (*J* 10.5), and **S30b**, m at 3.37–3.50, were the major products, with the minor compound, **29b**, m at δ_H 3.52–3.64, also evident. There was no evidence of **S30a**. Both the CDCl₃ and C₆D₆ ¹H NMR spectra contained overlapping peaks making it difficult to determine accurately the thiopyran diastereomeric ratio. The crude product mixture, which was loaded using Celite®, was purified using column chromatography on silica gel, employing ethyl acetate/hexane (5:95 to 20:80) as eluent, and gave benzyl (2*R**,3*R**)-3-octyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **29a** (46 mg, 31%), benzyl (2*R*,3*S*)-3-octyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **29b** (20 mg, 13%), and benzyl (2*R**,3*R**)-3-nonyltetrahydrothiophene-2-carboxylate 1,1-dioxide **S30a** (44 mg, 29%, of

SUPPORTING INFORMATION

which contains ~32% **S30b**, m at 3.37–3.50). **S30a** or **S30b** were not isolated as single pure compounds, but as a mixture. An enriched **S30b** sample was obtained by taking the first few test tubes of the second least polar component, and an enriched **S30a** sample was obtained by taking the last few test tubes of the second most polar component. **29a**, most polar component, white solid. Spectroscopic characteristics were consistent with previously reported data.^[19] **m.p.** 85–87 °C (lit. 86–88 °C);^[19b] **Spec. Rot.:** $[\alpha]_{\text{D}}^{20}$ –14.3 (c 1.0, CH₂Cl₂); **HPLC:** 56% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (300 MHz, CDCl₃):** δ = 0.83–0.93 (3H, m), 1.07–1.38 (15H, m), 1.97–2.18 (3H, m), 2.34–2.50 (1H, m), 2.83–3.00 (1H, m), 3.19 (1H, dt, *J* 14.1, 4.2), 3.70 (1H, d, *J* 10.5), 5.27 (2H, s), 7.28–7.43 (5H, m); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 14.0, 22.4, 22.6, 26.2, 28.3, 29.1, 29.30, 29.34, 31.8, 33.3, 38.9, 51.9, 67.9, 71.3, 128.4, 128.48, 128.54, 134.9, 164.0; **IR (neat):** 1727, 1302, 1129; **HRMS (ESI-TOF):** *m/z* [M+Na]⁺ calcd for C₂₁H₃₂O₄SNa, 403.1914, found 403.1919; **Elemental Analysis:** calcd (%) for C₂₁H₃₂O₄S: C, 66.28; H, 8.48. Found: C, 66.28; H, 8.41.


Benzyl (2*R*,3*S*)-3-octyltetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide^[19] (29b)


Benzyl (2*R*,3*S*)-3-octyltetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide **29b** (20 mg, 13%) was isolated as a colourless oil (least polar fraction). Spectroscopic characteristics were consistent with previously reported data.^[19] **HPLC:** 53% ee (determined by chiral phase HPLC); **Spec. Rot.:** $[\alpha]_{\text{D}}^{20}$ –11.2 (c 1.0, CH₂Cl₂); **¹H NMR (300 MHz, CDCl₃):** δ = 0.83–0.93 (3H, m), 1.09–1.35 (14H, m), 1.62 (1H, dq, *J* 14.1, 3.6), 1.70–1.86 (1H, m), 1.96–2.18 (2H, m), 2.27–2.42 (1H, m), 2.94 (1H, dq, *J* 13.9, 3.3), 3.52–3.64 (1H, m), 3.90 (1H, dd, *J* 4.5, 2.9), 5.14 (1H, d, *J* 12.1), 5.31 (1H, d, *J* 12.1), 7.36 (5H, br s); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 14.1, 22.6, 23.0, 25.0, 26.5, 29.2, 29.3, 31.8, 34.1, 39.6, 48.2, 67.8, 68.5, 128.5, 128.7, 134.8, 166.1; **IR (neat):** 1727, 1322, 1172, 1118; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₁H₃₃O₄S, 381.2094, found 381.2094.


Benzyl (2*R,3*R**)-3-nonyltetrahydrothiophene-2-carboxylate 1,1-dioxide (S30a)**


Benzyl (2*R**,3*R**)-3-nonyltetrahydrothiophene-2-carboxylate 1,1-dioxide **S30a** (44 mg, 29%, of which contains ~32% **S30b**, m at 3.36–3.50) was isolated as a colourless oil (an enriched **S30a** sample was obtained by taking the last few test tubes of the second most polar component); **¹H NMR (300 MHz, CDCl₃):** δ = 0.82–0.94 (3H, m), 1.15–1.35 (14H, m), 1.38–1.61 (2H, m), 1.71–1.90 (1H, m), 2.30–2.43 (1H, m), 2.70–2.86 (1H, m), 3.09 (1H, td, *J* 12.8, 6.9), 3.26 (1H, qd, *J* 12.9, 6.9, 1.9), 3.61 (1H, d, *J* 9.4), 5.23 (1H, d, *J* 12.3), 5.30 (1H, d, *J* 12.3), 7.29–7.43 (5H, m); **¹³C NMR (75.5 MHz, CDCl₃):** δ = 14.1, 22.7, 26.6, 26.8, 29.2, 29.4, 29.5, 31.8, 34.4, 40.2, 52.7, 68.3, 71.0, 128.4, 128.55, 128.6, 134.9, 165.5; **IR (neat):** 1740, 1308, 1267, 1179, 1114; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₁H₃₃O₄S, 381.2094, found 381.2092.

SUPPORTING INFORMATION


Benzyl (2*R**,3*S**)-3-nonyltetrahydrothiophene-2-carboxylate 1,1-dioxide (**S30b**)

Benzyl (2*R**,3*S**)-3-nonyltetrahydrothiophene-2-carboxylate 1,1-dioxide **S30b** was isolated as a mixture with **S30a** (an enriched **S30b** sample was obtained by taking the first few test tubes of the second least polar component); characteristic peaks of **S30b**: ^1H NMR (300 MHz, CDCl_3): δ = 3.37–3.50 (1H, m); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 27.6, 31.5, 40.0, 51.5, 67.7, 67.8, 165.2.

4.2.7. Cyclisation of α -diazo- β -oxosulfone **24**Methyl (1*R*,4*aS*,8*aR*)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide^[20] (**30a**)

The title compound was prepared following the procedure described for methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide **17a** using methyl 2-((2'-cyclohexylethyl)sulfonyl)-2-diazoacetate **24** (534 mg, 1.95 mmol), $\text{Rh}_2(2\text{S-F-2'-NA})_4$ **9b** (30.3 mg, 19.5 μmol) in deoxygenated DCM (15 mL). The diazo **24** solution was added dropwise over 120 minutes via syringe to the Schlenk tube using a syringe pump. The reaction solution was stirred overnight at -20°C before warming to room temperature. The reaction

solution was filtered through a short pad of Celite® and activated charcoal, and concentrated under reduced pressure to give the crude product, which was then analysed by ^1H NMR spectroscopy in CDCl_3 . The ^1H NMR in CDCl_3 showed very efficient C–H insertion in the synthesis of **30**, with a thiopyran diastereomeric ratio (96:4 dr, **30a**:**30b**, s at δ_{H} 3.85: m at δ_{H} 3.58–3.77). The crude product mixture, which was loaded using Celite®, was purified using column chromatography on silica gel, employing ethyl acetate/hexane (30:70) as eluent, and gave methyl (1*R*,4*aS*,8*aR*)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide **30a** (436 mg, 91%), and methyl (1*R**,4*aR**,8*aS**)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide **30b** (10 mg, 2%); **30a**, most polar component, white solid; **m.p.** 163–164 $^\circ\text{C}$ (lit. 163–164 $^\circ\text{C}$);^[20] **Spec. Rot.:** $[\alpha]_{\text{D}}^{20}$ –22.6 (c 1.0, CH_2Cl_2); **HPLC:** 84% ee (determined by chiral phase HPLC, see Table SI.6 for HPLC conditions); ^1H NMR (300 MHz, CDCl_3): δ = 0.96–1.39 (5H, m), 1.58–1.86 (4H, m), 1.90–2.03 (2H, m), 2.13 (1H, qd, J 11.7, 3.2), 2.93–3.22 (2H, m), 3.63 (1H, d, J 11.7), 3.85 (3H, s); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 24.9, 25.6, 30.75, 30.83, 32.7, 40.5, 42.9, 52.4, 53.2, 71.2, 164.0; **IR (neat):** 1733, 1291, 1127; **HRMS (ESI-TOF):** m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{19}\text{O}_4\text{S}$ 247.0993, found 247.0995. **Elemental Analysis:** calcd (%) for $\text{C}_{11}\text{H}_{18}\text{O}_4\text{S}$: C, 53.64; H, 7.37. Found: C, 53.55; H, 7.25.

Methyl (1*R**,4*aR**,8*aS**)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide^[20] (**30b**)

Methyl (1*R**,4*aR**,8*aS**)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide **30b** (10 mg, 2%) was isolated as a white solid (least polar component); **HPLC:** 0% ee (determined by chiral phase HPLC, see Table SI.6 for HPLC conditions); ^1H NMR (300 MHz, CDCl_3): δ = 0.92–1.11 (2H, m), 1.14–1.36 (2H, m), 1.62–2.14 (8H, m), 2.96 (1H, dq, J 14.0, 3.2), 3.58–3.77 (2H, m containing dd, J 4.6, 3.1), 3.80 (3H, s); ^{13}C NMR (75.5 MHz, CDCl_3): δ = 25.4, 25.5, 30.9, 31.1, 32.9, 33.6, 43.0, 48.5, 52.8, 68.9, 166.9; **IR (neat):** 1731, 1315, 1288, 1229, 1167, 1109; **HRMS**

SUPPORTING INFORMATION


(ESI-TOF): m/z $[M+H]^+$ calcd for $C_{11}H_{19}O_4S$ 247.1004; found 247.1008; **Elemental Analysis:** calcd (%) for $C_{11}H_{18}O_4S$: C, 53.64; H, 7.37. Found: C, 53.46; H, 7.37.

SUPPORTING INFORMATION


5. Synthesis of α -diazacetamides**Procedure B**

A 100 ml three-neck round-bottom flask was charged with water (10 ml), dichloromethane (5 ml) and sodium azide (5.5 eq.). The flask was cooled to 0 °C, after which trifluoromethanesulfonyl anhydride (1.1 eq.) was slowly added via syringe over 15 minutes while vigorously stirring the solution. The resulting solution was vigorously stirred at 0 °C for two hours after which the layers were separated. The aqueous layer was extracted with dichloromethane (5 ml) and the combined organic layer was washed with aqueous sodium carbonate (10 ml, 10%) and dried with magnesium sulfate. The dried solution of triflyl azide was added slowly to a solution of the relevant α -cyanoacetamide (1.0 eq) and triethylamine (1.1 eq.) in dichloromethane (30 ml for 10 mmol scale of α -cyanoacetamide) while stirring at 0 °C. The solution was allowed to slowly reach room temperature and reaction progression was monitored by IR spectroscopy. After complete disappearance of the azide stretch ($\sim 2100\text{ cm}^{-1}$), the solution was carefully concentrated under reduced pressure. The desired α -cyano- α -diazacetamide was afforded following purification by flash chromatography on silica gel using hexane:ethyl acetate (80:20) as eluent.^[21]

Note: The resonance for the diazo carbon is a weak signal in the ^{13}C NMR spectra and often is not observed for the derivatives across the series.


***N,N*-Dibenzyl-2-cyano-2-diazoacetamide^[21] (31)**

This title compound was prepared according to **Procedure B** from *N,N*-(dibenzyl)-2-cyanoacetamide (2.84 g, 10.80 mmol), sodium azide (6.60 g, 100 mmol), trifluoromethanesulfonic anhydride (1.9 mL, 11.2 mmol) and triethylamine (1.70 mL, 12.0 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow oil, 2.05 g (66%); ^1H NMR (400 MHz, CDCl_3): δ = 4.59 (4H, s), 7.19–7.38 (10H, m); ^{13}C NMR (100.6 MHz, CDCl_3): δ = 50.3, 109.7, 127.7, 128.1, 128.9, 135.5, 159.9; IR (neat): 2214, 2117, 1626.


***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-fluorobenzyl)acetamide^[21] (33)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-fluorobenzyl)acetamide (3.12 g, 12.5 mmol), sodium azide (5.581 g, 85.80 mmol), trifluoromethanesulfonic anhydride (2.30 mL, 14.0 mmol) and triethylamine (1.80 mL, 13.0 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 2.22 g (65%); m.p. 105–107 °C; ^1H NMR (400 MHz, CDCl_3): δ = 1.42 (9H, s), 4.67 (2H, s), 7.01–7.11 (2H, m), 7.13–7.22 (2H, m); ^{19}F NMR (376.5 MHz, CDCl_3): δ = –114.9; ^{13}C NMR (100.6 MHz, CDCl_3): δ = 28.5, 49.1, 60.4, 109.8, 115.7 ($^2J_{\text{CF}}$ 21.7), 127.6 ($^3J_{\text{CF}}$ 8.1), 134.1 ($^4J_{\text{CF}}$ 3.2), 160.9, 162.0 ($^1J_{\text{CF}}$ 246.0); IR (neat): 2213 (CN), 2121 (CN₂) 1635 (CO).


SUPPORTING INFORMATION

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-bromobenzyl)acetamide^[21] (34)**


This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-bromobenzyl)acetamide (2.07 g, 6.700 mmol), sodium azide (2.60 g, 40.0 mmol), trifluoromethanesulfonic anhydride (1.2 mL, 7.0 mmol) and triethylamine (0.98 mL, 7.00 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 2.03 g (90%); **m.p.** 109–111 °C (Lit.,^[21] 109–110 °C); **¹H NMR (400 MHz, CDCl₃):** δ = 1.41 (9H, s), 4.65 (2H, s), 7.10 (2H, d, *J* 8.4), 7.50 (2H, d, *J* 8.4); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 28.5, 49.3, 54.8, 60.4, 109.7, 121.3, 127.7, 131.9, 137.6, 160.9; **IR (neat):** 2213, 2119, 1634.

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-chlorobenzyl)acetamide^[21] (35)**

This compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-chlorobenzyl)acetamide (2.50 g, 9.40 mmol), sodium azide (5.37 g, 83.0 mmol), trifluoromethanesulfonic anhydride (1.63 mL, 10.0 mmol) and triethylamine (1.35 mL, 10.0 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 1.76 g (64%); **m.p.** 108–110 °C (Lit.,^[21] 109–113 °C); **¹H NMR (400 MHz, CDCl₃):** δ = 1.41 (9H, s), 4.67 (2H, s), 7.16 (2H, d, *J* 8.4), 7.34 (2H, d, *J* 8.4); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 28.5, 49.2, 54.8, 60.4, 109.7, 127.4, 128.9, 133.2, 137.1, 160.9; **IR (neat):** 2213, 2118, 1634.

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(2',6'-dichlorobenzyl)acetamide (36)**


This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(2',6'-dichlorobenzyl)acetamide (2.41 g, 8.10 mmol), sodium azide (4.00 g, 62.0 mmol), trifluoromethanesulfonic anhydride (1.41 mL, 8.50 mmol) and triethylamine (0.85 mL, 8.50 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Yellow crystals, 2.50 g (94%); **m.p.** 109–110 °C; **¹H NMR (400 MHz, CDCl₃):** δ = 1.33 (9H, s), 4.92 (2H, s), 7.17–7.24 (1H, m), 7.34 (2H, d, *J* 8.0); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 28.3, 48.1, 59.9, 110.0, 129.5, 129.6, 132.3, 135.8, 162.9; **IR (neat):** 2214, 2118, 1642; **HRMS (ESI-TOF):** *m/z* [M+Na]⁺ calcd for C₁₄H₁₄³⁵Cl₂N₄ONa 347.0437, found 347.0439.

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-methylbenzyl)acetamide^[21] (37)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-methylbenzyl)acetamide (1.72 g, 7.00 mmol), sodium azide (2.60 g, 40.0 mmol), trifluoromethanesulfonic anhydride (1.3 mL, 7.2 mmol) and triethylamine (1.00 mL, 7.20 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 1.56 g (83%); **m.p.** 86–88 °C


SUPPORTING INFORMATION

(Lit.,^[21] 85–86 °C); ¹H NMR (400 MHz, CDCl₃): δ= 1.42 (9H, s), 2.34 (3H, s), 4.67 (2H, s), 7.09 (2H, d, J 8.1), 7.17 (2H, d, J 8.0); ¹³C NMR (100.6 MHz, CDCl₃): δ= 21.1, 28.5, 49.5, 54.7, 60.3, 109.9, 125.9, 129.4, 135.3, 137.1, 160.9; IR (neat): 2213, 2117, 1634.

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(3',5'-dimethylbenzyl)acetamide (38)**


This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(3',5'-dimethylbenzyl) acetamide (2.78 g, 10.8 mmol), sodium azide (6.00 g, 92.0 mmol), trifluoromethanesulfonic anhydride (1.90 mL, 11.2 mmol) and triethylamine (1.60 mL, 11.2 mmol). Purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Yellow crystals, 1.79 g (58%); **m.p.**

105–107 °C; ¹H NMR (400 MHz, CDCl₃): δ= 1.42 (9H, s), 2.31 (6H, s), 4.64 (2H, s), 6.79 (2H, s), 6.90 (1H, s); ¹³C NMR (100.6 MHz, CDCl₃): δ= 21.4, 28.5, 49.7, 60.3, 109.9, 123.8, 129.1, 138.2, 138.3, 160.8; IR (neat): 2213, 2119, 1634; HRMS (ESI-TOF): *m/z* [M+Na]⁺ calcd for C₁₆H₂₀N₄ONa 307.1529, found 307.1533.

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(2',4',6'-trimethylbenzyl)acetamide (39)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(2',4',6'-trimethylbenzyl) acetamide (1.78 g, 6.50 mmol), sodium azide (3.60 g, 55.0 mmol), trifluoromethanesulfonic anhydride (1.10 mL, 6.80 mmol) and triethylamine (0.95 mL, 6.80 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Yellow crystals,


1.18 g (61%); **m.p.** 91–92 °C; ¹H NMR (400 MHz, CDCl₃): δ= 1.31 (9H, s), 2.26 (3H, s), 2.32 (6H, s), 4.64 (2H, s), 6.82 (2H, s); ¹³C NMR (100.6 MHz, CDCl₃): δ= 20.7, 20.8, 28.2, 47.8, 59.9, 109.8, 130.3, 131.0, 136.8, 137.2, 163.1; IR (neat): 2215, 2119, 1635; HRMS (ESI-TOF): *m/z* [M+Na]⁺ calcd for C₁₇H₂₂N₄ONa 321.1686, found 321.1685.

***N*-Benzyl-*N*-(*tert*-butyl)-2-cyano-2-diazoacetamide^[21] (40)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(benzyl)acetamide (2.04 g, 8.90 mmol), sodium azide (3.65 g, 60.80 mmol), trifluoromethanesulfonic anhydride (1.5 mL, 9.5 mmol) and triethylamine (1.3 mL, 9.5 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as eluent. Spectroscopic


characteristics were consistent with previously reported data.^[21] Yellow crystals, 1.65 g (72%); **m.p.** 88–92 °C (Lit.,^[21] 89–91 °C); ¹H NMR (400 MHz, CDCl₃): δ= 1.43 (9H, s), 4.71 (2H, s), 7.18–7.42 (5H, m); ¹³C NMR (100.6 MHz, CDCl₃): δ= 28.5, 49.7, 60.3, 109.8, 126.0, 127.5, 128.7, 138.4, 160.9; IR (neat): 2214, 2121, 1634.

SUPPORTING INFORMATION

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-nitrobenzyl)acetamide^[21] (41)**


This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-nitrobenzyl)acetamide (2.89 g, 10.5 mmol), sodium azide (6.00 g, 92.0 mmol), trifluoromethanesulfonic anhydride (1.85 mL, 11.0 mmol) and triethylamine (1.50 mL, 11.0 mmol). This crude product was purified by

flash chromatography on silica gel with hexane:ethyl acetate as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 1.570 g (50%); **m.p.** 125–127 °C (Lit.,^[21] 122–124 °C); **¹H NMR (400 MHz, CDCl₃):** δ= 1.43 (9H, s), 4.80 (2H, s), 7.43 (2H, d, *J* 8.8), 8.23–8.28 (2H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ= 28.4, 49.4, 54.8, 60.6, 109.6, 124.0, 126.8, 146.3, 147.3, 161.1; **IR (neat):** 2214, 2124, 1519, 1342.

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-carbomethoxybenzyl)acetamide^[21] (42)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-carbomethoxy benzyl)acetamide (0.79 g, 2.70 mmol), sodium azide (1.17 g, 18.0 mmol), trifluoromethanesulfonic anhydride (0.50 mL, 3.0 mmol) and triethylamine (0.43 mL, 3.0 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl


acetate as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 1.86 g (81%); **m.p.** 88–91 °C (Lit.,^[21] 90–93 °C); **¹H NMR (400 MHz, CDCl₃):** δ= 1.42 (9H, s), 3.92 (3H, s), 4.75 (2H, s), 7.31 (2H, d, *J* 8.2), 8.05 (2H, d, *J* 8.3); **¹³C NMR (100.6 MHz, CDCl₃):** δ= 28.5, 49.7, 52.2, 60.5, 109.6, 126.0, 129.4, 130.1, 143.8, 161.0, 166.8; **IR (neat):** 2214, 2125, 1719, 1636.

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-trifluoromethylbenzyl)acetamide^[21] (43)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-trifluoromethylbenzyl) acetamide (2.00 g, 6.70 mmol), sodium azide (2.60 g, 40.8 mmol), trifluoromethanesulfonic anhydride (1.2 mL, 7.0 mmol) and triethylamine (0.98 mL, 7.00 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as


eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 1.95 g (90%); **m.p.** 68–69 °C (Lit.,^[21] 65–67 °C); **¹H NMR (400 MHz, CDCl₃):** δ= 1.43 (9H, s), 4.76 (2H, s), 7.35 (2H, d, *J* 8.3), 7.64 (2H, d, *J* 8.3); **¹⁹F NMR (376.5 MHz, CDCl₃):** δ= –62.5; **¹³C NMR (100.6 MHz, CDCl₃):** δ= 28.5, 49.4, 60.5, 109.6, 124.0 (q, ¹*J*_{CF} 272.0), 125.8 (q, ³*J*_{CF} 3.8), 126.3, 129.8 (²*J*_{CF} 32.6), 142.7, 161.0; **IR (neat):** 2214, 2122, 1640.

SUPPORTING INFORMATION

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-cyanobenzyl)acetamide (44)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-cyanobenzyl) acetamide (3.19 g, 12.5 mmol), sodium azide (5.58 g, 85.80 mmol), trifluoromethanesulfonic anhydride (2.30 mL, 14.0 mmol) and triethylamine (1.80 mL, 13.0 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate as

eluent. Yellow crystals, 1.99 g (57%); **m.p.** 148–150 °C; **¹H NMR (400 MHz, CDCl₃)**: δ= 1.42 (9H, s), 4.75 (2H, s), 7.36 (2H, d, *J* 7.8), 7.69 (2H, d, *J* 8.1); **¹³C NMR (100.6 MHz, CDCl₃)**: δ= 28.5, 49.5, 60.6, 109.6, 111.5, 118.5, 126.7, 132.6, 144.2, 161.1; **IR (neat)**: 2228, 2214, 2123, 1638; **HRMS (ESI-TOF)**: *m/z* [M+H]⁺ calcd for C₁₅H₁₆N₅O 304.1169, found 304.1172.



***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-methoxybenzyl)acetamide^[21] (45)**

This title compound was prepared according to **Procedure B** from *N*-(*tert*-butyl)-2-cyano-*N*-(4'-methoxybenzyl) acetamide (3.27 g, 12.50 mmol), sodium azide (5.58 g, 85.8 mmol), trifluoromethanesulfonic anhydride (2.20 mL, 13.0 mmol) and triethylamine (1.82 mL, 13.0 mmol). The crude product was purified by flash chromatography on silica gel with hexane:ethyl acetate

as eluent. Spectroscopic characteristics were consistent with previously reported data.^[21] Yellow crystals, 2.72 g (76%); **m.p.** 108–111 °C; **¹H NMR (400 MHz, CDCl₃)**: δ= 1.41 (9H, s), 3.81 (3H, s), 4.65 (2H, s), 6.90 (2H, d, *J* 8.6), 7.12 (2H, d, *J* 8.5); **¹³C NMR (100.6 MHz, CDCl₃)**: δ= 28.5, 49.2, 55.3, 60.2, 109.9, 114.1, 127.2, 130.2, 158.9, 160.8; **IR (neat)**: 2213, 2120, 1633.

SUPPORTING INFORMATION

6. Aromatic Addition

Table SI.5: Aromatic addition catalyst screen of α -cyano- α -diazoacetamide **31**

Entry	Catalyst ^a	Time (h)	32 Yield (%) ^b	32 % ee ^c
1^d	Rh ₂ (OAc) ₄	1.0	90	-
2	Rh ₂ (2S-F-2'-NA) ₄ 9b	1.5	85	67
3	Rh ₂ (2S-MBrPA) ₄ 9h	1.5	84	53
4	Rh ₂ (2S-M-2'-NA) ₄ 9g	1.5	87	51
5	Rh ₂ (2S-FBrPA) ₄ 9d	1.5	88	59
6	Rh ₂ (2S-FOMePA) ₄ 9e	1.5	90	73
7^{d,e}	Rh ₂ (2S-FOMePA) ₄ 9e	12.0	75	60
8	Rh ₂ (2S-F-1'-NA) ₄ 9c	1.5	87	62
9	Rh ₂ (S-DOSP) ₄ 2	1.5	80	17
10	Rh ₂ (S-PTTL) ₄ 3	1.5	85	11 ^f
11	Rh ₂ (S-TCPTTL) ₄ 4	1.5	80	14
12	Rh ₂ (S-TFPTTL) ₄	1.5	82	32 ^f
13	CuPF ₆ -((R,R)-Ph-BOX)	12	88	36

^a 1.0 mol% of catalyst. ^b Purified by flash chromatography. ^c Enantiomeric excess determined by chiral HPLC analysis; dextrorotatory (+), 1S enantiomer predominates in each case, unless otherwise stated. ^d Reaction performed at room temperature. ^e Toluene used as solvent. ^f Levorotatory (-), 1R enantiomer

SUPPORTING INFORMATION






Figure SI.2: Graph of time, yield and enantiopurity versus temperature for the $\text{Rh}_2(2\text{S-F-2'-NA})_4$ **9b** catalysed transformation of α -cyano- α -diazoacetamide **31**.




Scheme SI.2: Impact of catalyst loading on the aromatic addition of affording α -cyano- α -diazoacetamide **33**.

SUPPORTING INFORMATION

Table SI.6: Rhodium acetate catalyzed aromatic addition reactions of α -cyano- α -diazoacetamides **31**, **33–45** ^[a]^[a]Isolated yields after chromatography.**Procedure C**


A round bottom flask was charged with dichloromethane (35 mL) and $\text{Rh}_2(2\text{S-FOMePA})_4$ **9e** (1.0 mol%). The flask was cooled to 0 °C, after which a solution of α -diazoacetamide (0.100 g) in CH_2Cl_2 (15 mL) was added over the course of 15 minutes. The reaction progress was monitored by IR spectroscopy. Following complete disappearance of the diazo stretch ($2119\text{--}2129\text{ cm}^{-1}$), the solution was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography using hexane:ethyl acetate (75:25) as eluent.

SUPPORTING INFORMATION

9-Aza-9-benzyl-1(S)-cyanobicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (32)


This title compound was prepared according to **Procedure C** from *N,N*-dibenzyl- α -cyano- α -diazoacetamide (0.10 g, 0.38 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Colourless crystals (0.080 g, 90%). Spectroscopic characteristics were consistent with previously reported data.^[21] **m.p.** 172–175 °C (Lit.,^[21]

172–174 °C); **Spec. Rot.:** [α]_D²⁰ +136.00 (c 0.200, CHCl₃); **HPLC:** 73% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 3.93 (1H, d, *J* 14.9), 4.16 (1H, d, *J* 14.9), 4.59 (2H, s), 5.14 (1H, d, *J* 8.8), 6.28–6.37 (1H, m), 6.40–6.49 (1H, m), 6.68–6.77 (2H, m), 7.22–7.41 (5H); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 41.9, 47.3, 49.7, 107.3 br, 113.0 br, 114.1, 122.6, 128.3, 129.6, 130.3, 128.5, 128.27, 129.1, 134.9, 167.4; **IR (neat):** 2238, 1704.

9-Aza-9-tert-butyl-1(S)-cyano-4-fluorobicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (46)

This title compound was prepared according to **Procedure C** from *N*-(*tert*-butyl)-2-cyano-2-diazo-*N*-(4'-fluorobenzyl) acetamide (0.10 g, 0.39 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.075 g, 83%); **m.p.** 175–177 °C (Lit.,^[21] 177–178 °C); **Spec. Rot.:** [α]_D²⁰ +119.67


(c 0.300, CHCl₃); **HPLC:** 88% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.48 (9H, s), 4.19 (1H, d, *J* 15.3), 4.43 (1H, d, *J* 15.3), 5.44 (1H, dd, *J* 9.7, 4.9), 6.34–6.44 (2H, m), 6.51 (1H, dd, *J* 16.0, 7.7); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 27.4, 45.5, 48.7, 55.7, 112.0 (²*J*_{CF} 28.7), 114.5, 115.7 br, 117.0 br, 120.0 (d, ³*J*_{CF} 11.3), 122.7 (d, ²*J*_{CF} 35.7), 161.0 (d, ¹*J*_{CF} 248.6), 166.2; **¹⁹F NMR (376.5 MHz, CDCl₃):** δ = −97.5; **IR (neat):** 2239, 1704.

9-Aza-9-tert-butyl-1(S)-cyano-4-bromobicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (47)


This title compound was prepared according to **Procedure C** from *N*-(*tert*-butyl)-2-cyano-2-diazo-*N*-(4'-bromobenzyl) acetamide (0.10 g, 0.33 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.089 g, 72%); **m.p.** 167–169 °C (Lit.,^[21] 169–171 °C); **Spec. Rot.:** [α]_D²⁰ +148.58

(c 0.140, CHCl₃); **HPLC:** 85% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.47 (9H, s), 4.15 (1H, d, *J* 15.4), 4.36 (1H, dd, *J* 15.3, 1.1), 5.14 (1H, d, *J* 9.3), 6.23 (1H, d, *J* 7.1), 6.57 (1H, d, *J* 9.4), 7.12 (1H, d, *J* 7.1); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 27.4, 44.1 br, 48.7, 55.7, 111.9 br, 114.1, 117.5 br, 122.0, 124.2, 131.9, 132.1, 166.2; **IR (neat):** 2238, 1702.


SUPPORTING INFORMATION

9-Aza-9-tert-butyl-1(S)-cyano-4-chlorobicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (48)

This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(4'-chlorobenzyl)acetamide (0.10 g, 0.38 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.079 g, 83%); **m.p.** 172–175 °C (Lit.,^[21] 178–179 °C); **Spec. Rot.:** [α]_D²⁰ +152.50 (c 0.080, CHCl₃); **HPLC:** 84% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.47 (9H, s), 4.17 (1H, d, *J* 15.2), 4.38 (1H, dd, *J* 15.2, 1.4), 5.19 (1H, d, *J* 9.3), 6.30–6.35 (1H, m), 6.43 (1H, dd, *J* 9.3, 1.0), 6.88 (1H, d, *J* 7.1); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 27.4, 43.7, 48.8, 55.7, 110.7 br, 114.1, 115.5 br, 121.4, 128.7, 129.6, 135.2, 166.2; **IR (neat):** 2237, 1703.

9-Aza-9-tert-butyl-1(R)-cyano-2,6-dichlorobicyclo[5.3.0]deca-2,4,6-trien-10-one (49)


This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(2',6'-dichlorobenzyl) acetamide (0.10 g, 0.34 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). White crystals (0.099 g, 98%); **m.p.** 122–124 °C; **Spec. Rot.:** [α]_D²⁰ +157.50 (c 0.080, CHCl₃); **HPLC:** 83% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.52 (9H, s), 4.23 (1H, d, *J* 16.6), 4.38 (1H, d, *J* 16.5), 6.63 (1H, d, *J* 6.7), 6.67–6.74 (1H), 6.82 (1H, d, *J* 11.4); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 27.4, 48.7, 51.0, 56.3, 112.5, 117.4, 119.0, 126.2, 127.5, 129.6, 130.0, 162.9; **IR (neat):** 2242, 1715; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₄H₁₅³⁵Cl₂N₂O, 297.0556, found 297.0559.

9-Aza-9-tert-butyl-1(S)-cyano-4-methylbicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (50)

This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(4'-methylbenzyl) acetamide (0.10 g, 0.41 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.086 g, 89%); **m.p.** 133–135 °C (Lit.,^[21] 132–133 °C); **Spec. Rot.:** [α]_D²⁰ +144.00 (c 0.100, CHCl₃); **HPLC:** 87% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.45 (9H, s), 2.11 (3H, s), 4.03 (1H, d, *J* 14.0), 4.25 (1H, d, *J* 14.0), 4.65 br (1H, d, *J* 8.2), 6.17 (1H, d, *J* 8.3), 6.22 (1H, d, *J* 7.2), 6.46 (1H, d, *J* 7.2); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 23.7, 27.4, 38.6 br, 49.0, 55.2, 96.2 br, 114.5, 122.1, 127.8, 128.1, 138.9, 167.4; **IR (neat):** 2238, 1702.

Note: Resonance for C(2) not detected due to signal broadening


SUPPORTING INFORMATION

9-Aza-9-tert-butyl-1(S)-cyano-3,5-dimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (51)

This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(3',5'-dimethylbenzyl) acetamide (0.10 g, 0.39 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.080 g, 88%); **m.p.** 191–192 °C; **Spec. Rot.:** [α]_D²⁰ +261.50 (c 0.100, CHCl₃); **HPLC:**


68% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.41 (9H, s), 2.00, 2.02 (2 × 3H, 2 × s), 3.38 (1H, br s), 3.73 (1H, d, *J* 12.2), 3.93 (1H, d, *J* 12.1), 5.77 (1H, s), 6.17 (1H, s); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 22.5, 22.6, 27.5, 49.8, 54.9, 113.4, 117.8, 128.1, 134.2, 136.3, 168.0; **IR (neat):** 2237, 1677; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₆H₂₁N₂O 257.1648, found 257.1647.

Note: Resonances for C(1), C(2)H and C(7) not detected due to signal broadening

9-Aza-9-tert-butyl-1(S)-cyano-2,4,6-trimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (52)


This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(2',4',6'-trimethylbenzyl) acetamide (0.10 g, 0.37 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.070 g, 76%); **m.p.** 184–185 °C; **Spec. Rot.:** [α]_D²⁰ +256.50 (c 0.100, CHCl₃); **HPLC:**

63% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.50 (9H, s), 1.84 (3H, s), 2.00 (3H, s), 2.10 (3H, s), 4.09 (1H, d, *J* 14.9), 4.28 (1H, d, *J* 14.8), 5.97 (1H, s), 6.41 (1H, s); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 17.8, 19.5, 24.3, 27.5, 48.3, 50.0, 55.4, 114.8, 116.1, 124.9, 127.8, 128.9, 130.0, 138.8, 166.8; **IR (neat):** 2236, 1699; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₁₇H₂₃N₂O 271.1805, found 271.1799.

9-Aza-9-tert-butyl-1(S)-cyanobicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (53)

This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-benzyl-acetamide (0.10 g, 0.44 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.080 g, 89%); **m.p.** 147–149 °C (Lit.,^[21] 147–148 °C); **Spec. Rot.:** [α]_D²⁰ +159.00 (c 0.200, CHCl₃); **HPLC:** 72% ee


(determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.47 (9H, s), 4.17 (H, dd, *J* 14.9, 1.1), 4.38 (H, dd, *J* 14.9, 1.9), 5.08 (1H, d, *J* 8.8), 6.34–6.44 (2H, m), 6.69–6.74 (2H, m); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 27.4, 43.3, 48.9, 55.4, 107.9 br, 113.7 br, 114.5, 122.2, 128.2, 129.4, 130.2, 167.1; **IR (neat):** 2236, 1700.

9-Aza-9-tert-butyl-1(R)-cyano-4-nitrobicyclo[5.3.0]deca-2,4,6-trien-10-one (54)

This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(4'-nitrobenzyl) acetamide (0.10 g, 0.37 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Colourless crystals (0.063 g, 50%); **m.p.** 124–126 °C (Lit.,^[21] 125–127 °C); **Spec. Rot.:** [α]_D²⁰ –79.17


SUPPORTING INFORMATION

(c 0.120, CHCl₃); **HPLC**: 32% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃)**: δ = 1.50 (9H, s), 4.32 (1H, d, *J* 16.7), 4.56 (1H, dd, *J* 16.7, 1.4), 5.55 (1H, d, *J* 9.7), 6.66 (1H, d, *J* 7.3), 7.33 (1H, d, *J* 9.8), 8.12 (1H, d, *J* 7.3); **¹³C NMR (100.6 MHz, CDCl₃)**: δ = 27.4, 45.2, 49.2, 56.0, 113.3, 115.5, 120.0, 123.3, 128.0, 129.4, 149.3, 165.3; **IR (neat)**: 2243, 1704, 1520, 1335.

9-Aza-9-tert-butyl-1(S)-cyano-4-methoxycarbonylbicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (55)



This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(4'-carbomethoxybenzyl) acetamide (0.10 g, 0.35 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.084 g, 82%); **m.p.** 170–172 °C (Lit.,^[21] 173–174 °C); **Spec.**

Rot.: [α]_D²⁰ +35.83 (c 0.120, CHCl₃); **HPLC**: 43% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃)**: δ = 1.48 (9H, s), 3.87 (CH₃, s), 4.19 (1H, d, *J* 15.5), 4.42 (1H, dd, *J* 15.7, 1.5), 5.11 (1H, d, *J* 9.0), 6.50 (1H, d, *J* 7.2), 7.07 (1H, d, *J* 9.0), 7.68 (1H, d, *J* 7.2); **¹³C NMR (100.6 MHz, CDCl₃)**: δ = 27.4, 41.9, 49.1, 52.6, 55.6, 105.3 br, 113.7, 115.5 br, 121.6, 128.2, 131.9, 133.7, 166.3, 166.4; **IR (neat)**: 2240, 1704.

9-Aza-9-tert-butyl-1(R)-cyano-4-trifluoromethylbicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (56)


This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(4'-trifluoromethylbenzyl) acetamide (0.10 g, 0.34 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals


(0.074 g, 76%); **m.p.** 153–155 °C (Lit.,^[21] 154–156 °C); **Spec. Rot.:** [α]_D²⁰ –24.29 (c 0.140, CHCl₃); **HPLC**: 27% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃)**: δ = 1.48 (9H, s), 4.15 (1H, d, *J* 15.1), 4.39 (1H, d, *J* 15.2), 5.08 (1H, d, *J* 8.8), 6.47 (1H, d, *J* 7.1), 6.63 (1H, d, *J* 8.9), 7.11 (1H, d, *J* 7.2); **¹³C NMR (100.6 MHz, CDCl₃)**: δ = 27.4, 40.3 br, 49.1, 55.7, 103.9 br, 113.1, 121.4, 123.1 (q, ¹J_{CF} 273.5), 124.2 (q, ³J_{CF} 3.0), 127.6 (q, ³J_{CF} 5.0), 131.7 (q, ²J_{CF} 30.7), 166.1; **¹⁹F NMR (376.5 MHz, CDCl₃)**: δ = –65.8; **IR (neat)**: 2245 (CN), 1703 (CO).

9-Aza-9-tert-butyl-1(S),4-dicyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (57)



This title compound was prepared according to **Procedure C** from *N*-(tert-butyl)-2-cyano-2-diazo-*N*-(4'-cyanobenzyl) acetamide (0.10 g, 0.40 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Colourless crystals (0.073 g, 80%); **m.p.** 153–155 °C; **Spec. Rot.:** [α]_D²⁰ +27.09 (c 0.120, CHCl₃); **HPLC**:

26% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃)**: δ = 1.48 (9H, s), 4.23 (1H, d, *J* 16.1), 4.46 (1H, dd, *J* 16.2, 1.6), 5.23 (1H, d, *J* 9.0), 6.53 (1H, d, *J* 7.0), 6.61 (1H, d, *J* 8.9), 7.26 (1H, d, *J* 6.5); **¹³C NMR (100.6 MHz, CDCl₃)**: δ = 27.4, 43.0, 49.1, 55.9, 111.0 br, 113.1, 115.1, 118.1, 120.7 br, 121.7, 128.4, 137.9, 165.5; **IR (neat)**: 2227, 1701; **HRMS (ESI-TOF)**: *m/z* [M+H]⁺ calcd for C₁₅H₁₆N₃O 254.1288, found 254.1289.

SUPPORTING INFORMATION

9-Aza-9-tert-butyl-1(S)-cyano-4-methoxybicyclo[5.3.0]deca-2,4,6-trien-10-one^[21] (58)


This title compound was prepared according to **Procedure C** from *N*-(*tert*-butyl)-2-cyano-2-diazo-*N*-(4'-methoxybenzyl)acetamide (0.10 g, 0.39 mmol) and Rh₂(2S-FOMePA)₄ **9e** (5.0 mg, 1.0 mol%) in dichloromethane (50 mL). Spectroscopic characteristics were consistent with previously reported data.^[21] Colourless crystals (0.080 g, 88%); **m.p.** 118–120 °C (Lit.,^[21] 119–120 °C); **Spec. Rot.:** [α]_D²⁰ +36.50 (c 0.200, CHCl₃); **HPLC:** 20% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.45 (9H, s), 3.69 (3H, s), 4.03 (1H, d, *J* 13.7), 4.25 (1H, d, *J* 13.8), 4.83 (1H, br s), 5.95–6.03 (2H, m), 6.25 (1H, d, *J* 8.1); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 27.4, 49.0, 55.1, 55.3, 109.1 br, 114.5, 117.7 br, 122.0, 158.6, 167.2; **IR (neat):** 2235, 1703.

2-Benzyl-3,6,8-trioxo-7-phenyl-2,3,3b,4,7,8-hexahydro-6H,10H-4,10-ethenopyrrolo-[3',4':1,3]cyclopropa[1,2-d][1,2,4]triazolo[1,2-a]pyridazine-3a(1H)-carbonitrile (59)

A 100 mL round bottom flask was charged with **32** (0.16 g, 0.62 mmol) and CH₂Cl₂ (20 mL). The flask was cooled to 0 °C after which 4-phenyl-1,2,4-triazolin-3,5-dione (0.108 g, 0.62 mmol) was added in one portion. The reaction solution was warmed to room temperature. The reaction solution was concentrated under reduced pressure and the solid residue was washed with chloroform to afford the pure cycloadduct **xx**. Colourless powder (0.136 g, 50%); **m.p.** 200–203 °C; **¹H NMR (400 MHz, DMSO-*d*₆):** δ = 2.48–2.53 (2H, m), 3.45 (1H, s, *J* 10.4), 3.86 (1H, s, *J* 10.4), 4.39 (2H, ABq, *J* 24.7, *H*_A δ = 4.46, *H*_B δ = 4.32), 5.49 (1H, dd, *J* 6.0, 1.4), 5.59–5.66 (1H, m), 6.43–6.51 (1H, m), 6.56–6.64 (1H, m), 7.24–7.55 (10H, m); **¹³C NMR (100.6 MHz, DMSO-*d*₆):** δ = 25.7, 28.2, 31.1, 46.2, 47.6, 51.7, 53.4, 114.9, 126.1, 127.7, 128.0, 128.1, 128.7, 129.1, 129.2, 130.7, 135.8, 155.7, 156.0, 164.5; **IR (neat):** 2238, 1706, 1402; **HRMS (ESI-TOF):** *m/z* [M+H]⁺ calcd for C₂₆H₂₁N₄O₃ 438.1561, found 438.1562.


9-Aza-9-tert-butyl-1-cyano-4-(4-methylphenyl)bicyclo[5.3.0]deca-2,4,6-trien-10-one (60)

Prepared according to literature procedure^[22]



A Schlenk tube was charged with 9-aza-9-*tert*-butyl-1-cyano-4-bromobicyclo(5.3.0)deca-2,4,6-trien-10-one **47** (0.37 g, 1.21 mmol), palladium(II) acetate (0.014 g, 5 mol%), 4-tolylboronic acid (0.33 g, 2.44 mmol), SPhos (0.050 g, 10 mol%) and dioxane (12 mL). The reaction mixture was sparged with N₂ gas for 20 minutes after which aqueous K₃PO₄ (2.0 mL, 3.0 M) was added. The reaction mixture was stirred for 16 hours in a 25 °C oil bath. The solution was concentrated under reduced pressure and the residue purified by silica gel chromatography using hexane:ethyl acetate (80:20) as eluent; White crystals (0.246 g, 65%); **m.p.** 200–201 °C; **¹H NMR (400 MHz, CDCl₃):** δ = 1.47 (9H, s), 2.36 (3H, s), 4.10 (1H, d, *J* 14.3), 4.31 (1H, d, *J* 14.9), 4.88 (1H, d, *J* 8.5), 6.40 (1H, d, *J* 7.4), 6.50 (1H, d, *J* 8.5), 6.92 (1H, d, *J* 7.4), 7.19 (2H, d, *J* 8.0), 7.34 (2H, d, *J* 8.1); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 21.2, 27.5, 39.2 br, 49.1, 55.4, 98.1 br, 102.2 br, 114.3, 122.5, 126.8, 127.0, 127.2, 129.4, 137.8, 138.0, 142.3, 167.2; **IR (neat):** 2977, 2238, 1700; **HRMS (ESI-TOF):** *m/z* [M+Na]⁺ calcd for C₂₁H₂₂N₂ONa 341.1624, found 341.1627.

SUPPORTING INFORMATION


Methyl 9-aza-9-*tert*-butyl-4-methylbicyclo(5.3.0)deca-2,4,6-trien-10-one-1(*R*)-carboxylate (61)*Prepared according to literature procedure^[21]*

A 50 mL round bottom flask was charged with 9-aza-9-*tert*-butyl-1-cyano-4-methylbicyclo(5.3.0)deca-2,4,6-trien-10-one **50** (0.37 g, 1.5 mmol, 85% ee) and methanolic potassium hydroxide (10 mL, 2.2 M). The reaction solution was stirred at room temperature for 12 hours after which the solution was diluted with water (20 mL) and extracted with CH₂Cl₂ (2 × 20 mL). The organic solution was dried, concentrated

under reduced pressure and the residue purified by silica gel chromatography using hexane:ethyl acetate (75:25) as eluent; White crystals (0.163 g, 40%); **m.p.** 143–145 °C; **Spec. Rot.:** [α]_D²⁰ +320.72 (c 0.070, CHCl₃); **HPLC:** 77% ee (determined by chiral phase HPLC, see **Table SI.6** for HPLC conditions); **¹H NMR (400 MHz, CDCl₃):** δ = 1.45 (9H, s), 2.01 (3H, s), 3.62 (3H, s), 4.18 (1H, d, *J* 14.6), 4.38 (1H, d, *J* 14.6), 5.50 (1H, d, *J* 10.2), 6.11 (1H, d, *J* 6.5), 6.22 (1H, d, *J* 6.5), 6.36 (1H, d, *J* 10.2); **¹³C NMR (100.6 MHz, CDCl₃):** δ = 24.4, 27.4, 49.6, 53.9, 54.6, 60.5, 119.4, 122.5, 126.0, 130.3, 132.3, 137.5, 166.8, 172.1; **IR (neat):** 2975, 1696, 1654; **HRMS (ESI-TOF):** *m/z* [M+Na]⁺ calcd for C₁₆H₂₁NO₃Na 298.1414, found 298.1411.

SUPPORTING INFORMATION

7. Synthesis of 2-allyl-2-methoxycarbonyl-2,3-dihydrobenzofuran-3-one

7.1 Synthesis of α -diazo- β -keto esterMethyl 2-diazo-3-(2-allyloxyphenyl)-3-oxopropionate^[23] (**62**)


Methyl 3-(2-allyloxyphenyl)-3-oxopropionate (0.64 g, 2.7 mmol), *p*-ABSA (0.70 g, 2.7 mmol), potassium carbonate (0.49 g, 3.6 mmol) and acetonitrile (30 mL) were used following the procedure described for **16** to give, following column chromatography on silica gel employing hexane/ethyl acetate (90:10) as the eluent, the α -diazo- β -keto ester **62** (0.59 g, 83%) as a yellow oil. Spectroscopic characteristics were consistent with

previously reported data.^[23] ¹H NMR (400 MHz, CDCl₃): δ = 3.74 (3H, s), 4.51–4.57 (2H, finely split dt, *J* 5.0, 1.5), 5.27 (1H, dd, *J* 10.7, 1.3), 5.37 (1H, dd, *J* 17.3, 1.5), 5.92–6.04 (1H, m), 6.90 (1H, d, *J* 8.4), 6.98–7.04 (1H, m), 7.35 (1H, dd, *J* 7.6, 1.5), 7.37–7.45 (1H, m); IR (neat): 2124 (CN₂), 1727, 1697 (CO), 1622, 1311, 752.

7.2 Dihydrobenzofuranone synthesis

General procedure for rhodium catalysed oxonium ylide formation-[2,3]-sigmatropic rearrangements to afford dihydrobenzofuranones

A solution of α -diazocarbonyl (100 mg, 1 equiv.) in solvent (5 mL) was added dropwise over ~15 min to a stirring solution of Rh(II) catalyst (1 mol%) in solvent (5 mL). The mixture was stirred at the temperature indicated until reaction completion was indicated by IR spectroscopy. The reaction mixture was then cooled to room temperature, concentrated under reduced pressure to give the crude product and a ¹H NMR spectrum obtained. Purification by column chromatography employing ethyl acetate in hexane as eluent gave the pure cyclisation product.

2-Allyl-2-methoxycarbonyl-2,3-dihydrobenzofuran-3-one^[24] (**63**)



A solution of methyl 2-diazo-3-(2-allyloxyphenyl)-3-oxopropionate **62** (100 mg, 0.38 mmol) in toluene (5 mL) was added dropwise over ~15 min to a solution of **9b** (6 mg, 1 mol%) in toluene (5 mL). The mixture was heated under reflux while stirring for 2 h then cooled to room temperature and concentrated under reduced pressure. Column chromatography on

silica gel employing hexane/ethyl acetate (95:5) as the eluent gave the pure dihydrobenzofuranone **63** (64.3 mg, 72%) as a white solid. Spectroscopic characteristics were consistent with previously reported data.^[24] m.p. 58–60 °C; HPLC: 74% ee (determined by chiral phase HPLC, see Table SI.6 for HPLC conditions); ¹H NMR (400 MHz, CDCl₃): δ = 2.84 (1H, dd, *J* 14.5, 7.1), 3.07 (1H, dd, *J* 14.5, 7.1), 3.77 (3H, s), 5.12 (1H, d, *J* 10.1), 5.23 (1H, dd, *J* 17.0, 0.8), 5.61–5.74 (1H, m), 7.13 (1H, t, *J* 7.4), 7.23 (1H, d, *J* 8.7), 7.62–7.70 (2H, m); IR (neat): 1748, 1709 (CO), 1607, 1250, 929, 752.



SUPPORTING INFORMATION

8. NMR Spectra



2-Phenylacetic acid (S1)

*tert*-Butyl 2-phenylacetate (S2)


SUPPORTING INFORMATION

tert*-Butyl 2-(naphthalen-2-yl)acetate (S3)**tert*-Butyl 2-(naphthalen-1-yl)acetate (S4)**


SUPPORTING INFORMATION

***tert*-Butyl 2-(4-bromophenyl)acetate (S5)**¹H NMR (400 MHz, CDCl₃)


SUPPORTING INFORMATION

***tert*-Butyl 2-(4-bromophenyl)-2-diazoacetate (6d)**




SUPPORTING INFORMATION




***tert*-Butyl 2-(4-methoxyphenyl)-2-diazoacetate (6e)**

¹³C NMR (75.5 MHz, CDCl₃)






SUPPORTING INFORMATION




***tert*-Butyl (2*S*)-2-(1''*R*,2''*R*,4''*S*)-fenchyloxy-2-phenylacetate (7a)**¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

¹H NMR (400 MHz, CDCl₃) ^{13}C NMR (100.6 MHz, CDCl_3)



SUPPORTING INFORMATION

***tert*-Butyl (2*S*)-2-(1'*R*,2'*R*,4'*S*)-fenchyloxy-2-(naphthalen-1'-yl)acetate (7c)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION



***tert*-Butyl (2*S*)-2-(4'-bromophenyl)-2-(1''*R*,2''*R*,4''*S*)-fenchyloxyacetate (7d)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION



***tert*-Butyl (2*S*)-2-(1'*R*,2'*R*,4'*S*)-fenchyloxy-2-(4'-methoxyphenyl)acetate (7e)**

SUPPORTING INFORMATION




tert-Butyl (2S)-2-(1''R,2''S,5''R)-menthyloxy-2-phenylacetate (7f)



SUPPORTING INFORMATION




tert-Butyl 2-(1''R,2''R,5''S)-menthyloxy-2-(naphthalen-2-yl)acetate (7g)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION

tert-Butyl (2S)-2-(4'-bromophenyl)-2-(1''R,2''R,5''S)-menthyloxyacetate (7h)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION

(2S)-2-(1''R,2''R,4''S)-Fenchyloxy-2-phenylacetic acid (8a)

¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)


SUPPORTING INFORMATION

(2S)-2-(1''R,2''R,4''S)-Fenchyloxy-2'-(naphthalen-2'-yl)acetic acid (8b)


¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

[illegible]





The chemical structure shows a bicyclic ether system (a norbornane derivative) connected via an oxygen atom to a chiral center. This chiral center is also bonded to a naphthalene ring and a carboxylic acid group (CO_2H).



The chemical structure shows a bicyclic ether system, specifically a norbornene derivative, substituted with a naphthalene ring and a carboxylic acid group. The naphthalene ring is attached to the bicyclic system via an ether linkage. The carboxylic acid group is attached to the naphthalene ring at the 1-position, with a wedge bond indicating stereochemistry.






SUPPORTING INFORMATION



(2S)- 2-(4'-Bromophenyl)-2-(1''R,2''R,4''S)-fenchyloxyacetic acid (8d)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION

(2S)-2-(1''R,2''R,4''S)-Fenchyloxy-2-(4'-methoxy)phenylacetic acid (8e)







¹H NMR (300 MHz, CDCl₃)





SUPPORTING INFORMATION

(2S)- 2-(4'-Bromophenyl)-2-(1''R,2''S,5''R)-menthyloxyacetic acid (8h)

¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





Dirhodium tetrakis [(2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-phenylacetate] (2S-FPA) (9a)

¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION

Dirhodium tetrakis [(2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-(naphthalen-2'-yl)acetate]



(2S-F-2'-NA) (9b)

¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION

Dirhodium tetrakis [(2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-(naphthalen-1'-yl)acetate]


(2S-F-1'-NA) (9c)







SUPPORTING INFORMATION

Dirhodium tetrakis [(2S)-2-(4'-bromophenyl)-2-(1''R,2''R,4''S)-fenchyloxyacetate]

(2S-FBrPA) (9d)





SUPPORTING INFORMATION

Dirhodium tetrakis [(2*S*)-2-(1''*R*,2''*R*,4''*S*)-fenchyloxy-2-(4'-methoxyphenyl)acetate](2*S*-FMeOPA) (9e)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION


Dirhodium tetrakis [(2S)-2-(1''R,2''S,5''R)-menthyloxy-2-phenylacetate] (2S-MPA) (9f)

¹³C NMR (75.5 MHz, CDCl₃)



SUPPORTING INFORMATION


Dirhodium tetrakis [(2S)-2-(1''R,2''S,5''R)-menthyloxy-2-(naphthalen-2'-yl)acetate]

(2S-M-2'-NA) (9g)




SUPPORTING INFORMATION

Dirhodium tetrakis [(2*S*)-2-(4'-bromophenyl)-2-(1''*R*,2''*S*,5''*R*)-menthyloxyacetate](2*S*-MBrPA) (9h)



[illegible]COC(=O)Cc1ccccc1OBn

Website Type	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1. Entertainment	7.37	7.36	7.34	7.34	7.32	7.30	7.30	7.28	7.26	7.25	7.24	7.24
2. News	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
3. Sports	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
4. Education	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
5. Health	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
6. Finance	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
7. Technology	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
8. Travel	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
9. Shopping	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
10. Social Media	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
11. Business	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24
12. Government	6.91	6.90	6.92	6.93	6.95	7.10	7.12	7.20	7.22	7.23	7.24	7.24

COc1ccccc1COC(=O)OCC

SUPPORTING INFORMATION

Methyl 2-(2-(benzyloxy)phenyl)-2-diazoacetate (10)

¹³C NMR (100.6 MHz, CDCl₃)

¹H NMR (400 MHz, CDCl₃)

c1ccccc1C(=N)C(=O)OCC2=CC=CC=C2


Integration values (from left to right): 7.60, 7.59, 7.53, 7.52, 7.44, 7.39, 7.38, 7.36, 7.34, 7.33, 7.28, 7.25, 7.23, 7.21, 7.16, 7.14, 7.13, 7.11, 7.09, 7.05, 7.02, 7.01, 6.96, 6.95, 6.90, 6.89, 5.27, 5.24, 5.16, 5.10, 5.03, 5.00, 4.99, 4.97, 4.92, 4.94, 4.90, 4.88, 4.78, 4.77, 4.76, 1.56, -0.00.

¹³C NMR (100.6 MHz, CDCl₃)


190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm

SUPPORTING INFORMATION



Isopropyl 2-(2-(benzyloxy)phenyl)-2-diazoacetate (13)



¹³C NMR (100.6 MHz, CDCl₃)



SUPPORTING INFORMATION

(2*R*,3*R*)-trans-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran^[17] (11a)**(2*S*,3*R*)-cis-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran^[17] (11b)**

¹H NMR (400 MHz, CDCl₃)


Chemical structure: (S)-2-benzyl-2-phenyl-1,3-dioxolane-5-carboxylate

Chemical shift (ppm): 170.70, 159.36, 140.63, 135.41, 129.73, 128.78, 128.67, 128.52, 128.41, 128.33, 128.26, 125.86, 123.73, 121.00, 109.96, 85.52, 77.37, 77.23, 77.08, 76.73, 67.46, 55.85, 1.99, 1.55, 1.31, 1.29, 1.26, 0.88, 0.87, 0.85, 0.83, 0.07, -0.00.



Integration: 11.09, 1.33, 2.03, 1.00, 2.02, 1.00.

 The chemical structure is (S)-1-benzyl-2-(benzyloxycarbonyl)-2,3-dihydrobenzofuran. The ¹³C NMR spectrum shows peaks at 170.1, 160.1, 139.1, 138.1, 137.1, 136.1, 135.1, 134.1, 133.1, 132.1, 131.1, 130.1, 129.1, 128.1, 127.1, 126.1, 125.1, 124.1, 123.1, 122.1, 121.1, 120.1, 119.1, 118.1, 117.1, 116.1, 115.1, 114.1, 113.1, 112.1, 111.1, 110.1, 109.1, 108.1, 107.1, 106.1, 105.1, 104.1, 103.1, 102.1, 101.1, 100.1, 99.1, 98.1, 97.1, 96.1, 95.1, 94.1, 93.1, 92.1, 91.1, 90.1, 89.1, 88.1, 87.1, 86.1, 85.1, 84.1, 83.1, 82.1, 81.1, 80.1, 79.1, 78.1, 77.1, 76.1, 75.1, 74.1, 73.1, 72.1, 71.1, 70.1, 69.1, 68.1, 67.1, 66.1, 65.1, 64.1, 63.1, 62.1, 61.1, 60.1, 59.1, 58.1, 57.1, 56.1, 55.1, 54.1, 53.1, 52.1, 51.1, 50.1, 49.1, 48.1, 47.1, 46.1, 45.1, 44.1, 43.1, 42.1, 41.1, 40.1, 39.1, 38.1, 37.1, 36.1, 35.1, 34.1, 33.1, 32.1, 31.1, 30.1, 29.1, 28.1, 27.1, 26.1, 25.1, 24.1, 23.1, 22.1, 21.1, 20.1, 19.1, 18.1, 17.1, 16.1, 15.1, 14.1, 13.1, 12.1, 11.1, 10.1, 9.1, 8.1, 7.1, 6.1, 5.1, 4.1, 3.1, 2.1, 1.1, 0.1 ppm.



SUPPORTING INFORMATION

(2*S*,3*R*)-cis-3-Benzoyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14b)

SUPPORTING INFORMATION



(2*R*,3*R*)-trans-3-Isopropoxyxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (15a)

SUPPORTING INFORMATION

(2*S*,3*R*)-cis-3-Isopropoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (15b)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl 2-(2-(benzyloxy)phenyl)-2-oxoacetate (S19)



¹H NMR (400 MHz, CDCl₃)

c1ccccc1C(=O)OCc2ccccc2


Chemical structure: c1ccccc1C(=O)OCc2ccccc2

Peak list (ppm): 7.53, 7.53, 7.51, 7.51, 7.51, 7.51, 7.56, 7.56, 7.54, 7.54, 7.53, 7.53, 7.42, 7.42, 7.38, 7.38, 7.37, 7.37, 7.34, 7.34, 7.33, 7.33, 7.32, 7.32, 7.31, 7.31, 7.30, 7.30, 7.28, 7.28, 7.28, 7.28, 7.26, 7.26, 7.25, 7.25, 7.23, 7.23, 7.20, 7.20, 7.19, 7.19, 7.18, 7.18, 7.09, 7.09, 7.07, 7.07, 7.05, 7.05, 6.99, 6.99, 5.53, 5.03, 4.98, 4.98, 4.86, 4.86, 4.80, 4.80, 4.77, 4.60, 4.60, 1.61, 1.60, 1.35, 1.35, 1.28, 1.28, 1.26, 1.26, 0.89, 0.89, 0.88, 0.88, 0.86, 0.86, 0.85, 0.85, 0.78, 0.78, -0.00, -0.00.


Integration values: 0.99, 1.03, 10.66, 1.04, 1.06, 2.01, 2.00.

SUPPORTING INFORMATION

Benzyl 2-(2-(benzyloxy)phenyl)-2-hydroxyacetate (S21)




¹³C NMR (100.6 MHz, CDCl₃)







SUPPORTING INFORMATION

The ^1H NMR and ^{13}C NMR spectra of the C–H insertion products isolated in this work are reported below. For the compounds we have previously reported, namely the *cis* thiopyran dioxides and the α -diazocarbonyl compounds (**16**, **19–24**) the spectroscopic details are in agreement with previously reported data.^[19–20]





Methyl 2-diazo-2-((4'-phenylbutyl)sulfonyl)acetate (16**)**



SUPPORTING INFORMATION

Methyl 2-diazo-2-((4'-(*p*-tolyl)butyl)sulfonyl)acetate (19)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)


SUPPORTING INFORMATION


Methyl 2-diazo-2-((4'-(4''-methoxyphenyl)butyl)sulfonyl)acetate (20)

¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)


¹H NMR (300 MHz, CDCl₃)

21







¹H NMR (300 MHz, CDCl₃)

22







SUPPORTING INFORMATION





Benzyl 2-diazo-2-(dodecylsulfonyl)acetate (**23**)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl 2-((2'-cyclohexylethyl)sulfonyl)-2-diazoacetate (24)





¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (17a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl (2S,3S)-3-phenyltetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide (17b)



¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION



For the sulfolanones in some instances signals for the minor diastereoisomer can be seen in the spectra; these are reported in the experimental section.

Methyl (2*R,3*R**)-3-benzyltetrahydrothiophene-2-carboxylate 1,1-dioxide (18a)**

¹H NMR (300 MHz, CDCl₃)



¹³C NMR (75.5 MHz, CDCl₃)



¹H NMR (300 MHz, CDCl₃)

S22

COC(=O)CS(=O)(=O)C/C=C/c1ccccc1

Chemical structure of **S22** is shown in the inset: COC(=O)CS(=O)(=O)C/C=C/c1ccccc1.





¹³C NMR (150.9 MHz, CDCl₃)

S22





COC(=O)CCS(=O)(=O)C/C=C/c1ccccc1

165.56
135.54
133.16
128.44
127.76
126.72
126.72
77.24
77.01
76.75
57.68
53.39
52.98
25.67





SUPPORTING INFORMATION

Methyl (2R,3S)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (25a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)



SUPPORTING INFORMATION

Methyl (2*R*,3*R*)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (25b)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION





Methyl (2*R**,3*R**)-3-(4'-methylbenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (S23a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl 2-((4'-(*p*-tolyl)but-3'-en-1'-yl)sulfonyl)acetate (S24)





SUPPORTING INFORMATION

Methyl (2R,3S)-3-(4'-methoxyphenyl)tetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide (26a)





¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl (2S,3S)-3-(4'-methoxyphenyl)tetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide (26b)





¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl (2*R**,3*R**)-3-(4'-methoxybenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (S25a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)





SUPPORTING INFORMATION

Methyl 2-((4'-(4''-methoxyphenyl)but-3'-en-1'-yl)sulfonyl)acetate (S26)

¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)


SUPPORTING INFORMATION

Methyl (2R,3S)-3-(4'-fluorophenyl)tetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide (27a)


¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

^{19}F NMR (282.4 MHz, CDCl_3)







-114.27





SUPPORTING INFORMATION

Methyl (2S,3S)-3-(4'-fluorophenyl)tetrahydro-2H-thiopyran-2-carboxylate 1,1-dioxide (27b)





¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

^{19}F NMR (282.4 MHz, CDCl_3)





SUPPORTING INFORMATION

Methyl (2*R**,3*R**)-3-(4'-fluorobenzyl)tetrahydrothiophene-2-carboxylate 1,1-dioxide (S27a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)





SUPPORTING INFORMATION

^{19}F NMR (282.4 MHz, CDCl_3)




SUPPORTING INFORMATION

Methyl 2-((4'-(4''-fluorophenyl)but-3'-en-1'-yl)sulfonyl)acetate (S28)

¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION

¹⁹F NMR (282.4 MHz, CDCl₃)



¹H NMR (400 MHz, CDCl₃)

28a





Chemical shift (ppm): 7.85, 7.84, 7.83, 7.82, 7.81, 7.80, 7.79, 7.78, 7.77, 7.76, 7.75, 7.74, 7.73, 7.72, 7.71, 7.70, 7.69, 7.68, 7.67, 7.66, 7.65, 7.64, 7.63, 7.62, 7.61, 7.60, 7.59, 7.58, 7.57, 7.56, 7.55, 7.54, 7.53, 7.52, 7.51, 7.50, 7.49, 7.48, 7.47, 7.46, 7.45, 7.44, 7.43, 7.42, 7.41, 7.40, 7.39, 7.38, 7.37, 7.36, 7.35, 7.34, 7.33, 7.32, 7.31, 7.30, 7.29, 7.28, 7.27, 7.26, 7.25, 7.24, 7.23, 7.22, 7.21, 7.20, 7.19, 7.18, 7.17, 7.16, 7.15, 7.14, 7.13, 7.12, 7.11, 7.10, 7.09, 7.08, 7.07, 7.06, 7.05, 7.04, 7.03, 7.02, 7.01, 7.00, 6.99, 6.98, 6.97, 6.96, 6.95, 6.94, 6.93, 6.92, 6.91, 6.90, 6.89, 6.88, 6.87, 6.86, 6.85, 6.84, 6.83, 6.82, 6.81, 6.80, 6.79, 6.78, 6.77, 6.76, 6.75, 6.74, 6.73, 6.72, 6.71, 6.70, 6.69, 6.68, 6.67, 6.66, 6.65, 6.64, 6.63, 6.62, 6.61, 6.60, 6.59, 6.58, 6.57, 6.56, 6.55, 6.54, 6.53, 6.52, 6.51, 6.50, 6.49, 6.48, 6.47, 6.46, 6.45, 6.44, 6.43, 6.42, 6.41, 6.40, 6.39, 6.38, 6.37, 6.36, 6.35, 6.34, 6.33, 6.32, 6.31, 6.30, 6.29, 6.28, 6.27, 6.26, 6.25, 6.24, 6.23, 6.22, 6.21, 6.20, 6.19, 6.18, 6.17, 6.16, 6.15, 6.14, 6.13, 6.12, 6.11, 6.10, 6.09, 6.08, 6.07, 6.06, 6.05, 6.04, 6.03, 6.02, 6.01, 6.00, 5.99, 5.98, 5.97, 5.96, 5.95, 5.94, 5.93, 5.92, 5.91, 5.90, 5.89, 5.88, 5.87, 5.86, 5.85, 5.84, 5.83, 5.82, 5.81, 5.80, 5.79, 5.78, 5.77, 5.76, 5.75, 5.74, 5.73, 5.72, 5.71, 5.70, 5.69, 5.68, 5.67, 5.66, 5.65, 5.64, 5.63, 5.62, 5.61, 5.60, 5.59, 5.58, 5.57, 5.56, 5.55, 5.54, 5.53, 5.52, 5.51, 5.50, 5.49, 5.48, 5.47, 5.46, 5.45, 5.44, 5.43, 5.42, 5.41, 5.40, 5.39, 5.38, 5.37, 5.36, 5.35, 5.34, 5.33, 5.32, 5.31, 5.30, 5.29, 5.28, 5.27, 5.26, 5.25, 5.24, 5.23, 5.22, 5.21, 5.20, 5.19, 5.18, 5.17, 5.16, 5.15, 5.14, 5.13, 5.12, 5.11, 5.10, 5.09, 5.08, 5.07, 5.06, 5.05, 5.04, 5.03, 5.02, 5.01, 5.00, 4.99, 4.98, 4.97, 4.96, 4.95, 4.94, 4.93, 4.92, 4.91, 4.90, 4.89, 4.88, 4.87, 4.86, 4.85, 4.84, 4.83, 4.82, 4.81, 4.80, 4.79, 4.78, 4.77, 4.76, 4.75, 4.74, 4.73, 4.72, 4.71, 4.70, 4.69, 4.68, 4.67, 4.66, 4.65, 4.64, 4.63, 4.62, 4.61, 4.60, 4.59, 4.58, 4.57, 4.56, 4.55, 4.54, 4.53, 4.52, 4.51, 4.50, 4.49, 4.48, 4.47, 4.46, 4.45, 4.44, 4.43, 4.42, 4.41, 4.40, 4.39, 4.38, 4.37, 4.36, 4.35, 4.34, 4.33, 4.32, 4.31, 4.30, 4.29, 4.28, 4.27, 4.26, 4.25, 4.24, 4.23, 4.22, 4.21, 4.20, 4.19, 4.18, 4.17, 4.16, 4.15, 4.14, 4.13, 4.12, 4.11, 4.10, 4.09, 4.08, 4.07, 4.06, 4.05, 4.04, 4.03, 4.02, 4.01, 4.00, 3.99, 3.98, 3.97, 3.96, 3.95, 3.94, 3.93, 3.92, 3.91, 3.90, 3.89, 3.88, 3.87, 3.86, 3.85, 3.84, 3.83, 3.82, 3.81, 3.80, 3.79, 3.78, 3.77, 3.76, 3.75, 3.74, 3.73, 3.72, 3.71, 3.70, 3.69, 3.68, 3.67, 3.66, 3.65, 3.64, 3.63, 3.62, 3.61, 3.60, 3.59, 3.58, 3.57, 3.56, 3.55, 3.54, 3.53, 3.52, 3.51, 3.50, 3.49, 3.48, 3.47, 3.46, 3.45, 3.44, 3.43, 3.42, 3.41, 3.40, 3.39, 3.38, 3.37, 3.36, 3.35, 3.34, 3.33, 3.32, 3.31, 3.30, 3.29, 3.28, 3.27, 3.26, 3.25, 3.24, 3.23, 3.22, 3.21, 3.20, 3.19, 3.18, 3.17, 3.16, 3.15, 3.14, 3.13, 3.12, 3.11, 3.10, 3.09, 3.08, 3.07, 3.06, 3.05, 3.04, 3.03, 3.02, 3.01, 3.00, 2.99, 2.98, 2.97, 2.96, 2.95, 2.94, 2.93, 2.92, 2.91, 2.90, 2.89, 2.88, 2.87, 2.86, 2.85, 2.84, 2.83, 2.82, 2.81, 2.80, 2.79, 2.78, 2.77, 2.76, 2.75, 2.74, 2.73, 2.72, 2.71, 2.70, 2.69, 2.68, 2.67, 2.66, 2.65, 2.64, 2.63, 2.62, 2.61, 2.60, 2.59, 2.58, 2.57, 2.56, 2.55, 2.54, 2.53, 2.52, 2.51, 2.50, 2.49, 2.48, 2.47, 2.46, 2.45, 2.44, 2.43, 2.42, 2.41, 2.40, 2.39, 2.38, 2.37, 2.36, 2.35, 2.34, 2.33, 2.32, 2.31, 2.30, 2.29, 2.28, 2.27, 2.26, 2.25, 2.24, 2.23, 2.22, 2.21, 2.20, 2.19, 2.18, 2.17, 2.16, 2.15, 2.14, 2.13, 2.12, 2.11, 2.10, 2.09, 2.08, 2.07, 2.06, 2.05, 2.04, 2.03, 2.02, 2.01, 2.00, 1.99, 1.98, 1.97, 1.96, 1.95, 1.94, 1.93, 1.92, 1.91, 1.90, 1.89, 1.88, 1.87, 1.86, 1.85, 1.84, 1.83, 1.82, 1.81, 1.80, 1.79, 1.78, 1.77, 1.76, 1.75, 1.74, 1.73, 1.72, 1.71, 1.70, 1.69,





28a

O=S(=O)C1(Cc2ccccc2)CCCC1C(=O)c3ccccc3





Chemical Shift (ppm)	Assignment
~192	Carbonyl (C=O)
~138, ~135, ~132, ~128, ~125	Aromatic (C ₆ H ₅)
~75	Sulfone (SO ₂)
~55, ~45, ~35, ~25	Aliphatic (C ₄ H ₈)

SUPPORTING INFORMATION





Benzyl (2*R*,3*R*)-3-octyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (29a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

¹H NMR (300 MHz, CDCl₃) ^{13}C NMR (75.5 MHz, CDCl_3)





SUPPORTING INFORMATION

Benzyl (2*R**,3*R**)-3-nonyltetrahydrothiophene-2-carboxylate 1,1-dioxide (S30a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)





SUPPORTING INFORMATION

Methyl (1*R*,4*aS*,8*aR*)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide (30a)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)





SUPPORTING INFORMATION

Methyl (1*R**,4*aR**,8*aS**)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide (30b)¹H NMR (300 MHz, CDCl₃)¹³C NMR (75.5 MHz, CDCl₃)

SUPPORTING INFORMATION



***N,N*-Dibenzyl-2-cyano-2-diazoacetamide (31)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-fluorobenzyl)acetamide (33)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





^{19}F NMR (376.5 MHz, CDCl_3)







SUPPORTING INFORMATION

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-bromobenzyl)acetamide (34)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION





***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-chlorobenzyl)acetamide (35)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(2',6'-dichlorobenzyl)acetamide (36)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-methylbenzyl)acetamide (37)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

¹H NMR (400 MHz, CDCl₃) ^{13}C NMR (100.6 MHz, CDCl_3)





SUPPORTING INFORMATION

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(2',4',6'-trimethylbenzyl)acetamide (39)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION

***N*-Benzyl-*N*-(*tert*-butyl)-2-cyano-2-diazoacetamide (40)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-nitrobenzyl)acetamide (41)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION



***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-methoxycarbonylbenzyl)acetamide (42)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-trifluoromethylbenzyl)acetamide (43)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





¹⁹F NMR (376.5 MHz, CDCl₃)



SUPPORTING INFORMATION





***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-cyanobenzyl)acetamide (44)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)




SUPPORTING INFORMATION

***N*-(*tert*-Butyl)-2-cyano-2-diazo-*N*-(4'-methoxybenzyl)acetamide (45)**¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION



9-Aza-9-benzyl-1(S)-cyano-4-bicyclo[5.3.0]deca-2,4,6-trien-10-one (32)

¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





¹H NMR (400 MHz, CDCl₃) ^{13}C NMR (100.6 MHz, CDCl_3)

SUPPORTING INFORMATION





^{19}F NMR (376.5 MHz, CDCl_3)





SUPPORTING INFORMATION





9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-bromobicyclo[5.3.0]deca-2,4,6-trien-10-one (47)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-chlorobicyclo[5.3.0]deca-2,4,6-trien-10-one (48)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

¹H NMR (400 MHz, CDCl₃) ^{13}C NMR (100.6 MHz, CDCl_3)





SUPPORTING INFORMATION

9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-methylbicyclo[5.3.0]deca-2,4,6-trien-10-one (50)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION

9-Aza-9-*tert*-butyl-1(*S*)-cyano-3,5-dimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (51)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION

9-Aza-9-*tert*-butyl-1(*S*)-cyano-2,4,6-trimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (52)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION

9-Aza-9-*tert*-butyl-1(*S*)-cyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (53)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)





SUPPORTING INFORMATION

9-Aza-9-*tert*-butyl-1(*R*)-cyano-4-nitrobicyclo[5.3.0]deca-2,4,6-trien-10-one (54)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION



9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-methoxycarbonylbicyclo[5.3.0]deca-2,4,6-trien-10-one (55)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





9-Aza-9-*tert*-butyl-1(*R*)-cyano-4-fluorobicyclo[5.3.0]deca-2,4,6-trien-10-one (56)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





^{19}F NMR (376.5 MHz, CDCl_3)



SUPPORTING INFORMATION


9-Aza-9-*tert*-butyl-1(*S*),4-dicyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (57)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-methoxybicyclo[5.3.0]deca-2,4,6-trien-10-one (58)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION





2-Benzyl-3,6,8-trioxo-7-phenyl-2,3,3b,4,7,8-hexahydro-6H,10H-4,10-ethenopyrrolo[3',4':1,3]cyclopropa[1,2-d][1,2,4]triazolo[1,2-a]pyridazine-3a(1H)-carbonitrile (59)



SUPPORTING INFORMATION

9-Aza-9-*tert*-butyl-1-cyano-4-(4-methylphenyl)bicyclo[5.3.0]deca-2,4,6-trien-10-one (60)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

SUPPORTING INFORMATION

Methyl-9-aza-9-*tert*-butyl-4-methylbicyclo[5.3.0]deca-2,4,6-trien-10-one-1(*R*)-carboxylate (61)¹H NMR (400 MHz, CDCl₃)¹³C NMR (100.6 MHz, CDCl₃)

¹H NMR (400 MHz, CDCl₃)

NMR (400 MHz, CDCl₃)

Chemical structure of methyl 2-methyl-2-((2-oxo-2H-chromene-2-ylidene)ethyl)acrylate is shown in the inset.








Chemical shifts (ppm): 7.68, 7.68, 7.67, 7.66, 7.66, 7.27, 7.27, 7.26, 7.26, 7.25, 7.25, 7.15, 7.15, 7.12, 7.12, 5.72, 5.72, 5.70, 5.69, 5.68, 5.68, 5.65, 5.65, 5.62, 5.62, 5.24, 5.24, 5.21, 5.21, 5.09, 5.09, 3.77, 3.05, 3.05, 3.04, 3.04, 2.87, 2.87, 2.83, 2.83, 1.65, 1.35, 1.35, 1.26, 1.26, 1.20, 1.20, 0.88, 0.88, 0.85, 0.85, -0.00.

Integrations: 1.98, 1.00, 1.00, 0.99, 1.01, 1.01, 3.01, 1.00, 1.00.







SUPPORTING INFORMATION

9. HPLC Chromatograms







Table SI.7 HPLC Chromatograms

Compound	Compound Number	Column	λ max (cm ⁻¹)	Mobile Phase (Hexane: IPA)	Temp (°C)	Flow Rate (mL/min)	Retention Time	
							Enantiomer	Min
	11a	Phenomenex Lux [®] 3 μ m Amylose-1	210	99 : 1	25	1.0	(+)-(2S,3S)	11
							(-)-(2R,3R)	12
	11b	Phenomenex Lux [®] 3 μ m Amylose-1	210	99 : 1	25	1.0	(-)-(2S,3R)	15
							(+)-(2R,3S)	17
	14a	Phenomenex Lux [®] 3 μ m Amylose-1	210	99 : 1	25	1.0	(+)-(2S,3S)	17
							(-)-(2R,3R)	19
	14b	Phenomenex Lux [®] 3 μ m Amylose-1	210	95 : 5	25	1.0	(-)-(2S,3R)	12
							(+)-(2R,3S)	16
	15a	Daicel Chiralcel [®] OJ-H	210	99 : 1	25	1.0	(-)-(2R,3R)	10
							(+)-(2S,3S)	14
	15b	Phenomenex Lux [®] 3 μ m Amylose-1	210	95 : 5	25	1.0	(-)-(2S,3R)	6.5
							(+)-(2R,3S)	6.7
	17a	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	90 : 10	25	1.0	(-)-(2R,3S)	35
							(+)-(2S,3R)	38








SUPPORTING INFORMATION

Compound	Compound Number	Column	λ max (cm ⁻¹)	Mobile Phase (Hexane: IPA)	Temp (°C)	Flow Rate (mL/min)	Retention Time	
							Enantiomer	Min
	25a	Phenomenex Lux [®] 3 μ m Amylose-1	212	80 : 20	25	1.0	(-)-(2 <i>R</i> ,3 <i>S</i>)	14
							(+)-(2 <i>S</i> ,3 <i>R</i>)	16
	27a	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	80 : 20	25	1.0	(-)-(2 <i>R</i> ,3 <i>S</i>)	17
							(+)-(2 <i>S</i> ,3 <i>R</i>)	20
	26a	Phenomenex Lux [®] 3 μ m Amylose-1	226.2	80 : 20	25	1.0	(-)-(2 <i>R</i> ,3 <i>S</i>)	19
							(+)-(2 <i>S</i> ,3 <i>R</i>)	23
	28a	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	90 : 10	25	1.0	(-)	28
							(+)	41
	29a	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	90 : 10	25	1.0	(+)-(2 <i>S</i> ,3 <i>S</i>)	13
							(-)-(2 <i>R</i> ,3 <i>R</i>)	18
	30a	Phenomenex Lux [®] 3 μ m Amylose-1	216	90 : 10	25	1.0	(+) (1 <i>S</i> ,4 <i>aR</i> ,8 <i>aS</i>)	19
							(-) (1 <i>R</i> ,4 <i>aS</i> ,8 <i>aR</i>)	25




SUPPORTING INFORMATION


Compound	Compound Number	Column	λ max (cm ⁻¹)	Mobile Phase (Hexane: IPA)	Temp (°C)	Flow Rate (mL/min)	Retention Time	
							Enantiomer	Min
	32	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1R)	16
							(+)-(1S)	24
	46	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1R)	8
							(+)-(1S)	11
	47	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1R)	8
							(+)-(1S)	12
	48	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1R)	8
							(+)-(1S)	11
	49	Phenomenex Lux [®] 3 μ m Amylose-1	214.5	95 : 05	25	0.5	(-)-(1S)	19
							(+)-(1R)	20
	50	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1R)	6
							(+)-(1S)	9

SUPPORTING INFORMATION


Compound	Compound Number	Column	λ max (cm ⁻¹)	Mobile Phase (Hexane: IPA)	Temp (°C)	Flow Rate (mL/min)	Retention Time	
							Enantiomer	Min
	51	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1 <i>R</i>)	6
							(+)-(1 <i>S</i>)	7
	52	Phenomenex Lux [®] 3 μ m Amylose-1	211.0	90 : 10	25	0.5	(-)-(1 <i>R</i>)	11
							(+)-(1 <i>S</i>)	12
	53	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1 <i>R</i>)	7
							(+)-(1 <i>S</i>)	9
	54	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1 <i>R</i>)	16
							(+)-(1 <i>S</i>)	23
	55	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1 <i>R</i>)	12
							(+)-(1 <i>S</i>)	15
	56	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1 <i>R</i>)	7
							(+)-(1 <i>S</i>)	10
	57	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	90 : 10	25	0.5	(-)-(1 <i>R</i>)	26
							(+)-(1 <i>S</i>)	44

SUPPORTING INFORMATION

Compound	Compound Number	Column	λ max (cm ⁻¹)	Mobile Phase (Hexane: IPA)	Temp (°C)	Flow Rate (mL/min)	Retention Time	
							Enantiomer	Min
	58	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-)-(1 <i>R</i>)	8
							(+)-(1 <i>S</i>)	11
	61	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(+)-(1 <i>R</i>)	30
							(-)-(1 <i>S</i>)	32
	63	Phenomenex Lux [®] 3 μ m Amylose-1	210	99 : 1	25	0.5	2 <i>S</i>	29
							2 <i>R</i>	31


(2*R,3*R**)-trans-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (11a)**

*Isolated from the reaction of **10** in the presence of $Rh_2(OAc)_4$.


(2*R*,3*R*)-2,3-trans-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (11a)

*Isolated from the reaction of **10** in the presence of $Rh_2(2S-M-2'-NA)_4$ **9g** (Table 1, entry 9).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
11a	Phenomenex Lux® 3 μ m Amylose-1	210	99:1	25	1.0	(+) (2 <i>S</i> ,3 <i>S</i>)	11
						(-) (2 <i>R</i> ,3 <i>R</i>)	12


(2*S,3*R**)-cis-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (11b)**

**Isolated from the reaction of 10 in the presence of Rh₂(OAc)₄.*


(2*S*,3*R*)-2,3-cis-3-Methoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (11b)

**Isolated from the reaction of 10 in the presence of Rh₂(2*S*-M-2'-NA)₄ 9g (Table 1, entry 9).*

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
11b	Phenomenex Lux® 3 μ m Amylose-1	210	99:1	25	1.0	(-) (2 <i>S</i> ,3 <i>R</i>)	15
						(+) (2 <i>R</i> ,3 <i>S</i>)	17


(2*R,3*R**)-trans-3-Benzoyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14a)**

**Isolated from the reaction of 12 in the presence of Rh₂(OAc)₄.*


(2*R*,3*R*)-2,3-trans-3-Benzoyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14a)

**Isolated from the reaction of 12 in the presence of Rh₂(2*S*-MPA)₄ 9f (Table 2, entry 14).*

Compound	Column	λ _{max} (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
14a	Phenomenex Lux® 3μm Amylose-1	210	99:1	25	1.0	(+) (2 <i>S</i> ,3 <i>S</i>)	17
						(-) (2 <i>R</i> ,3 <i>R</i>)	19


(2*S,3*R**)-cis-3-Benzoyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14b)**

**Isolated from the reaction of 12 in the presence of Rh₂(OAc)₄.*


(2*S*,3*R*)-2,3-cis-3-Benzoyloxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (14b)

**Isolated from the reaction of 12 in the presence of Rh₂(2*S*-MPA)₄ 9f (Table 2, entry 14).*

Compound	Column	λ _{max} (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
14b	Phenomenex Lux® 3μm Amylose-1	210	95:5	25	1.0	(-) (2 <i>S</i> ,3 <i>R</i>)	12
						(+) (2 <i>R</i> ,3 <i>S</i>)	16


(2*R,3*R**)-trans-3-Isopropoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (15a)**

Isolated from the reaction of **13 in the presence of $Rh_2(OAc)_4$.*


(2*R*,3*R*)-2,3-trans-3-Isopropoxycarbonyl-2-phenyl-2,3-dihydrobenzofuran (15a)

Isolated from the reaction of **13 in the presence of $Rh_2(2S\text{-MPA})_4$ **9f** (Table 2, entry 22).*

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
15a	Daicel Chiralcel® OJ-H	210	99:1	25	1.0	(-) (2 <i>R</i> ,3 <i>R</i>)	10
						(+) (2 <i>S</i> ,3 <i>S</i>)	14


(2*S,3*R**)-cis-3-Isopropoxy carbonyl-2-phenyl-2,3-dihydrobenzofuran (15b)**

Isolated from the reaction of **13 in the presence of Rh₂(OAc)₄.*


(2*S*,3*R*)-2,3-cis-3-Isopropoxy carbonyl-2-phenyl-2,3-dihydrobenzofuran (15b)

Isolated from the reaction of **13 in the presence of Rh₂(2*S*-MPA)₄ **9f** (Table 2, entry 22).*

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
15b	Phenomenex Lux® 3μm Amylose-1	210	95:5	25	1.0	(-) (2 <i>S</i> ,3 <i>R</i>)	6.5
						(+) (2 <i>R</i> ,3 <i>S</i>)	6.7


Methyl (2*R**,3*S**)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (17a)

*Isolated from reaction of **16** in the presence of $Rh_2(OAc)_4$ at room temperature.


Methyl (2*R*,3*S*)-3-phenyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (17a)

*Isolated from reaction of **16** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Table 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
17a	Phenomenex Lux® 3 μ m Amylose-1	209.8	90:10	25	1.0	(-) (2 <i>R</i> ,3 <i>S</i>)	35
						(+) (2 <i>S</i> ,3 <i>R</i>)	38


Methyl (2*R**,3*S**)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (25a)

*Isolated from reaction of **19** in the presence of $Rh_2(OAc)_4$ at room temperature.


Methyl (2*R*,3*S*)-3-(*p*-tolyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (25a)

*Isolated from reaction of **19** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Table 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
25a	Phenomenex Lux® 3 μ m Amylose-1	212	80:20	25	1.0	(-) (2 <i>R</i> ,3 <i>S</i>)	14
						(+) (2 <i>S</i> ,3 <i>R</i>)	16


Methyl (2*R,3*S**)-3-(4'-methoxyphenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (26a)**

*Isolated from reaction of **20** in the presence of $Rh_2(OAc)_4$ at room temperature.


Methyl (2*R*,3*S*)-3-(4'-methoxyphenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (26a)

*Isolated from reaction of **20** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Table 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
26a	Phenomenex Lux® 3µm Amylose-1	226.2	80:20	25	1.0	(-) (2 <i>R</i> ,3 <i>S</i>)	19
						(+) (2 <i>S</i> ,3 <i>R</i>)	23


Methyl (2*R,3*S**)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (27a)**

*Isolated from reaction of **21** in the presence of $Rh_2(OAc)_4$ at room temperature.


Methyl (2*R*,3*S*)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (27a)

*Isolated from reaction of **21** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Table 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
27a	Phenomenex Lux® 3 μ m Amylose-1	209.8	80:20	25	1.0	(-) (2 <i>R</i> ,3 <i>S</i>)	17
						(+) (2 <i>S</i> ,3 <i>R</i>)	20


((2*R,3*S**)-1,1-Dioxido-3-phenyltetrahydro-2*H*-thiopyran-2-yl)(phenyl)methanone (28a)**

*Isolated from reaction of **22** in the presence of $Rh_2(OAc)_4$ at room temperature.


((2*R,3*S**)-1,1-Dioxido-3-phenyltetrahydro-2*H*-thiopyran-2-yl)(phenyl)methanone (28a)**

*Isolated from reaction of **22** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Table 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
28a	Phenomenex Lux® 3µm Amylose-1	209.8	90:10	25	1.0	(-)	28
						(+)	41


Benzyl (2*R**,3*R**)-3-octyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (29a)

*Isolated from reaction of **23** in the presence of $Rh_2(OAc)_4$ at room temperature.


Benzyl (2*R*,3*R*)-3-octyltetrahydro-2*H*-thiopyran-2-carboxylate 1,1-dioxide (29a)

*Isolated from reaction of **23** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Table 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
29a	Phenomenex Lux® 3 μ m Amylose-1	209.8	90:10	25	1.0	(+) (2 <i>S</i> ,3 <i>S</i>)	13
						(-) (2 <i>R</i> ,3 <i>R</i>)	18


Methyl (1*R,4*aS**,8*aR**)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide (30a)**

*Isolated from reaction of **24** in the presence of $Rh_2(OAc)_4$ at room temperature.


Methyl (1*R*,4*aS*,8*aR*)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide (30a)

*Isolated from reaction of **24** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Table 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
30a	Phenomenex Lux® 3 μ m Amylose-1	216	90:10	25	1.0	(+) (1 <i>S</i> ,4 <i>aR</i> ,8 <i>aS</i>)	19
						(-) (1 <i>R</i> ,4 <i>aS</i> ,8 <i>aR</i>)	25


9-Aza-9-benzyl-1(*R)-cyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (32)**

*Isolated from reaction of **31** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-benzyl-1(*S*)-cyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (32)

*Isolated from reaction of **31** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
32	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	16
						(+) (1 <i>S</i>)	24


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-fluorobicyclo[5.3.0]deca-2,4,6-trien-10-one (46)**

*Isolated from reaction of **33** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-fluorobicyclo[5.3.0]deca-2,4,6-trien-10-one (46)

*Isolated from reaction of **33** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
46	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	8
						(+) (1 <i>S</i>)	11


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-bromobicyclo[5.3.0]deca-2,4,6-trien-10-one (47)**

*Isolated from reaction of **34** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-bromobicyclo[5.3.0]deca-2,4,6-trien-10-one (47)

*Isolated from reaction of **34** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
47	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	8
						(+) (1 <i>S</i>)	12


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-chlorobicyclo[5.3.0]deca-2,4,6-trien-10-one (48)**

*Isolated from reaction of **35** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-chlorobicyclo[5.3.0]deca-2,4,6-trien-10-one (48)

*Isolated from reaction of **35** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
48	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	8
						(+) (1 <i>S</i>)	11


9-Aza-9-*tert*-butyl-1(*R)-cyano-2,6-dichlorobicyclo[5.3.0]deca-2,4,6-trien-10-one (49)**

*Isolated from reaction of **36** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*R*)-cyano-2,6-dichlorobicyclo[5.3.0]deca-2,4,6-trien-10-one (49)

*Isolated from reaction of **36** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
49	Phenomenex Lux® 3 μ m Amylose-1	214.5	95 : 05	25	0.5	(-) (1S)	19
						(+) (1R)	20


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-methylbicyclo[5.3.0]deca-2,4,6-trien-10-one (50)**

**Isolated from reaction of 37 in the presence of Rh₂(OAc)₄ at room temperature.*


9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-methylbicyclo[5.3.0]deca-2,4,6-trien-10-one (50)

**Isolated from reaction of 37 in the presence of Rh₂(2S-FOMePA)₄ 9e (Table 5).*

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
50	Phenomenex Lux [®] 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	6
						(+) (1 <i>S</i>)	9


9-Aza-9-*tert*-butyl-1(*R)-cyano-3,5-dimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (51)**

*Isolated from reaction of **38** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*S*)-cyano-3,5-dimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (51)

*Isolated from reaction of **38** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
51	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	6
						(+) (1 <i>S</i>)	7


9-Aza-9-tert-butyl-1(R*)-cyano-2,4,6-trimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (52)

*Isolated from reaction of **39** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-tert-butyl-1(S)-cyano-2,4,6-trimethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (52)

*Isolated from reaction of **39** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
52	Phenomenex Lux® 3 μ m Amylose-1	211.0	90 : 10	25	0.5	(-) (1R)	11
						(+) (1S)	12


9-Aza-9-tert-butyl-1(R*)-cyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (53)

*Isolated from reaction of **40** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-tert-butyl-1(S)-cyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (53)

*Isolated from reaction of **40** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
53	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1R)	7
						(+) (1S)	9


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-nitrobicyclo[5.3.0]deca-2,4,6-trien-10-one (54)**

*Isolated from reaction of **41** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*R*)-cyano-4-nitrobicyclo[5.3.0]deca-2,4,6-trien-10-one (54)

*Isolated from reaction of **41** in the presence of $Rh_2(2S\text{-FOMePA})_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
54	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1R)	16
						(+) (1S)	23


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-methoxycarbonylbicyclo[5.3.0]deca-2,4,6-trien-10-one (55)**

*Isolated from reaction of **42** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-methoxycarbonylbicyclo[5.3.0]deca-2,4,6-trien-10-one (55)

*Isolated from reaction of **42** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
55	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	12
						(+) (1 <i>S</i>)	15


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-trifluoromethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (56)**

*Isolated from reaction of **43** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-trifluoromethylbicyclo[5.3.0]deca-2,4,6-trien-10-one (56)**

*Isolated from reaction of **43** in the presence of $Rh_2(2S\text{-FOMePA})_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
56	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1R)	7
						(+) (1S)	10


9-Aza-9-*tert*-butyl-1(*R*^{*}),4-dicyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (57)

*Isolated from reaction of **44** in the presence of $Rh_2(OAc)_4$ at room temperature.


9-Aza-9-*tert*-butyl-1(*S*),4-dicyanobicyclo[5.3.0]deca-2,4,6-trien-10-one (57)

*Isolated from reaction of **44** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
57	Phenomenex Lux® 3 μ m Amylose-1	209.8	90 : 10	25	0.5	(-) (1 <i>R</i>)	26
						(+) (1 <i>S</i>)	44


9-Aza-9-*tert*-butyl-1(*R)-cyano-4-methoxybicyclo[5.3.0]deca-2,4,6-trien-10-one (58)**

*Isolated from reaction of **45** in the presence of $Rh_2(OAc)_4$ at room temperature.

9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-methoxybicyclo[5.3.0]deca-2,4,6-trien-10-one (58)


*Isolated from reaction of **45** in the presence of $Rh_2(2S-FOMePA)_4$ **9e** (Table 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
58	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(-) (1 <i>R</i>)	8
						(+) (1 <i>S</i>)	11


Methyl 9-aza-9-*tert*-butyl-4-methylbicyclo[5.3.0]deca-2,4,6-trien-10-one-1(*R*)-carboxylate (61)

Basic hydrolysis of enantioenriched 50 (Scheme 4).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
61	Phenomenex Lux® 3 μ m Amylose-1	209.8	85 : 25	25	1.0	(+) (1 <i>R</i>)	30
						(-) (1 <i>S</i>)	32

(*R)-2-Allyl-2-methoxycarbonyl-2,3-dihydrobenzofuran-3-one (63)**

*Isolated from the reaction of **62** in the presence of $Rh_2(OAc)_4$.

(*R*)-2-Allyl-2-methoxycarbonyl-2,3-dihydrobenzofuran-3-one (63)


*Isolated from the reaction of **62** in the presence of $Rh_2(2S-F-2'-NA)_4$ **9b** (Scheme 5).

Compound	Column	λ max (nm)	Mobile Phase (Hex:IPA)	Temp (°C)	Flow (mL/min)	Retention Time	
						Enantiomer	min
63	Phenomenex Lux® 3 μ m Amylose-1	210	99 : 1	25	0.5	2S	29
						2R	31

10. Crystal Structures and Data

(+)-*tert*-Butyl (2*S*)-2-(1''*R*,2''*R*,4''*S*)-fenchyloxy-2-(naphthalen-2'-yl)acetate (**7b**)

The stereochemistry was determined by single crystal X-ray diffraction on a crystalline sample of (**2S**)-**7b** grown by slow evaporation over a number of days from a saturated solution of (**2S**)-**7b** in acetonitrile in a 20 mL vial.




An ORTEP view of (**2S**)-**7b** showing the structure and relative stereochemistry. Anisotropic parameters are drawn at the 30% probability level.

The X-ray crystallography data of (**2S**)-**7b** can be found in **Table SI.7**.

(-)-tert-Butyl (2S)-2-(1''R,2''R,4''S)-fenchyloxy-2-(naphthalen-1'-yl)acetate (7c)

The stereochemistry was determined by single crystal X-ray diffraction on a crystalline sample of **(2S)-7c** grown by slow evaporation over a number of days from a saturated solution of **(2S)-7c** in acetonitrile in a 20 mL vial.




*An ORTEP view of **(2S)-7c** showing the structure and relative stereochemistry. Anisotropic parameters are drawn at the 30% probability level. Only one disordered component is shown for clarity.*

The X-ray crystallography data of **(2S)-7c** can be found in **Table SI.7**.

(+)-tert-Butyl (2S)-2-(4'-bromophenyl)-2-(1''R,2''R,4''S)-fenchyloxyacetate (7d)

The stereochemistry was determined by single crystal X-ray diffraction on a crystalline sample of **(2S)-7d** grown by slow evaporation over a number of days from a saturated solution of **(2S)-7d** in acetonitrile in a 20 mL vial.




*An ORTEP view of **(2S)-7d** showing the structure and relative stereochemistry. Anisotropic parameters are drawn at the 30% probability level.*

The X-ray crystallography data of **(2S)-7d** can be found in **Table SI.7**.

(-)-tert-Butyl (2S)-2-(1''R,2''S,5''R)-menthyloxy-2-phenylacetate (7f)

The stereochemistry was determined by single crystal X-ray diffraction on a crystalline sample of **(2S)-7f** grown by slow evaporation over a number of days from a saturated solution of **(2S)-7f** in acetonitrile in a 20 mL vial.




An ORTEP view of **(2S)-7f** showing the structure and relative stereochemistry. Anisotropic parameters are drawn at the 30% probability level.

The X-ray crystallography data of **(2S)-7f** can be found in **Table SI.7**.

(-)-tert-Butyl (2S)-2-(4'-bromophenyl)-2-(1''R,2''S,5''R)-menthyloxyacetate (7h)

The stereochemistry was determined by single crystal X-ray diffraction on a crystalline sample of **(2S)-7h** grown by slow evaporation over a number of days from a saturated solution of **(2S)-7h** in acetonitrile in a 20 mL vial.




*An ORTEP view of **(2S)-7h** showing the structure and relative stereochemistry. Anisotropic parameters are drawn at the 30% probability level.*

The X-ray crystallography data of **(2S)-7h** can be found in **Table SI.7**.

**(-)-Methyl (2*R*,3*S*)-3-(4'-fluorophenyl)tetrahydro-2*H*-thiopyran-2-carboxylate
1,1-dioxide (**27a**)**

The stereochemistry was determined by single crystal X-ray diffraction on a crystalline sample of **27a** grown by slow evaporation over a number of days from a saturated solution of **27a** in ethyl acetate in a 25 mL roundbottom flask.




*An ORTEP view of (2*R*,3*S*)-**27a** showing the structure and relative stereochemistry. Anisotropic parameters are drawn at the 50% probability level.*

The X-ray crystallography data of **27a** can be found in **Table SI.7**.

(-)-Methyl (1*R*,4*aS*,8*aR*)-octahydro-1*H*-isothiochromene-1-carboxylate 2,2-dioxide (30a)

The stereochemistry was determined by single crystal X-ray diffraction on a crystalline sample of **30a** grown by slow evaporation over a number of days from a saturated solution of **30a** in ethyl acetate in a 25 mL roundbottom flask.




An ORTEP view of (1*R*,4*aS*,8*aR*)-**30a** showing the structure and relative stereochemistry. Anisotropic parameters are drawn at the 50% probability level.

The X-ray crystallography data of **30a** can be found in **Table SI.7**.

(+) 9-Aza-9-*tert*-butyl-1(*S*)-cyano-4-bromobicyclo[5.3.0]deca-2,4,6-trien-10-one
(47)

The stereochemistry was determined by single crystal X-ray diffraction on crystalline sample of **47** crystallised from chloroform.



An ORTEP view of **47** showing the structure and relative stereochemistry. Anisotropic displacement parameters are drawn at the 30% probability level. There is disorder in the *tert*-butyl group.

The X-ray crystallography data of **47** can be found in **Table SI.7**.

SUPPORTING INFORMATION

Table SI.8: Crystallographic Data

Compound No	7b	7c	7d	7f	7h
CCDC No.	2081765	2081766	2081767	2081768	2081769
Crystal System	orthorhombic	orthorhombic	orthorhombic	orthorhombic	orthorhombic
Space Group, <i>Z</i>	<i>P</i> 2 ₁ 2 ₁ 2 ₁ , 4	<i>P</i> 2 ₁ 2 ₁ 2 ₁ , 4	<i>P</i> 2 ₁ 2 ₁ 2 ₁ , 4	<i>P</i> 2 ₁ 2 ₁ 2 ₁ , 4	<i>P</i> 2 ₁ 2 ₁ 2 ₁ , 4
Empirical Formula	C ₂₆ H ₃₄ O ₃	C ₂₆ H ₃₄ O ₃	C ₂₂ H ₃₁ BrO ₃	C ₂₂ H ₃₄ O ₃	C ₂₂ H ₃₃ BrO ₃
Formula Weight	394.53	394.53	423.38	346.49	425.39
Crystal size (mm)	0.33 x 0.26 x 0.12	0.60 x 0.55 x 0.12	0.43 x 0.36 x 0.30	0.33 x 0.29 x 0.25	0.30 x 0.27 x 0.24
Wavelength, (Å)	1.54178	0.71073	1.54178	1.54178	1.54178
<i>a</i> (Å)	10.3931(2)	11.0136(15)	6.3385(2)	8.8806(2)	8.7929(2)
<i>b</i> (Å)	14.9104(3)	12.953(2)	11.9385(3)	10.9577(3)	10.8463(3)
<i>c</i> (Å)	15.0088(3)	16.420(3)	29.4096(7)	22.7011(6)	24.7189(6)
α (°)	90	90	90	90	90
β (°)	90	90	90	90	90
γ (°)	90	90	90	90	90
Volume, <i>V</i> (Å ³)	2325.84(8)	2342.5(6)	2225.49(10)	2209.07(10)	2357.45(10)
Temperature (K)	296(2)	300(2)	296(2)	296(2)	296(2)
Calculated Density, (g·cm ⁻³)	1.127	1.119	1.264	1.042	1.199
μ (mm ⁻¹)	0.563	0.071	2.644	0.527	2.496
<i>F</i> (000)	856	856	888	760	896
θ range	4.18 – 67.31	3.10 – 26.82	4.00 – 67.28	5.61 – 67.36	6.18 – 66.93
No. unique reflections	3940	4961	3822	3789	3922
No. observed reflections	3896	3472	3791	3684	3809
<i>R</i> ₁ [<i>I</i> > 2 σ (<i>I</i>)]	0.0356	0.0461	0.0313	0.0395	0.0371
<i>wR</i> ₂	0.1020	0.1226	0.0830	0.1142	0.1021
<i>S</i> (Goof)	1.067	1.062	1.105	1.057	1.092
Flack	-0.01(3)	0.0(5)	0.050(6)	0.09(4)	0.024(6)

SUPPORTING INFORMATION

Compound No	27a	30a	47
CCDC No.	2081770	2081771	2081772
Crystal System	monoclinic	monoclinic	orthorhombic
Space Group, <i>Z</i>	<i>P</i> 2 ₁ , 2	<i>P</i> 2 ₁ , 2	<i>P</i> 2 ₁ 2 ₁ 2 ₁
Empirical Formula	C ₁₃ H ₁₅ FO ₄ S	C ₁₁ H ₁₈ O ₄ S	C ₁₄ H ₁₅ BrN ₂ O
Formula Weight	286.31	246.31	307.19
Crystal size (mm)	0.39 x 0.31 x 0.16	0.30 x 0.10 x 0.02	0.35 x 0.29 x 0.25
Wavelength, (Å)	0.71073	1.54178	0.71073
<i>a</i> (Å)	5.0934(9)	5.0811(2)	9.8104(9)
<i>b</i> (Å)	10.1689(19)	10.4886(4)	35.977(3)
<i>c</i> (Å)	13.539(2)	11.6887(4)	8.0365(7)
α (°)	90	90	90
β (°)	96.887(3)	94.910(2)	90
γ (°)	90	90	90
Volume, <i>V</i> (Å ³)	696.2(2)	620.65(4)	2836.5(4)
Temperature (K)	296	293	293
Calculated Density, (g·cm ⁻³)	1.366	1.318	1.439
μ (mm ⁻¹)	0.251	2.316	2.889
<i>F</i> (000)	300	264	1248
θ range	1.51 – 27.18	7.60 – 66.56	1.13 – 26.00
No. unique reflections	2730	1144	5474
No. observed reflections	1762	1082	3332
<i>R</i> ₁ [<i>I</i> > 2 σ (<i>I</i>)]	0.0441	0.0544	0.0480
<i>wR</i> ₂	0.1048	0.1566	0.1200
<i>S</i> (Goof)	1.031	1.116	1.019
Flack	0.03(6)	0.03(4)	0.009(9)

10. Author Contributions

The synthetic work described in the paper was undertaken by Aoife M. Buckley, Daniel C. Crowley, Thomas A. Brouder and Alan Ford (equal contribution); the crystallography was undertaken by U. B. Rao Khandavilli and Simon E. Lawrence, while Anita R. Maguire had overall responsibility for the project.

11. References

- [1] APEX2 v2009.3-0. Bruker AXS Inc, Madison, WI, **2009**.
- [2] a) G. M. Sheldrick, *Acta Crystallogr., Sect. C: Struct. Chem.* **2015**, *71*, 3–8; b) C. F. Macrae, I. J. Bruno, J. A. Chisholm, P. R. Edgington, P. McCabe, E. Pidcock, L. Rodriguez-Monge, R. Taylor, J. van de Streek, P. A. Wood, *J. Appl. Crystallogr.* **2008**, *41*, 466–470.
- [3] T. León, A. Correa, R. Martin, *J. Am. Chem. Soc.* **2013**, *135*, 1221–1224.
- [4] J. Ke, C. He, H. Liu, H. Xu, A. Lei, *Chem. Commun.* **2013**, 49, 6767–6769.
- [5] S. A. Lee, *Fluorine Chem.* **2001**, *109*, 55–57.
- [6] W. A. Moradi, S. L. Buchwald, *J. Am. Chem. Soc.* **2001**, *123*, 7996–8002.
- [7] R. J. Delley, S. Bandyopadhyay, M. A. Fox, C. Schliehe, D. R. W. Hodgson, F. Hollfelder, A. J. Kirby, A. C. O'Donoghue, *Org. Biomol. Chem.* **2012**, *10*, 590–596.
- [8] D. Zhao, Y. Jiang, D. Ma, *Tetrahedron* **2014**, *70*, 3327–3332.
- [9] X. Ma, S. B. Herzon, *J. Org. Chem.* **2016**, *81*, 8673–8695.
- [10] Z. Song, Y. Wu, T. Xin, C. Jin, X. Wen, H. Sun, Q.-L. Xu, *Chem. Commun.* **2016**, 52, 6079–6082.
- [11] T. Hashimoto, Y. Naganawa, T. Kano, K. Maruoka, *Chem. Commun.* **2007**, 5143–5145.
- [12] P. G. Mattingly, M. J. Miller, *J. Org. Chem.* **1981**, *46*, 1557–1564.
- [13] U. B. R. Khandavilli, A. M. Buckley, A. R. Maguire, M. S. R. N. Kiran, U. Ramamurty, S. E. Lawrence, *CrystEngComm* **2021**.
- [14] G. H. P. Roos, M. A. McKerver, *Synth. Commun.* **1992**, *22*, 1751–1756.
- [15] J. Lee, J.-H. Lee, S. Y. Kim, N. A. Perry, N. E. Lewin, J. A. Ayres, P. M. Blumberg, *Biorg. Med. Chem.* **2006**, *14*, 2022–2031.
- [16] E. Mannekens, D. Tourwé, W. D. Lubell, *Synthesis* **2000**, 2000, 1214–1216.
- [17] H. Saito, H. Oishi, S. Kitagaki, S. Nakamura, M. Anada, S. Hashimoto, *Org. Lett.* **2002**, *4*, 3887–3890.
- [18] S. P. Pappas, B. C. Pappas, J. E. Backwell, *J. Org. Chem.* **1967**, *32*, 3066–3069.
- [19] a) A. E. Shiely, L.-A. Clarke, C. J. Flynn, A. M. Buckley, A. Ford, S. E. Lawrence, A. R. Maguire, *Eur. J. Org. Chem.* **2018**, 2277–2289; b) C. J. Flynn, C. J. Elcoate, S. E. Lawrence, A. R. Maguire, *J. Am. Chem. Soc.* **2010**, *132*, 1184–1185.
- [20] T. A. Brouder, C. N. Slattery, A. Ford, U. B. R. Khandavilli, E. Skořepová, K. S. Eccles, M. Lusi, S. E. Lawrence, A. R. Maguire, *J. Org. Chem.* **2019**, *84*, 7543–7563.
- [21] S. Mo, J. Xu, *ChemCatChem* **2014**, *6*, 1679–1683.
- [22] A. Fececu, L. E. Sangster, D. B. C. Martin, *Organic Letters* **2018**, *20*, 3151–3155.
- [23] T. Ye, C. F. Garcia, M. A. McKerver, *J. Chem. Soc., Perkin Trans. 1* **1995**, 1373–1379.
- [24] J. Fu, H. Shang, Z. Wang, L. Chang, W. Shao, Z. Yang, Y. Tang, *Angew. Chem. Int. Ed.* **2013**, *52*, 4198–4202.